University of Louisville

ThinkIR: The University of Louisville's Institutional Repository
Electronic Theses and Dissertations
8-2020

Mechanisms of chromate-induced suppression of RAD51: a one
environmental health approach.
Rachel M. Speer
University of Louisville

Follow this and additional works at: https://ir.library.louisville.edu/etd
Part of the Medical Pharmacology Commons, and the Medical Toxicology Commons

Recommended Citation
Speer, Rachel M., "Mechanisms of chromate-induced suppression of RAD51: a one environmental health
approach." (2020). Electronic Theses and Dissertations. Paper 3485.
https://doi.org/10.18297/etd/3485

This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's
Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized
administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of
the author, who has retained all other copyrights. For more information, please contact thinkir@louisville.edu.

MECHANISMS OF CHROMATE-INDUCED SUPPRESSION OF RAD51: A ONE
ENVIRONMENTAL HEALTH APPROACH

By

Rachel M. Speer
B.S., Rochester Institute of Technology, 2013
M.S., University of Louisville, 2017

A Dissertation
Submitted to the Faculty of the
School of Medicine of the University of Louisville
In Partial Fulfillment of the Requirements
For the Degree of

Doctor of Philosophy in Pharmacology and Toxicology

Department of Pharmacology and Toxicology
University of Louisville
Louisville, Kentucky

August 2020

Copyright 2020 by Rachel M. Speer
All Rights Reserved

MECHANISMS OF CHROMATE-INDUCED SUPPRESSION OF RAD51: A ONE
ENVIRONMENTAL HEALTH APPROACH
By
Rachel M. Speer
B.S. Rochester Institute of Technology, 2013
M.S., University of Louisville, 2017
A Dissertation Approved on
June 25, 2020
by the following Dissertation Committee:

_____________________________________
John Pierce Wise, Sr., Ph.D.

_______________________________
Levi Beverly, Ph.D.

_______________________________
Lu Cai, Ph.D.

_______________________________
J. Christopher States, Ph.D.

_______________________________
Qunwei Zhang, Ph.D.

ii

DEDICATION
This dissertation is dedicated to all the sea turtles, whales, alligators, and
other wildlife that have made the experience of my Ph.D. such an amazing
adventure. It has been an exceptional pleasure to get to relish in the majesty of
50-ton whales gliding gently alongside the boat or watching baby sea turtles
emerge from a nest to make their way to the ocean for the first time. The
experiences with these incredible creatures provided much-needed respite and I
carried those moments with me whenever times were especially difficult. To all the
alligators I wrestled, lionfish I caught (and ate), and whales I revered, although you
didn’t make it into these pages, you still hold a special place in my heart as a part
of my experience of the past 5 years.

iii

ACKNOWLEDGEMENTS
First, I must thank my advisor, Dr. John Wise, who has been so incredible
supportive over the past 7 years. We have had quite an adventure from the
beginning, and I am so grateful for the opportunity I had to move to Louisville from
Maine and be a part of the lab. I could not have imagined all of the incredible
opportunities I have had because of John’s support and confidence in my ability to
succeed. I am especially grateful for the many opportunities to attend conferences,
all the incredible field work I got to be a part of, and always making an extra effort
to apply for awards and other opportunities. John has provided excellent guidance
over the years and has never steered me in a wrong direction.
I would also like to thank my doctoral committee: Dr. Levi Beverly, Dr. Lu
Cai, and Dr. Chris States, and Dr. Qunwei Zhang for all their knowledge, guidance,
and suggestions as I worked my way through developing my dissertation. Thank
you to Dr. Hein for all the guidance and support over the past 5 years as a leader
of the Department of Pharmacology and Toxicology, and to everyone in the
Department for the opportunity to learn so much more through the research you
do and inspiration over the years.
I must also thank the collaborators of the work accomplished in this
dissertation. Although the work in this dissertation is my own, it is written in plural
first person due to the collaborative effort that went into its completion. I must thank
iv

my fellow lab members who contributed to third experiment repeat analysis: Tayler
Croom-Pérez, Jennifer Toyoda, Idoia Meaza, Johnny Wise, and Haiyan Lu. I also
thank Jennifer Toyoda and Idoia Meaza for their contributions to the RNAseq
analysis. I also thank Dr. Ron Walter and Dr. Yuan Lu for their help in the
bioinformatic analysis of the RNAseq data and Dr. Maiying Kong and Qian Xu for
their help with the biostatistical analysis of the RNAseq data. The leatherback sea
turtle work would not have been possible without our collaborators at the U.S. Fish
and Wildlife Service, Vieques and the Vieques Conservation and historical trust.
Specifically, I want to thank Mike Barandiaran and Erick Bermúdez for all the long
hours in the field collecting samples and learning about their work. The depth of
Erick’s knowledge on all the flora and fauna in Vieques is something I was always
treasure. I would also like to thank Lirio Marquez for always welcoming me into the
Trust and to participate in the great work you do. To Mark Martin Bras, I thank you
for all of the unforeseen problem solving that goes along with field work, all the
guidance on navigating through precarious situations, and of course the amazing
opportunities to explore, learn, and make the world a more magical place.
I have also had the opportunity to work in a great lab over the years. I thank
Dr. Amie Homes for the excellent training she provided to me as a brand-new
scientist early on. I also want to thank the members of the lab who have provided
guidance and suggestions over the years: Jamie Young, Jeny Toyoda, Idoia
Meaza, Haiyan Lu, Cyndi Browning, Tayler Croom-Pérez, Adam Pérez, Sean
Raph, Johnny Wise, and Sandy Wise. I specifically want to thank Cyndi Browning

v

for all her support both personally and research-related since our times together in
the lab and beyond that.
Finally, I must thank my family and friends who have always been
supportive. Thank you for always having confidence in my ability to succeed and
providing so much support. To my partner, Suli who has always pushed me to be
better and offered so much advice and perspective. I have grown so much with
your help. I also want to thank Sharlie for all the support and keeping me well fed
over these past 5 years. A special thanks is due to my mom and dad for your
undying support and love. I am so grateful for everything you have ever done for
me.
This dissertation would not have been possible without all the financial
support provided by several different sources. The Integrated Programs in
Biomedical Sciences and the Department of Pharmacology and Toxicology
provided my first two years of support at the University of Louisville. I was
supported for two years by the National Institute of Environmental Health Sciences
T32 Training Grant [T32ES0111564-12] (to J.P.W. and R.M.S.). My last semester
I have been supported by the Dissertation Completion Award from the University
of Louisville’s Graduate School. I also received numerous travel and research
awards from the University of Louisville and Society of Toxicology that allowed me
to present my work at conferences around the country. This work was supported
by the National Institute of Environmental Health Sciences [ES016893 to J.P.W]
and the Jewish Heritage Foundation for Excellence (to J.P.W.).

vi

ABSTRACT
MECHANISMS OF CHROMATE-INDUCED SUPPRESSION OF RAD51: A ONE
ENVIRONMENTAL HEALTH APPROACH
Rachel M. Speer
June 25, 2020
Lung cancer is the leading cause of cancer death. Lung cancer is commonly
associated with smoking, however, 1 in 5 women and 1 in 12 men who develop
lung cancer are never-smokers. Environmental exposures, therefore, account for
a significant portion of lung cancer cases. Hexavalent chromium [Cr(VI)] is a global
environmental contaminant and known human lung carcinogen. Cr(VI) and other
carcinogenic metals induce chromosome instability, an early event in lung cancer.
Structural chromosome instability arises in part due to failed DNA repair.
Particulate Cr(VI), the most potent form of Cr(VI), induces DNA double strand
breaks and inhibits the high-fidelity DNA repair mechanism, homologous
recombination. Specifically, the effector step of homologous recombination is
affected shown by RAD51 failure.
RAD51 failure is due to inhibited expression, inhibited localization to double
strand breaks, or a combination of these two mechanisms. Little is known about
the mechanisms of Cr(VI)-inhibited expression. However, Cr(VI) exposure results
in downregulation of global expression, and it has been suggested epigenetic
changes affect expression profiles after Cr(VI) exposure. Studies show changes in
vii

acetylation of the RAD51 promoter affect E2F1-mediated RAD51 transcription by
altering the “histone code” as potential epigenetic mechanisms of inhibited
expression. Studies also show changes in microRNAs are an additional epigenetic
mechanism of Cr(VI)-altered expression, and this may provide an additional
mechanism of inhibited RAD51 expression.
The mechanisms of particulate Cr(VI)-induced RAD51 failure were
investigated in a human lung cells, and key events were confirmed in a wildlife
model, leatherback sea turtle (Dermochelys coriacea) cells. The leatherback
model was included as a part of the One Environmental Health Approach to
investigate particulate Cr(VI) carcinogenesis across species. This type of analysis
is used to identify how two species with different environmental adaptations may
have alternative responses to chemical exposures. Therefore, the hypothesis of
this dissertation is: Prolonged exposure to particulate Cr(VI) inhibits RAD51
expression through E2F1-inhibited transcription and alteration of microRNA
expression profiles, and these effects are paralleled in a leatherback sea turtle
model.
We found particulate Cr(VI) inhibits RAD51 and E2F1 nuclear and whole
cell protein and mRNA levels in human lung cells. Therefore, we aimed to show
E2F1 modulates the RAD51 response to particulate Cr(VI). We found E2F1
overexpression did not rescue particulate Cr(VI)-induced RAD51-failure after
prolonged (120 h) exposure. However, when we knocked down E2F1 we found
E2F1 knockdown does not inhibit RAD51 mRNA or protein expression but does
reduce nuclear foci formation after acute (24 h) particulate Cr(VI) exposure when
viii

RAD51 is normally functional. These results suggest E2F1 may affect RAD51
localization to double strand breaks, but not expression after Cr(VI) exposure. As
an alternative mechanism of inhibited RAD51 expression we next performed RNA
sequencing (RNAseq) analysis to asses Cr(VI)-altered microRNA (miRNA)
expression. This study showed Cr(VI) significantly affected global miRNA
expression, a subset of which target homologous recombination genes and RAD51
expression directly. These data advance our understanding of how Cr interferes
with a critical cellular pathway that contributes to carcinogenesis.
We previously reported particulate Cr(VI) induces structural chromosome
instability in leatherback lung cells similarly to data in human lung cells with some
differences. In this dissertation we confirmed particulate Cr(VI) induces DNA
double strand breaks in leatherback lung cells. In analysis of DNA repair we found
lower levels RAD51 foci after prolonged particulate Cr(VI) exposure compared to
acute exposure in leatherback lung cells. However, the sister chromatid exchange
assay showed homologous recombination is functional after prolonged particulate
Cr(VI) exposure. These results are dissimilar to results in human lung cells
indicating there are significant differences in the mechanistic response to
particulate Cr(VI) exposure between human and leatherback lung cells.
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CHAPTER 1: INTRODUCTION

Part I: Chromium background
Metals are associated with both industrial uses and biological processes.
Some metals like iron (Fe), copper (Cu) and magnesium (Mg) are essential and
have well characterized roles in biology. Other metals such as mercury (Hg) and
lead (Pb) have no known biological functions but have been widely used in
industry. Chromium (Cr) has extensive commercial uses and used to be
considered an essential nutrient (Vincent, 2017). Cr has been used in a diverse
range of applications for more than 200 years leading to industrial and societal
advancements. The physical and chemical properties of Cr including its varying
degrees of solubility, valence states and bright colors make it a desirable and
useful resource. Consequently, the ever increasing and ubiquitous use of Cr has
led to global environmental contamination and associated increased health risks.
Negative health risks have been documented and associated with Cr exposure for
well over a century dating back to the 1800s (IARC, 1980; Newman, 1980).
However it wasn’t until 1980 that Cr was classified as a human carcinogen, and
since then there have been several large assessments that aimed to better identify
risk associated with Cr exposure (ATSDR, 2000; ATSDR, 2012; IARC, 1980;
IARC, 1990).
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Chemical and physical properties
Cr is a transition metal that occurs in the environment from natural and
anthropogenic sources. The EPA’s Toxics Release Inventory Program reported in
2016 12,259,441 lbs of Cr and 50,433,180 lbs of Cr compounds were released into
the environment by anthropogenic means accounting for approximately 90% of the
total release of Cr in the environment (TRI, 2016). Anthropogenic sources of Cr
consist of the burning of fossil fuels and industrial processes notably the chrome
plating industry, electroplating, cement work, leather tanneries and the production
of dyes and pigments.
Cr comes in many different forms ranging in solubility and valence state
forming compounds with other elements including potassium (K), sodium (Na), Pb,
zinc (Zn), barium (Ba) among others. The valence states of Cr range from (-2) to
(+6) with trivalent [Cr(III)] and hexavalent Cr [CrVI)] being the most prevalent and
stable valence states (Kotas and Stasicka, 2000). Cr is found in the environment
predominantly in the trivalent state. However, the desirable properties of Cr are
associated with Cr(VI). Therefore, Cr(III) from the environment is converted into
Cr(VI) compounds through a chemical process using sodium ash to produce
soluble sodium chromate (ATSDR, 2012; Barnhart, 1997). Then, sodium chromate
is converted to other particulate or soluble chromate compounds. As a result Cr(VI)
in the environment is predominantly anthropogenic and is found in air, water and
soil.
Studies show the major form of Cr in water is hexavalent, in soil is trivalent,
and 1/3 of Cr released into the air is hexavalent (Kotas and Stasicka, 2000; Pettine
2

and Millero, 1990). However, the ratio of different valence states of Cr in the
environment vary depending on pH and the presence of reducing agents (CesponRomero et al., 1996). When considering human health, Cr(III) and Cr(VI) are
considered to be the physiologically relevant forms due to their stability and
widespread exposure to them.
Chromate-worker exposures and regulations
Cr is mined from the Earth’s crust predominantly in the trivalent form and is
then processed into Cr(VI). Exposure in the Cr industry begins with the processing
where the high temperatures required to convert Cr(III) to Cr(VI) create inhalation
exposures (IARC, 1990; Langard and Norsheth, 1975). However, exposure to
Cr(VI) extends far beyond this where it is used in many other industrial
applications. The United States remains one of the largest chromate producers
and users (Papp, 2015). Thus, there are occupational regulations aimed to
decrease health risks associated with Cr(VI) exposure.
The Occupational Safety and Health Administration's (OSHA) permissible
exposure level for Cr(VI) is 5 ug/m 3 as an 8‐hour time weighted average (OSHA,
2006). OSHA assumes a working lifetime is 45 years. In sum, this evaluation
means over the course of a working lifetime a chromate worker would experience
225 ug/m3 work years of exposure. These health standards were last updated in
2006 leaving 14 years of Cr(VI) research unaccounted for in the OSHA health
assessment. It is important to also remember different types of Cr(VI) occupations
have different levels and types of risk of exposure. Additionally, worldwide
regulations for Cr exposure vary widely. There are large Cr industries in many
3

countries like Pakistan and China, which have less regulations than the United
States posing significant health risk to Cr workers. For example, in China total
atmospheric Cr emissions has grown at an average rate of 8.8% from 1990 to 2009
(Cheng et al., 2014). This growth also creates an elevated worldwide health risk.
Health risks have been associated with Cr exposure since the early 19 th
century when a Scottish chrome pigment worker was identified with nasal tumors
(Bagchi et al., 1995). Since then, over 80 Cr occupations have arisen leading to
extensive occupational exposure (IARC, 1990). Accordingly, there have been
many epidemiology studies indicating high incidences of cancers associated with
chromate workers (Davies, 1984; Davies et al., 1991; Gibb et al., 2015; Gibb et al.,
2000; Langard and Vigander, 1983; Machle and Gregorius, 1948; Mancuso and
Hueper, 1951). It is important to note these studies include only male subjects,
which is a factor of societal limitations as men were and still are the primary
employees of the chromate industry.
Methods for evaluating Cr exposure
Assessing Cr exposure in chromate workers can be challenging, however
there have been many studies investigating the different methods used for these
analyses (Table 1.1). There are currently several methods to track Cr exposure in
workers including assessing exhaled breath condensate and measuring Cr in red
blood cells, plasma, and urine. However, each of these methods has limitations
and we will discuss these limitations with each method. In general, it can be difficult
to compare between studies that evaluate Cr exposure due to the lack of detail in
the study methods used. For instance, the length of time workers used ventilation
4

masks throughout the day may not be reported or specific details on the collection
methods may be vague.
Exhaled breath condensate has been used to assess Cr speciation in
chromate workers and to assess biomarkers that might be used in exposure
assessments. Goldoni et al., 2006 aimed to evaluate soluble Cr(VI) in exhaled
breath condensate from chromate workers and in environmental air (Goldoni et al.,
2006). Previous studies suggest Cr(VI) could be reduced to Cr(III) in the respiratory
tract extracellularly, but a Cr(VI)/Cr(III) equilibrium was not determined (Caglieri et
al., 2005; De Flora et al., 1996; Petrilli et al., 1986). Therefore, this study aimed to
determine if Cr(VI) persists in the lung. They found 15 h post workplace exposure
Cr(VI) was detectable in the exhaled breath condensate of chromate workers
indicating Cr(VI) does persist in the lung.
Studies evaluating Cr speciation in exhaled breath condensate are limited
in their ability to stabilize Cr in its different valence states and the sensitivity of the
analysis. Leese et al., 2016 aimed at establishing methodologies to improve this
type of exposure assessment and implemented their methods in a 2017 study
evaluating exhaled breath condensate in chromate and non-chromate workers
(Leese et al., 2016). They measured the differences in Cr(VI) in exhaled breath
condensate at the beginning of the workweek (Monday morning) and again at the
end of the workweek (Thursday afternoon) and found chromate workers had a
significant increase of Cr(VI) and Cr(III) in their exhaled breath condensate
compared to non-chromate workers (Leese et al., 2017). While measuring Cr(VI)
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in exhaled breath condensate has been successful, it still has experimental hurdles
to overcome and is best used in conjunction with other monitoring methods.
Another method for monitoring Cr(VI) exposure is by measuring Cr
concentrations in red blood cells. Cr in red blood cells is representative of Cr that
reaches the bloodstream in the hexavalent state whereas measuring Cr in plasma
represents Cr that reached the blood stream in the reduced state, Cr(III) (Goldoni
et al., 2010). Devoy et al., 2016 evaluated the selectivity of red blood cells
accumulating Cr after Cr(VI) exposure using whole blood samples (Devoy et al.,
2016). They found Cr levels in red blood cells are a good candidate to indicate
internal dosing from a recent exposure of approximately 8-10 weeks. However,
this study used an in vitro system and was limited by its applicability of exposure
periods. Minoia and Cavalleri, 1988 compared Cr levels in red blood cells between
individuals who worked primarily with Cr(VI) and workers who worked primarily
with Cr(III) compounds (Minoia and Cavalleri, 1988). They found Cr red blood cell
and plasma concentrations were significantly higher in Cr(VI) workers whereas
only plasma Cr concentrations increased in Cr(III) workers. This outcome confirms
Cr(VI) can reach the bloodstream, Cr(VI) readily enters cells while Cr(III) does not
and red blood cells can be used to monitor Cr(VI) exposure.
Perhaps, the most widely used method to evaluate Cr exposure has been
monitoring urine Cr levels. Unexposed reference ranges have been evaluated by
several studies to find a range of 0.24 to 1.8 ug/L (OSHA, 2006). However humans
exposed to 0.01 to 0.1 mg/m3 Cr(VI) for an 8-hour time-weighted average had
urinary excretion levels from 24.7 to 37 mg/L Cr (OSHA, 2006). Tola et al., 1977
6

found measuring Cr in the urine was an accurate predictor of short-term exposure
to soluble Cr (Tola et al., 1977). Several other studies have evaluated Cr levels in
urine over the years showing elevated levels in chromate industry workers (Pesch
et al., 2018; Saner et al., 1984; Stridsklev et al., 2004).The type of chromate work
has been shown to influence post-exposure levels of Cr in the urine as described
by Lindberg and Vesterberg, 1989 (Lindberg and Vesterberg, 1989). They found
reported urinary Cr levels did not decrease in chrome platers to the same extent
as other studies urinary levels decrease in welders of Cr-alloyed stainless steel
(Tossavainen et al., 1980). This result further highlights differences between
occupational exposures. Despite widespread use of monitoring Cr exposure by Cr
urine levels it has its limitations including it is relatively unreliable for chronic
exposure measurements and it cannot be used to discern between Cr(III) and
Cr(VI) exposure.
Non chromate-worker exposures
Cr(VI) is ubiquitous in the environment due to its widespread use and the
lack of regulations concerning Cr(VI) waste and air pollution for many decades
after the industrial revolution began. Today, Cr(VI) is continually released in to the
environment through the burning of fossil fuels and regulated release from many
different industrial sources (IARC, 1990). Regulation of Cr(VI) waste in some
countries is not as strict as it is in the United States further increasing the risk of
exposure.
Studies show Cr released into the atmosphere can travel through air
currents and around the world. Urban and rural areas in the United States have
7

been monitored for Cr levels in ambient air and found to range from 0.001 to 0.1
ug/m3. Levels of Cr taken over the Atlantic have ranged from 0.007 to 1.1 ng/m 3,
in Hawaii were measured to be 67 ug/m 3 and in the Baltimore harbor 226 ug/m 3
(Bowen, 1979; Fishbein, 1976; IARC, 1990). Additionally, Cr travels through
groundwater and is found throughout the world’s oceans (Fishbein, 1976). Cr(VI)
has been shown to be the predominant form of Cr in sea water (Pettine and Millero,
1990). Further, many studies in urban areas have assessed Cr(VI) in air
considering the proximity of factories that use Cr(VI) and indicate elevated levels
of Cr(VI) in these areas (Khlystov and Ma, 2006). Nonetheless, Cr(VI) is also found
far removed from industry-heavy regions where air pollution is expected to be
relatively low (Rowbotham et al., 2000). A recent study in Korea found particulate
lead chromate is a specific source of atmospheric Cr(VI) pollution due to its
widespread use in traffic paint and other applications, and the use of lead chromate
was a specific source of concern for public health (Lee et al., 2006). These studies
confirm Cr(VI) is ubiquitous in the environment and exposure to it is widespread
and can contribute to co-exposures.
The environmental contamination of Cr(VI) raises concern of exposure to
non-chromate workers and as such there is an urgent need to investigate the
effects of low, long term exposures. Currently, many low-dose, long-term Cr(VI)
studies focus on Cr(VI) in drinking water. However, inhalation is considered to be
primary route of Cr(VI) exposure. Few studies have measured the effects of Cr(VI)
in non-chromate workers. However, Hwang et al., 2017 measured Cr in the blood
of individuals who lived near a cement plant in Korea where Cr is used and found
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their mean Cr levels to be 3.8 ug/L which is above estimated levels in other studies
which range from 0.12 ug/L to 2.37 ug/L (Hwang et al., 2017; Kim, 2004; Nisse et
al., 2017). Nonetheless, much more research needs to be done evaluating the
risks of Cr(VI) exposure in the general population.
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Table 1.1. Studies on Methods for Evaluating Cr Exposures

Study
Population

Methodology

Study Findings

24 chromeplating workers

Exhaled breath
condensate collected
before and after a
Friday work shift and
before the work shift
the following Monday.

Cr- exhaled breath condensate
levels increased from before
shift to after shift (5.3 ug/L to 6.4
ug/L) on Friday but were
considerably lower the following
Monday morning (2.8 ug/L).

Caglieri et
al., 2006

Human whole
blood samples

Whole blood was
incubated with Cr(VI)
or Cr(III) then Cr was
measured in red blood
cells.

Cr(VI) but not Cr(III)
accumulated in red blood cells
and there was a strong
correlation between Cr(VI)
added to a blood sample the red
blood cell-Cr levels.

Devoy et
al., 2016

10 chromate
plating workers

Exhaled breath
condensate collected
immediately post-shift
and 15 h later.

Cr(VI) was reduced by 50% in
airway lining fluid at the end of
exposure and there was a
further 50% reduction after
about 15 h.

Goldoni et
al., 2006

14 non-smoking
male chrome
plating workers
exposed to
Cr(VI)

Exhaled breath
condensate and urine
were collected at the
beginning and end of
working shifts.

Urine-Cr correlated with plasmaCr at the end of the working
shift, red blood cell-Cr correlated
with exhaled breath condensate
-Cr at the beginning of the shift.

Goldoni et
al., 2010

58 workers
occupationally
exposed to
Cr(VI)
compounds and
22 unexposed
controls

Urine and Exhaled
breath condensate
samples were
collected at the start
of a shift Monday
morning (pre-work
week) and on
Thursday afternoon
(post-work week).

Exhaled breath condensate from
workers has higher levels of
Cr(III) and Cr(VI) than the
control group and higher levels
of total Cr in their urine. There
was no significant difference
between pre- and post-work
week exhaled breath
condensate samples for Cr(III)
or Cr(VI).

Leese et
al., 2017

10 chrome
platers over a
weekend and 23
chrome platers
over 31 days of
vacation

Urine was collected in
the weekend group
and from the last
working day before
vacation and on the
first working day after
vacation in the
vacation group.

Urine-Cr was >0.5 ug/L in all
individuals. The half-time of Cr in
the weekend group was 65 h.
Urine-Cr in the vacation group
decreased from 4.2 ug/L at the
beginning of exposure break to
1.0 ug/liter at the end of the
break.

Lindberg
and
Vesterberg,
1989

Fifty male steel
welders from 14
companies

Respirable welding
fume was collected in
the breathing zone of
the welders during a
working shift and urine

Cr content in pre-shift urine was
a stronger determinant than
airborne shift exposure when
correlating with post-shift urinary
Cr. The proportion of Cr(VI) in

Pesch et
al., 2018
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Reference

samples were
collected before and
after the work shift.

total Cr varied considerably in
the welding fumes collected.

12 normal
adults;
34 male tannery
workers

Hair samples were
taken from the
suboccipital area of
the head. 24 h urine
samples were
obtained

Compared with normal adult
values, urine-Cr concentration,
Cr/Creatinine ratio, daily Cr
excretion, and hair-Cr were
significantly higher in Cr
workers.

Saner et
al., 1984

7 welders
monitored up to
1 week

Whole-day air
measurements, Blood
was collected pre- and
post-work Monday,
Wednesday and
Friday. Urine was
collected 3 times
daily.

Air concentrations had a mean
3
of 200 ug/m total Cr and 11.3
3
ug/m Cr(VI). Mean levels of Cr
after work in whole blood,
plasma and erythrocytes were
1.25, and 1.68 and 0.9 ug/L,
respectively. The mean level for
Cr in urine after work was 3.96
ug/g creatinine.

Stridsklev
et al., 2004

6 high alloy CrNi steel welders

Air was collected each
day in the morning
and afternoon (5
days). Urine samples
were collected 3 times
per day (5 days).
Blood was collected 2
days.

The proportion of Cr(VI) in the
air was higher than 50% of total
Cr during welding with coated
electrodes and less than 10%
produced during metal-inert gas
welding was Cr(VI). Cr in urine
correlated with air exposures.

Tola et al.,
1977
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Cr(VI) and respiratory cancer
The lung is considered to be a primary target of Cr(VI) carcinogenesis and
there are many studies supporting the carcinogenic risks associated with inhalation
of Cr(VI). In 1948 an epidemiology study evaluating chromate workers found
21.8% of chromate worker deaths were attributed to respiratory cancers; 16 times
higher than expected in the control population (Machle and Gregorius, 1948).
Since then numerous epidemiology studies on chromate workers have shown
increased incidences of respiratory cancers associated with Cr(VI) exposure
(Davies, 1984; Davies et al., 1991; Gibb et al., 2015; Gibb et al., 2000; Languard
and Vigander, 1983). While many of these studies specifically found lung cancer
to be the carcinogenic endpoint, some studies also revealed an increased risk for
nasal and sinus cancers (ATSDR, 2012).
It is well known the solubility of Cr(VI) plays a role in the carcinogenic
potential of chromate compounds. The less soluble forms persist in the lung
leading to lung cancers and are believed to be the more potent form of Cr(VI)
(Ishikawa et al., 1994a; Ishikawa et al., 1994b). There have been few epidemiology
studies that have been able to target a specific chromate compound due to the
complexity of occupational exposures. However, a factory that worked specifically
with zinc chromate pigments found an increased incidence of chromate tumors in
its workers (Langard and Vigander, 1983). Further, a zinc chromate production
factory where workers were exposed to sodium chromate (a raw material to
produce zinc chromate) and zinc chromate found an increase in the incidence of
bronchial carcinomas (Langard and Norseth, 1975). These epidemiology studies
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support Cr(VI)-induced lung cancer and are further supported by animal models
and cell culture studies.
Inhalation and intratracheal deposition studies in mice and rats have
confirmed the carcinogenicity of Cr(VI) in the lung (Levy and Vennitt, 1986;
Takahashi et al., 2005; Toya et al., 1999). Levy and Venitt, 1986 found only
particulate and not soluble Cr(VI) intrabronchial implantation increased tumors in
rats (Levy et al., 1986). Cell culture studies further confirm the carcinogenicity of
particulate and soluble Cr(VI). Wise et al., 2002 and Wise et al., 2006a found
particulate lead chromate was more cytotoxic and genotoxic to human lung cells
than soluble sodium chromate. Similarly, lead chromate induced neoplastic
transformation of C3H10T1/2 mouse embryo cells while soluble calcium chromate
did not further supporting the conclusion less soluble chromate compounds are
more carcinogenic (Patierno et al., 1988). More recently lung epithelial BEAS-2B
cells have been shown to be transformed with Cr(VI) compounds in several studies
(Azad et al., 2010; Park et al., 2016; Sun et al., 2011; Wise et al., 2006a). These
studies indicate Cr(VI) has carcinogenic potential, but further insight into
mechanistic information is ongoing.
To date most studies have assessed Cr(VI) carcinogenicity using soluble
chromate compounds despite the evidence that the particulate form is more
carcinogenic creating a clear information gap. Therefore, Cr(VI) research requires
the expansion of studies using particulate forms of Cr(VI) in addition to including
more mechanistic data concerning Cr(VI) carcinogenesis. Other data gaps lie in
investigating respiratory cancers associated with exposures to substances that
13

contain Cr(VI). While the studies above directly evaluated Cr(VI) compounds, other
types of studies involving welding fumes that are known to contain Cr(VI) as a
primary component have also been evaluated. A recent study investigated metal
arc-stainless steel welding fume found increased lung tumorigenesis in A/J mice
(Falcone et al., 2017). The welding fume in this study was collected from the actual
welding process characterized to predominantly contain metal-rich particulate
matter of which a main constituent is Cr(VI). Further, this exposure closely models
exposures that chromate workers in stainless steel welding may experience.
These data have been valuable in the risk assessment for Cr(VI). However, risk
assessment has more recently been requiring mechanistic data to better
understand risk.
Mechanisms of Cr(VI) carcinogenesis
Investigation into the mechanisms underlying Cr(VI) carcinogenesis have
been ongoing for decades. However, due to the complexities of carcinogenesis
and the dynamisms of Cr inside cells much remains to be understood about the
overall mechanism and its details. While some of the processes of Cr(VI)
carcinogenesis align with well understood mechanisms of carcinogenesis, others
are specific to metals and others unique interactions between Cr and cellular
components. There are three drivers of carcinogenesis that are well accepted
among researchers: mutations, epigenetic changes, and genomic instability. There
is scientific evidence that the key drivers of Cr(VI) carcinogenesis most likely are
epigenetic changes and genomic instability. Cr(VI) is known to be a weak mutagen
and does not induce mutations in key tumor suppressor or oncogenes suggesting
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mutations are not a strong driver of Cr(VI) carcinogenesis (Ewis et al., 2001;
Holmes, et al., 2008; Kondo et al., 1997; Wise, 2012). We will discuss key features
that have been investigated in these drivers of carcinogenesis and the events that
lead to their development. Additionally, we will briefly consider malignant cell
transformation and second stage carcinogenesis that are hypothesized to
contribute to the progression of Cr(VI)-induced tumors.
Physical-chemical mechanisms
The specific valence states of Cr play a significant role in the toxicity of Cr
compounds. First, consideration is given to the exposure route of Cr(VI). Cr(VI)
can enter the body through ingestion, dermal absorption and inhalation. If ingested
Cr(VI) is largely reduced in the gut to Cr(III), which is poorly absorbed through the
mucosal membranes and poses little health risk (De Flora et al., 1997; Donaldson,
1966). However, this topic is controversial. Dermal absorption and inhalation of
Cr(VI) both result in the internalization and cellular exposure to Cr(VI).
Studies show Cr(VI) compounds dissolve extracellularly and the chromate
oxyanion enters cells using anion transport channels (Wise et al., 1993; Xie et al.,
2004). Once inside the cell Cr(VI) is rapidly reduced to Cr(III) by Nicotinamide
adenine dinucleotide phosphate (NAPDH), ascorbate, glutathione (GSH), and thiol
groups on cysteine (Figure 1.1) (Quievryn et al., 2003, Quievryn et al., 2006; Cai
et al., 2012, Zhitkovich et al., 2002). If Cr(VI) is reduced by ascorbate the Cr(V)
intermediate is not formed and only Cr(IV) forms as an intermediate. However,
other reducing agents result in both Cr(V) and Cr(IV) intermediates. The reduction
process results in the release of reactive oxygen species that can cause oxidative
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damage to critical molecules in the cell including DNA, RNA, protein, and lipids
(Leonard et al., 2004; Wang et al., 2011). It is widely accepted that the reduction
process is a key process in Cr(VI) carcinogenesis. However, if a chromate particle
enters the cell through phagocytosis there appears to be no toxic effect and no
apparent effect of the cation (Xie et al., 2004).
There have been considerable studies into whether and how Cr (in any
valence state) can interact or bind with the major constituents of the body (i.e.
lipids, proteins, and nucleic acids) resulting in damage. For example, several in
vitro studies where DNA molecules are combined with Cr in test tubes show Cr(III)
and Cr(V) can bind to DNA molecules (Standeven et al., 1992; Stearns et al.,
1995). However, cell model systems and in vivo studies are less clear. This
ambiguity is due to the difficultly in measuring the Cr intermediates as they are
short lived and assays to measure them are insensitive.
Several studies showed Cr can bind to DNA directly altering its
conformation or in the event of DNA replication lead to a DNA breaks (Borges et
al., 1991; Cupo and Wetterhahn, 1985; Madhusudanan et al., 1999; Tsapakos et
al., 1983; Standeven et al., 1992; Zhitkovich et al., 1996). Studies on the binding
of Cr with DNA reveal there are inconsistencies in the binding mechanism and
exactly where Cr can bind is uncertain. Recently, Zhou et al., 2016 sought to
investigate the binding of Cr(III) with both the phosphate backbone of DNA and the
nucleobases. They found Cr(III) could weakly bind to the DNA phosphate
backbone in a reversible interaction likely through electrostatic forces. However,
Cr(III) also interacted with nucleobases forming stable cross-links. It is important
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to note when neutral or high pH was restored in these experiments Cr(III) gradually
lost its binding ability likely due to hydrolysis. This study reveals some binding
kinetics about Cr to DNA, but whether it is physiologically relevant remains elusive.
There has been little other research into the direct interaction of Cr with cellular
molecules, and this part of the Cr(VI) carcinogenesis mechanism remains
uncertain.
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Figure 1.1. Mechanisms of intracellular Cr(VI) reduction. This figure
shows the mechanisms by which Cr(VI) is reduced to Cr(III) inside the cell.
Glutathione can reduce Cr(VI) in a one- or two-electron reaction whereas
cysteine is almost exclusively considered to reduce Cr(VI) in a one-electron
reaction with NADPH providing electrons. Ascorbate reduces Cr(VI) in a twoelectron reaction skipping the Cr(V) intermediate and immediately forming
Cr(IV). As a result of all these reductions reactive oxygen species are formed
which can lead to oxidative damage to nucleic acids, proteins and lipids.
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The range in the solubility of Cr compounds further affects how Cr interacts with
biological systems. Particulate forms of Cr(VI) are considered to be the more
hazardous form because Cr(VI) is first and foremost considered a lung carcinogen
(Holmes et al., 2010; Patierno et al., 1988; Xie et al., 2004). When soluble Cr(VI)
is inhaled it can be cleared by the lung whereas inhalation of Cr(VI) particles leads
to their deposition at bifurcation sites (Ishikawa et al., 1994a; Ishikawa et al.,
1994b). Here, the Cr(VI) particles slowly dissolve over time releasing Cr(VI)
oxyanions leading to prolonged exposures. While soluble and particulate chromate
compounds can both induce respiratory cancers solubility plays a significant role
in potency.
DNA damage and chromosome instability
One of the key results of intracellular Cr(VI) reduction is the induction of
DNA damage. DNA breaks may result from direct or indirect oxidative damage and
DNA double strand breaks are well documented following Cr(VI) exposure (Qin et
al., 2014; Wise et al., 2003; Wise et al., 2002; Xie et al., 2009). DNA double strand
breaks can arise due to the collapse of a replication fork or the conversion of a
single strand break to a double strand breaks during the replication process. Cr(VI)
has been shown to affect mismatch repair which is used to repair Cr-DNA adducts
(Zecevic et al., 2009). Failure of this process can lead to a stalled replication fork
and ultimately double strand breaks (Barbour, 2003). DNA double strand breaks
can lead to chromosomal instability if left unresolved (Masuda and Takahashi,
2002). Chromosome instability is known to occur in a majority of lung cancers and
has been specifically documented in chromate-induced tumors (Maeng et al.,
19

2004). Chromosome instability can occur in the form of numerical chromosome
instability as a change in the number of chromosomes or as structural
chromosome instability in the form of translocations or DNA breaks contributing to
Cr(VI) carcinogenesis (Albertson et al., 2003). First, we will focus on structural
chromosome instability and the current known mechanisms of Cr(VI)-induced
structural chromosome instability and then follow with a discussion of numerical
structural chromosome instability.
Cr(VI) causes DNA double strand breaks. Interestingly, Cr(VI)-induced
DSBs develop in late S and G2 of the cell cycle resulting in a G2 arrest Luczak et
al., 2015; Reynolds et al., 2004; Xie et al., 2009). If these breaks were repaired
structural chromosome instability would not occur. Therefore, investigators have
been researching how Cr(VI) interferes with DNA repair mechanisms. There are
two primary DNA double strand break repair pathways; homologous recombination
and non-homologous end joining. non homologous end joining is considered a low
fidelity pathway due to the loss of genetic material in the repair process. Further,
a study by Camyre et al., 2007 found non homologous end joining is not critical in
protecting cells against Cr(VI) exposure. Homologous recombination is considered
a high-fidelity repair mechanism and has been shown to be critical in preventing
chromosome instability. Additionally, several studies have shown homologous
recombination is impaired following Cr(VI) exposure and is critical in maintaining
genomic stability (Bryant et al., 2006; Stackpole et al., 2007; Tamblyn et al., 2009;
Tian et al., 2016). This effect occurs after prolonged exposures and there is a
specific loss of the effector step of homologous recombination through the loss of
RAD51 (Browning et al., 2016; Qin et al., 2014). While Cr(VI) is known to affect
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homologous recombination, the underlying mechanisms in this pathway remain to
be determined.
Numerical chromosome instability has been well documented in lung
tumors with 70 to 80% of tumors exhibiting severe aneuploidy (Masuda and
Takahashi, 2002). Many cell culture studies support this finding especially
following chronic exposures to Cr(VI) and were characterized by hypodiploidy,
hyperdiploidy, polyploidy and tetraploidy (Guerci et al., 2000; Holmes et al., 2010,
Rodrigues et al., 2009; Seoane et al., 2002). Since these findings, investigation
into the mechanisms of numerical chromosome instability have also been
investigated. Numerical chromosome instability can arise because of improper
segregation during mitosis and impaired centrosome regulation. Specifically, the
spindle assembly checkpoint is critical in maintaining proper division. Spindle
assembly checkpoint bypass has been observed in Cr(VI) exposed cells and is
associated with aneuploidy (Holmes et al., 2010; Seoane et al., 2002). Cr(VI)
exposure caused a decrease in MAD2, which is a key component in regulating the
spindle assembly checkpoint (Wise et al., 2006b).
Another key component required for correct chromosome separation during
cell division are centromeres. Centromeres are responsible for pulling the
chromosomes to the two poles of a cell during division to ensure proper
chromosomal segregation. However, Holmes et al., 2010 found chronic Cr(VI)
resulted in an increase in supernumerary centromeres. Ultimately, this outcome
means during segregation chromosomes can be pulled to multiple poles resulting
in abnormal numbers of chromosomes in the daughter cells. Further, Martino et
21

al., 2015 found there was a correlation between supernumerary centrosomes and
numerical chromosome instability and critical proteins in centrosome regulated
were impaired following Cr(VI) exposure. This study further demonstrated key
structural components required to prevent premature centromere separation are
also compromised following prolonged Cr(VI) exposure.
Taken together there is significant evidence both structural and numerical
chromosome instability play a role in the mechanism of Cr(VI)-induced
carcinogenesis. Ultimately, abnormal numbers of chromosomes or deletions or
insertions in whole chromosomes or genes can result in aberrant gene expression
that leads to carcinogenic outcomes. While the specific pathways involved in
maintaining fidelity in these mechanisms are still being investigated, there is
significant evidence genomic instability is a key driver of Cr(VI) carcinogenesis.
Figure 1.2 illustrates proposed mechanisms of Cr(VI) carcinogenesis.
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Figure 1.2. Mechanisms of numerical and structural chromosome
instability in Cr(VI) carcinogenesis. This figure shows some of the major
mechanisms underlying chromosome instability in our proposed mechanism
of Cr(VI) carcinogenesis. Particulate Cr(VI) dissolves extracellularly and if the
cation enters the cell there is no contribution to the effect. Similarly, if the
Cr(VI) particle enters the cell by phagocytosis there is also no contribution to
the effect. When the Cr(VI) oxyanion enters the cell it is reduced to Cr(III) and
ROS are produced. The reactive oxygen species can induce oxidative
damage which base excision repair (BER) attempts to repair. However, if it
fails double strand breaks form. Positively charged Cr intermediates and
Cr(III) form as result of the intracellular reduction process potentially binding
to cellular elements including the formation of DNA-Cr adducts or crosslinks
and consequentially stalled replication forks and the formation of a DNA
double strand break. Crosslink repair or mismatch repair (MMR) can attempt
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to resolve these effects, but if they fail will result in double strand breaks. The
formation of double strand breaks results in a G2 arrest as the attempts to
repair the damage. Cr(VI)-impaired homologous recombination repair leads
to the use of a low fidelity repair mechanism and structural chromosome
instability. At the same time, Cr(VI) induces spindle assembly checkpoint
bypass and premature centriole disengagement leading to centrosome
amplification and numerical chromosome instability. Underlying structural
and numerical chromosome instability are Cr(VI)-induced epigenetic
alterations, which have yet to be elucidated. Finally, taken together structural
and numerical chromosome instability contribute to the neoplastic
transformation of Cr(VI) exposed and cancer.
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Alterations in epigenetics and gene expression
Another major driver of carcinogenesis is epigenetic changes. Changes in
the epigenome can result in gene expression changes and ultimately
carcinogenesis. Epigenetic modifications are involved in the upregulation and
downregulation of genes though DNA methylation, histone modifications, histone
variants, miRNA expression and nucleosome repositioning (Sharma et al., 2010).
Gene expression and epigenetic studies are ongoing in Cr(VI) carcinogenesis.
There is limited information about changes in gene expression in Cr(VI)-induced
tumors and epigenetic alterations, but cell culture analysis has uncovered complex
alterations.
Studies in chromate tumors have revealed limited information about
changes in gene expression. Takahashi et al., 2005 found MLH1 and MLH2
expression was decreased in chromate tumors. Similarly, other changes in gene
expression in chromate tumors have been seen including increased cyclin D1 and
decreased survivin (Halasova et al., 2010; Katabami, 2000). Interestingly, 61.3%
of chromate tumors were found to have gene variants in the surfactant B gene in
a study by Ewis et al., 2006.
Cell culture studies have revealed numerous changes in gene expression
following Cr(VI) exposure (Sun et al., 2009; Sun et al., 2011, Ye and Shi, 2001).
Recently, BEAS-2B cells were evaluated using single-cell RNA sequencing for
changes in gene expression following a chronic 2 month exposure to Cr(VI) (Park
et al., 2017). This study found Cr(VI) with or without a CRISPR/cas9 deletion of
Gene 33, a protein involved in transformation, induced differential expression of
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over 80 genes. Interestingly, these genes were involved in cell adhesion, oxidative
stresses, protein ubiquitination, epithelial-mesenchymal transition/metastasis and
WNT signaling (Park et al., 2017).
Gene expression is widely regulated by epigenetic mechanisms, however,
studies on epigenetic changes in tumors has been limited and are focused on
methylation changes. For example, Ali et al., 2011 found tumors from those
exposed to Cr had increased aberrant methylation of tumor suppressor genes at
a higher frequency than in tumors from unexposed individuals. Additionally,
methylation in multiple tumor suppressor genes has also been found in tumors
derived from ex-chromate workers (Kondo et al., 2006; Toya et al., 1999). A recent
study found mitochondrial DNA isolated from the blood of chromate workers was
hypomethylated, however, this study was focused on using this endpoint as a
biomarker for Cr(VI) exposure (Linging et al., 2016). Hu et al., 2018 found
hypermethylation of CpG sites in DNA repair genes, including RAD51, increased
in Cr(VI) exposed workers compared to non-exposed workers and this outcome
correlated with blood Cr levels. Further this study confirmed these results in 16HBE
cells treated with Cr(VI). Methylation changes have also been observed in other
cell culture studies. Hu et al., 2016 found hypermethylation of the CpG islands of
the tumor suppressor p16 in 16HBE cells treated with Cr(VI) which correlated with
decreased expression of p16. More broadly, both particulate and soluble Cr(VI)
was investigated in genome-wide methylation of DNA in human B lymphoblastoid
cells. This study found DNA methylation changes only correlated with the
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expression of a subset of genes indicating there are multiple mechanisms
controlling their expression (Lou et al., 2015).
Changes in histone modifications are also being investigated in Cr(VI)
carcinogenesis. Wei et al., 2004 found Cr(VI) can crosslink a histone deacetylase
to inducible promoters resulting in decreased gene expression. Additionally,
acetylation of histone tails is commonly associated with increased gene
expression. The acetylation of histone H4 of the stressor protein Nupr1 was found
to be downregulated following Cr(VI) exposure in BEAS-2B cells and was
associated with increased expression of Nupr1 protein, of which overexpression is
associated with cancers (Chen et al., 2016). Another epigenetic histone
modification is biotinylation. Xia et al., 2014 found differential histone biotinylation
and differential distribution of biotinidase in 16HBE cells depending on the
concentration of Cr(VI). Furthermore, they found histone deacetylation plays a role
in histone biotinylation further adding to complexity of these mechanisms.
No studies to date have investigated miRNAs in chromate tumors. However,
one study evaluated miRNAs in the blood of chromate workers but found only
decreased miR-3940-5p levels were associated with blood Cr (Li et al., 2014).
There are limited but increasing numbers of cell culture studies that support the
involvement of miRNAs in Cr(VI) carcinogenesis. Li et al., 2016 investigated miR3940-5p and its involvement in homologous recombination using 16HBE cells. This
study found miR-3940-5p enhanced the homologous recombination response
following treatment with Cr(VI). He et al., 2013 found changes in miRNA
expression associated with Cr(VI)-transformed BEAS-2B cells and the reduction
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was associated with the upregulation of several proteins involved in proliferation
and angiogenesis. A recent study in BEAS-2B cells found Cr(VI) exposure induced
malignant cell transformation associated with increased miR-21 expression and
the inhibition of a tumor suppressor (Pratheeshkumar et al., 2017). These studies
highlight the complexities and connectedness between different mechanisms of
carcinogenesis. Specifically, miRNAs and other epigenetic alterations affect gene
expression and vital pathways that lead to proper cell homeostasis.
Part II: Focus of this dissertation
Repair of Cr(VI)-induced double strand breaks
Cr(VI) induces DNA double strand breaks, and the predominant repair
pathway for these breaks is homologous recombination. Several studies have
shown the importance of homologous recombination repair following Cr(VI)
exposure. One study investigated the protein Mus81, involved in resolving Holiday
junctions, a final step in the homologous recombination pathway (Tamblyn et al.,
2009). They found in Mus81-deficient cells Cr(VI) induced higher levels of
phosphorylated H2AX (gamma-H2AX) foci indicating resolution of double strand
breaks was inhibited. Tamblyn et al., 2009 complemented this study showing
delayed RAD51 foci removal in Mus81-deficient cells. Ultimately, exposure to a
DNA double strand break-inducing agent and inhibition of homologous
recombination repair results in structural chromosome instability. Two studies
confirmed this mechanism showing Cr(VI) increased chromosome aberrations in
BRCA2 or RAD51C-deficient cell lines (Bryant et al., 2006, Stackpole et al., 2007).
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These studies highlight the importance of homologous recombination repair in
preventing structural chromosome aberrations following Cr(VI) exposure.
There are three main steps in the homologous recombination pathway: the
sensing step, transducing step, and the effecting step. Double strand breaks are
sensed by the MRN complex (MRE11, RAD50, and NBS1), which acts to resect
the ends of the break using the nuclease activity of MRE11 (D’Amours and
Jackson, 2002; Williams et al., 2007). Studies show the sensing step of
homologous recombination repair is activated after Cr(VI) exposure and remains
active through prolonged exposures (Browning et al., 2016; Qin et al., 2014; Xie et
al., 2008; Xie et al., 2009). The sensing step by MRN is initiated by the
phosphorylation of H2AX on either side of a double strand break signaling
downstream recruitment of repair factors (Li and Heyer, 2008). This signal is
further transduced by ATM and ATR, which reciprocally leads to amplification of
the gamma-H2AX signal (Li and Heyer, 2008). Studies show Cr(VI) increases
signal transduction by gamma-H2AX, ATM, and ATR indicating these steps in the
homologous recombination pathway are activated and remain functional after
acute Cr(VI) exposure (Bryant et al., 2006, Luczak et al., 2015; Ha et al., 2004; Qin
et al., 2014; Xie et al., 2008; Xie et al., 2009; Wakeman et al., 2004) and prolonged
exposure (Browning et al., 2016; Qin et al., 2014; Xie et al., 2008; Xie et al., 2009).
After end resection the single stranded DNA of the break is coated with RPA
to protect the ends during downstream signaling and while further repair factors
are recruited (Georgaki and Hubscher, 1992). In the effecting step of homologous
recombination, RAD51 is recruited and loaded onto the single-stranded DNA
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replacing RPA (Baumann et al., 1996; Sung & Robberson, 1995). RAD51
recruitment is facilitated by the BRCA2/BARD1 protein complex and RAD51C,
which transport RAD51 into the nucleus and onto single stranded-DNA forming a
RAD51 nucleofilament (Amunugama et al., 2013; Liu et al., 2010; Sigurdsson et
al., 2001; Zhang et al., 2009). The RAD51 nucleofilament is then involved with the
search for a homologous sequence of DNA with RAD54 and strand invasion
resulting in high-fidelity repair of the double stranded break through Holiday
junction resolution (Constantinou et al., 2001).
We have shown while earlier steps in the homologous recombination
pathway remain functional following prolonged Cr(VI) exposure the key effector,
RAD51, is inhibited (Browning et al., 2016, Bryant et al., 2006; Qin et al., 2014).
Specifically, these studies reveal three major RAD51 effects after prolonged
particulate Cr(VI) exposure: 1) inhibited nuclear foci formation, 2) accumulation of
RAD51 protein in the cytoplasm and 3) reduced RAD51 protein levels. Qin et al.,
2014 and Bryant et al, 2006 showed RAD51 nuclear foci increased after 24 h Cr(VI)
exposure. However, Qin et al., 2014 further identified RAD51 nuclear foci was
strongly inhibited after prolonged 72 and 120 h exposures and it accumulated in
the cytoplasm. Similarly, RAD51 nuclear and whole cell protein levels decrease
after prolonged exposure (Browning et al., 2016). Browning et al., 2017a
investigated proteins involved in the transport and loading of RAD51 to form the
nucleofilament essential to complete homologous recombination repair. They
revealed one mechanism of inhibited-RAD51 function is through impaired RAD51
nuclear import mediator proteins. Specifically, Cr(VI) exposure reduced RAD51C

30

nuclear localization and RAD51C deficiency resulted in cytoplasmic accumulation
of RAD51. However, Cr(VI) did not affect the interaction of RAD51 with RAD51C
or its other import partner, BRCA2. These results partially explain RAD51
dysfunction, however, mechanism of Cr(VI)-inhibited RAD51 protein levels have
yet to be elucidated.
Expression of RAD51
E2F1 is a primary transcription factor for RAD51 and is involved in
homologous recombination repair. Studies show loss of E2F1 leads to RAD51 and
homologous recombination failure inducing effects similar to those observed
following prolonged Cr(VI) exposure (Chen et al., 2011; Choi and Kim, 2019; Wu
et al., 2014). One study by Kachap et al., 2010 showed histone deacetylase
inhibitors specifically inhibited E2F1-regulated transcription of RAD51 and induced
RAD51 cytoplasmic accumulation, which is a phenotype observed after prolonged
Cr(VI) exposure. However, no studies have investigated the effects of Cr(VI) on
E2F1 or the transcriptional control of RAD51.
The expression of RAD51 not only depends on the transcriptional control of
the gene, but also post-transcriptional processes. miRNAs play an important role
in the control of expression by targeting mRNA transcripts for degradation and
inhibiting translation to protein. They are short non-coding RNA transcripts known
to regulate about 60% of protein-coding transcripts (Friedman et al., 2009). It is
well known multiple miRNAs target a single mRNA transcript, and each miRNAs
has multiple transcript targets. However, the expression and balance of miRNAs
can determine how they regulate specific targets for post-transcriptional control.
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Studies have investigated miRNAs targeting RAD51 that also lead to inhibition of
homologous recombination repair (Gasparini et al., 2013; Huang et al., 2013; Lai
et al,. 2016; Wang et al., 2012). While Cr(VI) is known to effect the expression of
miRNAs no studies have investigated Cr(VI)-altered miRNAs that target RAD51 or
homologous recombination in general.
One Environmental Health approach
To understand how environmental toxicants, affect health it is important to
consider multiple perspectives. Environmental toxicants affect human health,
wildlife health, and ecosystem health. Traditionally, research has focused on
evaluating the effects of environmental toxicants from one of these three
perspectives. However, important information can be identified by incorporating
research perspectives from more than one area of health. This is especially true
for risk assessment purposes and developing a comprehensive view of how
environmental toxicants affect overall health. This idea of incorporating human,
animal, and ecosystem health developed into the One Health initiative, which
originally was termed based on comparing the study of infectious diseases in
animals with humans (Gibbs, 2014; Zinsstag et al., 2011). The concept of One
Health has expanded, and new subsets have emerged to accommodate a wide
range of disciplines and goals.
One Environmental Health is a subset of One Health specifically focused
on the study of toxicants (Pérez and Wise 2018). As a global environmental
pollutant, Cr(VI) is an excellent candidate for applying the One Environmental
Health approach. We have applied this approach to Cr(VI) research using several
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methods and model organisms. One advantage to the One Environmental Health
approach is investigating molecular mechanisms across species. This is especially
important in Cr(VI) research because the mechanisms of Cr(VI) carcinogenesis
are currently not well understood. Throughout evolution individual species have
developed adaptations to deal with different environments and challenges they
have been exposed to. These adaptations, in part, explain why cancer rates do not
always correlate with organism body size and life span.
Cancer arises through the accumulation of mutations and other genomic
alterations. Therefore, in theory, the larger an organism (i.e. the more cells they
contain) the more likely it is they would develop cancer. Additionally, the longer the
lifespan of an organism the more time there would be for these mutations and
genomic alterations to occur (Caulin and Maley, 2011). While these theories hold
true within species such as dogs and humans, it is not the case across species
(Hawley et al., 2013; Mwacalimba et al., 2015). Instead, cancer is most seen in
mammalian species with a wide range of sizes and lifespans (Hubbard et al.,
1983). These discoveries led to the concept of Peto’s Paradox, which says the
incidence of cancer does not correlate with the number of cells in an organism
(Leroi et al., 2003; Peto et al., 1975). One example of this is whales, which are
much larger and have similar lifespans as humans but develop cancers at much
lower rates (Nagy et al., 2007). Indeed, Li Chen et al., 2012 found Cr(VI) induced
lower levels of genomic instability in whale cell lines compared to human cell lines.
Further, Browning et al., 2017b found Cr(VI) does not inhibit homologous
recombination repair in North Atlantic right whale (Eublalaena glacialis) lung cells.
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Other groups have investigated mechanisms of carcinogenesis based on these
types of observations. For example, Sulak et al., 2016 identified copy number
expansion of TP53 in elephants, another large and long-lived species with lower
cancer rates than humans. TP53 plays an important role in the DNA damage
response. Therefore, having multiple copies may serve as a protective mechanism
against DNA damage-induced genomic alterations that lead to carcinogenesis.
While much research is done in mammalian species to investigate how
different organisms may be protected against carcinogenesis, reptiles offer unique
research opportunities. Reptiles range widely in size and longevity and have
unique physiological adaptations that may impact how they evolved protective
mechanisms against carcinogenesis (Allen et al., 2017; Harris et al., 2017). Chiari
et al., 2018 propose reptiles are an excellent parallel system to evaluate
differences and similarities with humans regarding carcinogenesis. Therefore, we
have included leatherback sea turtles (Dermochelys coriacea) as a reptilian model
in our research to apply the One Environmental Health approach.
Summary and dissertation aims
It has been well established Cr(VI) is a global environmental pollutant and
human lung carcinogen. Cr(VI) particles are inhaled and lodge at bifurcation sites
in the lung resulting in the long term dissolution of chromate anions. These
chromate anions enter cells and are reduced to the next stable valence state,
Cr(III) leading to the induction of DNA double strand breaks. We have previously
shown prolonged particulate Cr(VI) exposure inhibits the high-fidelity DNA repair
pathway, homologous recombination, by inhibiting RAD51 protein expression.
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The mechanisms of how Cr(VI) inhibits RAD51 expression have not been
investigated. E2F1 is considered the predominant transcription factor for RAD51,
however, the effects of Cr(VI) on E2F1-driven RAD51 expression are unknown.
Expression of RAD51 may also be mediated by miRNAs. It is currently unknown
how Cr(VI) affects miRNAs that target RAD51. Given the importance of RAD51 in
protecting genomic stability it is critical to understand how Cr(VI) may be affecting
RAD51 expression, and potential protective mechanisms to prevent this effect.
To better understand mechanisms of Cr(VI) carcinogenesis key outcomes
observed in human models can be explored in other organisms. Leatherback sea
turtles provide a unique model to evaluate Cr(VI) toxicity and determine if Cr(VI)
may pose a threat to leatherback health. Our previous studies show Cr(VI) is
cytotoxic and genotoxic to leatherbacks cells at similar levels to human cells,
however, there were some observable differences. Investigating the mechanisms
of Cr(VI)-induced genotoxicity in leatherbacks may provide important information
to better understand which mechanisms are conserved across species and
adaptations that may provide a biological advantage in one species over another
to cope with genotoxic insult.
Therefore, the central hypothesis of this project is: Prolonged exposure to
particulate Cr(VI) inhibits RAD51 expression through E2F1-inhibited transcription
and alteration of miRNA expression, and key events are paralleled in a leatherback
sea turtle model. This hypothesis will be tested by the following aims:
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Aim 1: Determine if E2F1 modulates the RAD51 response to particulate Cr(VI)
exposure.
This aim seeks to determine if E2F1 is critical for facilitating the RAD51
response to particulate Cr(VI) exposure. First, particulate Cr(VI) effects on RAD51
mRNA levels and protein half-life will be investigated to confirm altered
transcription is the predominant mechanism of reduced RAD51 protein. Next,
particulate Cr(VI) effects on E2F1 will be investigated. Finally, we will test if E2F1
overexpression can rescue particulate Cr(VI)-induced RAD51 failure after
prolonged exposure and if knocking down E2F1 can induce RAD51 failure after
acute particulate Cr(VI) exposure when RAD51 is normally functional.
Aim 2: Identify particulate Cr(VI)-altered miRNAs involved in RAD51 regulation and
homologous recombination repair.
This aim focuses on miRNAs altered by particulate Cr(VI) exposure. First,
global changes in miRNA expression patterns will be evaluated using RNAseq
analysis. Second, differential expression of miRNAs will be investigated to
determine their potential role in pathways of Cr(VI) carcinogenesis. Finally, Cr(VI)altered miRNAs involved in RAD51 and homologous recombination will be further
investigated to determine which of these miRNAs may play a significant role in
Cr(VI)-inhibited DNA repair.
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Aim 3: Characterize the effects of particulate Cr(VI) on homologous recombination
in leatherback sea turtle lung cells.
In this aim, the effects of particulate Cr(VI) exposure in leatherback lung
cells will be evaluated. First, DNA damage will be measured following acute and
prolonged Cr(VI) exposure. Second, the effects of particulate Cr(VI) on RAD51 will
be determined. Finally, homologous recombination repair function will be assessed
following particulate Cr(VI) exposure.
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CHAPTER 2: MATERIALS AND METHODS

This section contains the methods for all three aims of this dissertation. The
methods are arranged in alphabetical order and include a brief background of each
method.
Cell Culture
The lung is the primary target of particulate Cr(VI) with exposures occurring
via inhalation. Epidemiology studies in chromate workers show chromate-induced
tumors arise as cancers of the epithelium, primarily as squamous cell carcinomas
(Hirose et al., 2002; Ishikawa et al., 1994a). While epithelial cells are the ultimate
cell type transformed by Cr(VI) one study found Cr accumulates in fibroblasts in
the stromal layer of the lung, not the epithelial cells from which Cr(VI)-induced
cancers arise (Kondo et al., 2003). These data suggest fibroblasts accumulate Cr
and create an unhealthy microenvironment for adjacent epithelial cells, which may
contribute to their transformation into cancer cells. Indeed, the literature shows in
many different types of cancers fibroblasts play a key role altering the
microenvironment

by releasing

growth

factors,

chemokines,

and

other

components that contribute to carcinogenesis.
Epithelial cells are difficult to immortalize while maintaining normal
characteristics and chromosome structure. This dissertation considers the effects
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of Cr(VI) on chromosomes as a primary target of Cr(VI) exposure and therefore
the currently available immortalized epithelial cells are not suitable for this work.
Additionally, primary epithelial cells cannot be maintained long enough to carry out
the exposures required in this dissertation with consistency. Therefore, because
of these issues with epithelial cell culture and because fibroblasts have been
shown to be a key target of Cr(VI) exposure (Kondo et al., 2003), the primary cell
line used in this study is an hTERT immortalized human lung fibroblast cell line.
This cell line (from here on called WTHBF-6) was developed by the Wise
Laboratory from primary lung fibroblasts derived from healthy lung tissue of a 67year old Caucasian male. These cells have a normal diploid karyotype (46
chromosomes), normal growth parameters, and the same toxicological response
to metals as their parent primary cell line (Wise, et al., 2004).
WTHBF-6 cells were maintained in DMEM/F12 (Corning) supplemented
with 15% cosmic calf serum (Hyclone Laboratories), 1% penicillin/streptomycin
(Corning), 1% L-alanyl-L-glutamine (Corning), and 0.1 mM sodium pyruvate
(Hyclone Laboratories). They were cultured as adherent monolayers in a
humidified incubator at 37°C and 5% CO2. WTHBF-6 cells were fed every 2 days
and split every 3-4 days using 0.25% trypsin/1 mM EDTA (Gibco). Experiments
were performed on logarithmically growing cells.
Leatherback sea turtle lung cells (PGDC9-1LU cells) were used in
experiments where the One Environmental Health Approach was applied. These
primary cells were established by the Wise Laboratory from a leatherback sea
turtle embryo at our field site in Vieques, Puerto Rico (Speer et al., 2018). These
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cells exhibit a normal diploid karyotype (56 chromosomes) and normal growth
parameters. PGDC9-1LU cells were cultured in DMEM/F12 supplemented with
10% fetal bovine serum (Avantor), 1 % penicillin/streptomycin, 1% L-alanyl-Lglutamine, and 0.1 mM sodium pyruvate. Cells were cultured as adherent
monolayers in a humidified incubator at 26°C and 5% CO 2. Cells were fed every
2-3 days and split at least once per week using 0.1% trypsin-EDTA. Experiments
were performed on logarithmically growing cells.
Cell authentication and validation was continuously carried out for both cell
lines. Cells were confirmed to be mycoplasma negative monthly and monitored for
any growth or morphological changes. All cells were karyotyped when thawed for
use and again after every 3 months of continuous culture to ensure authenticity.
WTHBF-6 cells underwent standard tandem repeat analysis yearly. Short tandem
repeat analysis is currently not available for leatherback cells.
Cell equivalent protein extractions
Protein was extracted from cells for western blot analysis. It is well known
Cr(VI) causes global changes in expression and this is reflected by differences in
the amount of protein quantified in Cr(VI)-treated cells compared to control cells.
Therefore, cell equivalents were used as a measure to load the same number of
cells-worth of protein for each sample for western blot analysis. The extraction
method below, therefore, includes counting the number of cells in each sample
and adding the appropriate amount of extraction buffer to allow equal cell loading.
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WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for 48 h
before treating with zinc chromate for 24, 72, or 120 h. For protein half-life
experiments, at the end of the zinc chromate treatment 10 ug/ml cycloheximide
was added to all dishes and cells were harvested immediately (0 h) then 1, 2, 4, 6,
8, 10, and 12 h following. At the end of treatment media was aspirated and cells
were rinsed once with 1X PBS without calcium and magnesium. Cells were
trypsinized and the reaction was neutralized using fresh media. Cells were
centrifuged for 5 minutes at 1000 rpm (4ºC), the supernatant was aspirated, and
cells were resuspended in cold-PBS. Cells were counted using a Beckman Coulter
Multisizer 3 and centrifuged. The PBS was aspirated to 1 ml and 1 ml of cold-PBS
was used to dislodge the pellet and transfer the cells to a microcentrifuge tube.
Cells were centrifuged in a microcentrifuge 5 minutes at 3500 rpm (4ºC). The PBS
was gently aspirated, and samples were placed on ice.
Whole cell protein was extracted using cold Pierce RIPA buffer (Thermo
cat: 89900) with 10% phosphatase and protease inhibitors added immediately
before use. The volume of extraction buffer added to each sample was calculated
based on cell number resulting in the same number of cells per volume extraction
buffer. Extraction buffer was added to the cell pellet and pipetted up and down to
resuspend the pellet. Samples were placed on ice for 20 minutes, vortexing every
5 minutes at max speed for 5 seconds. Samples were then centrifuged at max
speed (14 x g) for 10 minutes (4ºC). The supernatant with the protein sample was
transferred to a fresh tube. Protein was quantified using the Pierce Rapid Gold
BCA kit and BSA standards (Thermo cat: A53227) on a Biotek microplate reader.
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Samples were boiled with 4X loading buffer + 10% 2-mercaptoethanol (Sigma
Aldrich) 5 minutes at 95ºC and stored at -20ºC.
Nuclear protein was extracted using the NE-PER Nuclear and Cytoplasmic
Extraction Reagents kits (Thermo cat: 78833) using the manufacturer’s
instructions with some modifications. After treatment, cells were collected using
the methods above to a cell pellet. Then, ice-cold cytoplasmic extraction buffer I
(plus 10% phosphatase and protease inhibitors) was added to each sample,
vortexed 15 seconds and placed on ice 10 minutes. Ice-cold cytoplasmic extraction
buffer II was added, vortexed 5 seconds and placed on ice 1 minute. The samples
were vortexed again 5 seconds and centrifuged at maximum speed (14 x g) 5
minutes. The supernatant with cytoplasmic protein was transferred to a fresh tube.
The pellet (nuclear fraction) was resuspended with ice-cold nuclear extraction
buffer and vortexed every 10 minutes for 15 seconds for a total of 40 minutes. The
samples were centrifuged at maximum speed (14 x g) 10 minutes and the
supernatant (nuclear protein) was transferred to fresh tubes. The supernatant with
the protein sample was transferred to a fresh tube. Protein was quantified using
the Pierce Rapid Gold BCA kit and BSA standards on a Biotek microplate reader.
Samples were boiled with 4X loading buffer + 10% 2-mercaptoethanol 5 minutes
at 95ºC and stored at -20ºC.
Cell equivalent western blot analysis
Immunoblotting or western blot analysis is a technique used to separate and
visualize specific proteins from a sample for quantification. In this method, proteins
are denatured, and the charges are neutralized to prevent charge-based
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interferences. The proteins are transferred through a gel matrix using
electrophoresis to separate the proteins based on size. Following electrophoresis,
the proteins are transferred to a membrane, which is then probed using antibodies
for a specific protein of interest. Fluorophores either directly attached to the primary
antibody or through secondary antibodies are then applied to quantitate the protein
of interest in the sample. We have specifically used cell-equivalent loading so that
each sample per experiment has the same number of cells-worth of protein to
accurately quantitate protein levels across samples.
Protein was loaded using cell equivalents and resolved on 10% Bis-Tris
SDS-PAGE gels (~1 h) and transferred to 0.45 uM nitrocellulose membranes
(Thermo cat: 88018) (~1.5 h). Immunoblots were dried (~1 h), rehydrated with 1X
tris buffered saline (TBS), and blocked with Odyssey blocking buffer (TBS) (Li-cor)
diluted 1:1 with TBS 1 h. Immunoblots were probed with RAD51 (Santa Cruz sc8349; 1:1000), E2F1 (Santa Cruz sc-251; 1:500), EGR1 (Cell Signaling clone 15F7
Cat: #4153, 1:1000), p130 (Santa Cruz clone A10 sc-374521, 1:500), phosphop130 (Invitrogen Cat: PA5-64769, 1:1000),

p53 (BD Pharm 554294, 1:500),

phospho-p53 (Ser15) (Cell Signaling 9284, 1:500), or E2F4 (Cell Signaling clone
E3G2G Cat: #40291, 1:1000) in odyssey blocking buffer (TBS) diluted 1:1 with
TBS + 0.2% tween-20 (Sigma Adrich) overnight. Equal loading was confirmed by
GAPDH (Genetex GT293; 1:500), H3 (Cell Signaling #9715, 1:500), or alphatubulin (GeneTex GT114, 1:1000) in odyssey blocking buffer (TBS) diluted 1:1 with
TBS + 0.2% tween-20. Immunoblots were incubated with IRDye secondary
antibodies (Li-Cor, 1:15,000) in odyssey blocking buffer (TBS) diluted 1:1 with TBS
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+ 0.2% tween-20 1 h and imaged on a Li-Cor Odyssey CLx. Results were
normalized to their respective loading control and then represented relative to the
untreated (0 ug/cm2 zinc chromate) control at each time point, respectively.
Cr(VI) preparation and treatment
The particulate Cr(VI) compounds are considered to be the most toxic and
carcinogenic. Zinc chromate was used as the representative particulate chromate
compound in this dissertation. Zinc chromate is a partially soluble particulate
chromate compound and epidemiology studies show it alone can induce lung
cancer (Kano et al., 1993). It has wide industrial use, especially as a rust inhibitor
and in pigment applications.
Zinc chromate (99.7% purity; CAS# 13530-65-9) was prepared according
to our published methods by washing twice with deionized H2O to remove water
soluble contaminants, rinsed twice with acetone (99.5% purity, Sigma Aldrich) to
remove organic contaminants, and thoroughly dried. Before use zinc chromate
was suspended in cold, sterile deionized H2O and stirred overnight at 4°C.
Dilutions were prepared the day of use and administered to cells as a suspension
of particles using a vortex. Zinc chromate treatments are represented as ug/cm 2 to
account for particles treatment across different exposure vessels. Cells were
treated with 0.1-0.3 ug/cm2 zinc chromate for WTHBF-6 cells and 0.1-0.4 ug/cm2
zinc chromate for PGDC9-1LU cells, which represents a sub lethal range of
cytotoxicity in each cell line, respectively. This range of concentrations also
represents documented exposures in the literature (Danadevi et al., 2004;
Ishikawa et al., 1994).
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Immunofluorescence
Analysis using immunofluorescence allows for visualization of native protein
localization, quantity in specific compartments of the cell, and interactions between
proteins among other applications. This technique involves using antibodies
conjugated

to

fluorescent

dyes

to

visualize

the

target

of

interest.

Immunofluorescence was applied in this dissertation to identify protein foci and
localization in the cytoplasm or nucleus of the cell.
WTHBF-6 or PGDC9-1LU cells were seeded on glass chamber slides precoated with FNC (Athenaes) and allowed to reenter logarithmic growth for 48 h
before treating with zinc chromate for 24, 72, or 120 h. At harvest, cells were fixed
with 4% paraformaldehyde for 10 minutes, permeabilized with 0.2% triton-X-100
for 5 minutes and blocked with 10% goat serum and 1% BSA in PBS with calcium
and magnesium for 1 h. Cells were incubated with RAD51 antibody (Santa Cruz
sc-8349; 1:200) or gamma-H2AX antibody (Cell Signaling #2577) in 1% BSA
overnight, washed with PBS 3 times 5 minutes each, and incubated with secondary
Alexa Fluor 488 rabbit 1:2000 (RAD51) or Alexa Fluor 594 1:2000 (gamma-H2AX)
1 h. Cells were washed with PBS 5 times for 5 minutes each and coverslips were
mounted with DAPI diamond (Thermo cat: P36962). RAD51 or gamma-H2AX
nuclear foci were scored visually in 100 cells per condition per time point using
fluorescent microscopy. Results were expressed as the percentage of cells with
>10 or >5 foci so that untreated controls had less than 5% of cells with this level of
foci.
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RAD51 nuclear and cytoplasmic protein quantification was assessed using
confocal microscopy. Images of 50 cells per condition per time point were obtained
with a Nikon A1 confocal laser microscope. Z-stack images were taken with a 60X
objective with a step size of 0.5 um. All camera settings were the same across all
images per experiment. Images were processed using the Denoise.ai noise
reduction technology in NIS-Elements software (Nikon) and maximum image
projections (MaxIPs) were created. The MaxIP images were analyzed in NISElements software using the auto-detect (region of interest) ROI program to
automatically detect nuclei. Then the outline of the cell was traced manually to
compare nuclear and cytoplasmic RAD51 total intensity levels at the single cell
level. Cells were considered positive for cytoplasmic accumulation if the
cytoplasmic intensity was greater than 95% of control cells.
Karyotype analysis
Karyotype analysis is a cytogenetic technique used to assess chromosomal
arrangements and can be used to confirm cell line authenticity or alterations made
to chromosomes after exposure to chemicals. We used g-banding (Giemsa
banding) karyotype analysis to confirm cell line authenticity throughout this project.
This method results in dark staining of adenine and thymine-rich heterochromatic
regions and light staining of euchromatic regions rich in guanine and cytosine
resulting in a banding pattern.
Cells were seeded immediately from a thawed cryovial or from growing
cells. Colcemid was added to cells to arrest in metaphase 1 or 4 hours before
harvest WTHBF-6 and PGDC9-1LU cells, respectively. At harvest, the media was
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collected to avoid loss of any loosely attached mitotic cells. Cells were washed
with PBS (without calcium and magnesium) and trypsin was added to lift cells off
the dishes. Cells were collected and centrifuged at 1000 rpm for 5 minutes at 4°C.
The supernatant was aspirated, and the cell pellet was resuspended with 10 ml of
0.75 M KCl for 17 minutes. One ml fixative (methanol:acetic acid; 3:1) was added
and the cells were pelleted again by centrifugation 5 minutes at 4°C and 1000 rpm.
The pellet was resuspended in 10 ml fixative 20 minutes at room temperature, the
fixative was changed twice, and cells were dropped onto wet microscope slides.
Slides were stained by digesting the cells with trypsin (1:250) in Gurr’s
buffer approximately 30 seconds – 1 minute which was stopped by dipping 3-4
times in 2% fetal bovine serum in Gurr’s buffer (Gibco). Slides were dipped 3-4
times in Gurr’s buffer (pH 7.0) then 70% ethanol, 95% ethanol and Gurr’s buffer
(pH 6.8) before staining approximately 3 minutes in Wright’s stain (Carolina
Biological). Slides were cover-slipped and imaged using an Applied Spectral
Imaging microscope and software. Ten metaphases were assessed per analysis.
Neutral comet assay
The comet assay is a method to measure DNA damage using single-cell
gel electrophoresis. The neutral comet assay specifically measures double strand
breaks. This assay is a sensitive measurement of DNA damage based on the
principle negatively charged DNA fragments (created as a result of DNA damage)
will migrate in an electrical current out of the cell creating a ‘comet tail’. Therefore,
more DNA damage in a cell the results in longer and/or more intense comet tails.
PDGC9-1LU cells were seeded in 6 well plates and allowed to rest 48 h before the
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media was replaced with fresh, warm media and cells were treated with 0, 0.1, 0.2,
0.3 and 0.4 ug/cm2 zinc chromate for 24 or 120 h.
At harvest, media was aspirated, and cells were washed with PBS (without
calcium and magnesium) before trypsin was used to collect cells. Cells were
centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant was aspirated, cells
were resuspended in PBS and counted. Cells were diluted to 100,000 cells/ml in
PBS and added to low melting point agarose at a ratio of 1:10. The cell-agarose
mixture was added to CometAssay® slides (R&D Systems) and chilled at 4°C 20
minutes. Slides were submerged in CometAssay® lysis solution (Trevigen) 30
minutes, rinsed with distilled water and submerged in enzyme digestion solution
with proteinase K (1 mg/ml) for 2 h at 37°C. Slides were rinsed and immersed in
chilled neutral electrophoresis buffer for 10 minutes. Electrophoresis was carried
out in CometAssay® units (Trevigen) at 21V in neutral electrophoresis buffer at
4°C for 20 minutes. Slides were sensed with distilled water and immersed in DNA
precipitation solution for 30 minutes at room temperature. Cells were brought into
a single plane by immersing in freshly prepared 70% ethanol for 5 minutes at room
temperature. Slides dried overnight and were stained with SYBR green (Sigma
Aldrich) 30 minutes.
Slides were analyzed using Comet Assay IV software (Instem). One
hundred cells per concentration per time point were analyzed for tail intensity. Tail
intensity measures the total intensity of the DNA in the tail.
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Overexpression transfections
Under certain conditions cells may have loss of protein expression that
affects other functions in the cell. Overexpression plasmids that contain high copy
numbers of a specific gene of interest can be transfected into cells to assess the
effects reconstituting or overexpressing a specific gene. Specifically, plasmid
vectors contain the gene of interest, the regulatory sequences required for
transcription (enhancer and promoter regions) and antibiotic resistance
sequences. These antibiotic resistance sequences allow for the correct selection
of bacteria for expansion and isolation of plasmids to transfect into cells.
Additionally, antibiotic resistance can be used to select for cells that were
successfully transfected.
An E2F1 expression plasmid (HA-E2F1 wt-pRcCMV plasmid; Addgene21667) and CMV500 vector control (Addgene-33348) were acquired as bacterial
stabs from Addgene. HA-E2F-1 wt-pRcCMV was a gift from William Kaelin
(Addgene

plasmid

#

21667;

http://n2t.net/addgene:21667;

RRID:

Addgene_21667) (Krek et al., 1994). CMV500 empty vector was a gift from
Charles Vinson (Addgene plasmid # 33348; http://n2t.net/addgene:33348; RRID:
Addgene_33348) (Rishi et al., 2004). Bacteria were streaked on agar plates and
single colonies were selected for expansion in LB broth with ampicillin. The
QIAGEN plasmid midi kit was used to isolate plasmids from bacteria according to
the manufacturer’s instructions. Briefly, Bacteria cultures were centrifuged at 6,000
x g for 15 minutes at 4°C. The pellet was resuspended in buffer, and DNA was
eluted and precipitated. Concentration and purity were confirmed using a
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NanoDrop ND-1000 spectrophotometer. Plasmids were assessed for appropriate
size by resolution on a DNA gel.

Figure 2.1. Exposure paradigm for E2F1 overexpression experiments following
120 h particulate Cr(VI) exposure.
WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for
48 h before treating with zinc chromate. After 72 h zinc chromate treatment cells
were transfected with Dharmafect kb transfection reagent (Horizon Discovery) per
the manufacturer’s instructions. Final concentration of plasmids were 1 ug/ml and
final Dharmafect kb was 3 ul/ml. After transfection cells were allowed to rest 48 h
(total 120 h zinc chromate and 48 h plasmid treatment) and harvested for whole
cell protein and immunofluorescence staining.
RNAseq Analysis
RNAseq is a genome wide expression profiling technique that uses nextgeneration sequencing and can be used to identify expression profiles of different
types of RNAs or identify novel RNA transcripts. Here we have used RNAseq
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specifically to probe for miRNAs after treating WTHBF-6 cells with particulate
Cr(VI). The goal was to identify which miRNAs are significantly upregulated or
downregulated in response to Cr(VI) exposure, then identify the targets of those
miRNAs, and which cellular pathways were targeted the most.
RNA isolation and next generation sequencing
WTHBF-6 cells were seeded, allowed to rest 48 h and treated with zinc
chromate for 24, 72, or 120 h. At harvest cells were harvested with the mirVana™
miRNA Isolation Kit (Thermo cat: AM1560) using manufacturer’s instructions for
the protocol to isolate total RNA. Briefly, cells were lysed directly in the culture
plates and homogenized. RNA was extracted using acid-phenol:chloroform and
the aqueous phase was transferred to filter cartridges. Total RNA was washed
several times using ethanol and eluted into a fresh tube.
Samples were sent to the University of Louisville CGeMM DNA Facility Core
for analysis. Library prep was performed using the TruSeq Small RNA Library Prep
Kit v2 (Illumina) with gel purification followed by library validation and quantification
to create miRNA libraries from 0.5-2 ug total RNA. 1x75 bp sequencing was
performed using NextSeq 500 High Output v2 (75 cycles) kit on the Illumina
NextSeq500 instrument. Ten million reads per sample were generated.
Bioinformatics
RNA sequencing (RNA-Seq) reads were first filtered using fastx-toolkit
(http://hannonlab.cshl.edu/fastx_toolkit/) (Hannon, 2010). Adaptor sequence
contamination, if it appeared in sequencing reads, were first removed. Base calls
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that show a Phred score < 20 (i.e., base call error rate > 1%) were subsequently
trimmed from both ends of a sequencing read to preserve the longest section of a
high-quality sequence read. Finally, sequencing reads that show base call quality
< 20 for over 25% of the remaining base calls were removed. For all data filter
steps, sequencing reads with lengths < 15 nucleotides were discarded. Filtered
sequencing reads were mapped to human non-coding RNA reference
transcriptome (Ensembl GRCh38) using Bowtie2 (Kim et al., 2013) ‘end-to-end’
mode, followed by discarding transcriptome mapping results that yielded mapping
score < 20 (i.e., > 1% error rate) using samtools (Li et al., 2009; Li and Durbin,
2009). Expression profiles of all samples were next established using custom Perl
scripts (Lu et al., 2017; Lu et al., 2018). Only transcripts identified as “miRNA” in
Ensembl “transcript_biotype” database (Ensembl Version 98) were kept for further
analyses.
Differentially expressed miRNA analysis
In order to identify differentially expressed miRNAs after Cr(VI) exposure
raw read counts were normalized to fit a linear mixed effect model. miRNAs were
removed from the analysis if the sum of the raw reads across all conditions was
less than 10. Each raw read was divided by the sum of all the read counts in that
sample and multiplied by 1,000,000 (i.e. gene 1 normalized read = raw read count
of gene 1/(sum raw read of gene 1+2+3+…..n)*1,000,000. Adjusted p values were
determined using the Benjamini-Hochberg false discovery rate (FDR)-controlling
method for multiple hypothesis testing. miRNAs were considered significant if they
had an adjusted p value less than 0.01.
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Each treatment concentration (0.1, 0.2, 0.3 ug/cm 2 zinc chromate) was
compared to the 0 ug/cm2 zinc chromate control at its respective timepoint. These
analyses were done using GraphPad Prism v8.4.2 to create volcano plots for each
comparison. miRNAs were considered significantly up- or down-regulated for fold
change if the -Log10(adjusted p-value) was greater than 2 and the Log 2(Fold
change) was less than Log2(-2) or greater than Log2(2).
Venn diagrams were created to determine miRNAs significantly affected
across

treatment

concentrations

using

the

online

tool

Venny

v2.1

(https://bioinfogp.cnb.csic.es/tools/venny/) (Oliveros, 2007-2015).
The

Morpheus

online

data

analysis

tool

(https://software.broadinstitute.org/morpheus/) (Broad Institute) was used to
create heatmaps to visualize fold-change trends across treatments. miRNAs were
included in this analysis if they had a p-value less than 0.01 and a fold change
greater than 2 in at least one condition. Euclidean clustering using the average
linkage method was applied. In a separate analysis Euclidean k-clustering using
the average linkage method and a k =3 was applied.
In some cases, the mean counts of miRNAs were reported as ‘0’ in the
control or treated concentrations. Therefore, errors occur in the fold change
calculations. To deal with this issue ‘0.1’ was added to all miRNA means (i.e. 0 +
0.1 = 0.1; 20.2 + 0.1 = 20.3) for fold change analysis. Similarly, some adjusted p
values are reported as 0 because of the software analysis reporting methods. This
means the adjusted p-value for that miRNA was less than 0.001. Therefore, in
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order to avoid calculation errors in the Log(adjusted p-value) calculations 0.0001
was added to all the adjusted p-values.
Pathway analysis
For this analysis we performed a literature review of recent review papers
on Cr(VI) to identify pathways involved in Cr(VI) carcinogenesis. Pathways
involved in Cr(VI) carcinogenesis were then correlated to pathways identified in
the Kyoto Encyclopedia of Genes and Genetics (KEGG) online database
(https://www.genome.jp/kegg/). KEGG is an online resource used to understand
high-level functions and relationships in biological systems. This database
incorporates large-scale molecular datasets to identify relationships in biological
systems to better understand interactions.
For each condition lists of miRNAs that fit within the parameters set for the
volcano plot analysis (adjusted p-value <0.01, fold change >2) were populated.
The DIANA TOOLS mirPath v.3 (http://snf-515788.vm.okeanos.grnet.gr/) was
used to analyze the lists of miRNAs for each concentration at each timepoint
(Vlachos et al., 2015). mirPath is a web-based pathway analysis software that uses
statistical analysis of predicted or experimentally validated datasets of miRNAgene interactions and associates those interactions with pathways. The analysis
can be performed using the KEGG analysis function or gene ontology (GO)
analysis function. We were focused on pathway analysis and so the KEGG
analysis function was applied. The analysis can be performed using either Tarbase
v7.0, microT-CDS (v5.0), or TargetScan databases. Tarbase v7.0 accesses more
than 65,000 miRNA-gene interactions from experimentally validated datasets.
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microT-CDS predicts miRNA Recognition Elements (MREs) in the CDS or 3’UTR
regions of target genes. TargetScan is another predictive database that
determines the biological targets of miRNAs including 8mer, 7mer, and 6mer sites
matching the seed region of miRNAs and 3’ UTR sites on targets.
In this analysis we chose to use TargetScan in the mirPath analysis. The
annotations for each significantly up- or down-regulated miRNA at each
concentration and time point were converted from Ensembl Gene IDs
(ENSG00000283751) to the miRBase ID annotation (hsa-miR-xxx) using the
Biomart ensembl tool (https://useast.ensembl.org/info/data/biomart/index.html)
(Hunt et al., 2018). The miRBase annotations were linked to the miRBase
webpage where the MIMAT annotation determined and recorded for each miRNA.
The MIMAT annotation was used for uploading the miRNA lists to the mirPath web
page for analysis. Then the species was set to human, and the Targetscan
database was selected for the analysis. The p-value threshold was set to 0.05, the
TargetScan Score Type was set to “Context +” with a score of -0.4, and false
discovery rate (FDR) correction was selected. Hierarchical clustering and miRNAKEGG heatmaps were created using the “Significance Clusters/Heatmaps”
function, which utilizes the exact significance levels generated in the analysis. The
Fisher’s Exact Test (Hypergeometric Distribution) was applied as the enrichment
analysis method and pathways were merged using the ‘pathways union’ function.
The pathways targeted by miRNAs in each timepoint and concentration in
the mirPath results were cross-referenced with the pathways of Cr(VI)carcinogenesis identified in the KEGG database.
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Figure 2.2. mirPath analysis settings.
Target gene analysis
Analysis was performed to assess miRNAs identified in the RNA seq
analysis

that

affect

RAD51.

The

online

web

software,

miRSystem

(http://mirsystem.cgm.ntu.edu.tw/index.php) was used to identify miRNAs that
target RAD51 (Tzu-Pin et al., 2012). This database uses both miRNA target gene
prediction programs (DIANA, miRanda, miRBRidge, PicTar, PITA, rna22, and
TargetScan) and validated experimental data programs (TarBase and miRecords)
to determine miRNA-gene associations. miRSystem has the ability to search data
from miRNAs to target genes or target genes to miRNAs. For this analysis we used
the “target genes to miRNAs” function to search for miRNAs that target RAD51.
The results were downloaded which include all the miRNAs that regulate the target
based on the 7 predictive programs and 2 experimental validation programs. The
list of miRNAs from miRSystem was compared to the list of differentially expressed
miRNAs determined in the RNA seq analysis at each time point and concentration.
The list was separated by up- or down-regulated miRNAs.
We sought to characterize how well miRNAs significantly upregulated by
Cr(VI) match (align) to the RAD51 mRNA transcript. This was done using an online
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platform, (http://www.microrna.org/microrna/home.do), which determines miRNA
target sites on mRNA transcripts using the miRanda algorithm (Koppal et al., 2008,
Enright et al., 2005) and mirSVR scores to determine the likelihood of binding
(Koppal et al., 2010).
siRNA transfections
Small interfering RNAs (siRNAs) are short, non-coding RNA molecules
usually about 20-25 base pairs in length that interfere in expression within the RNA
interference pathway in cells. This mechanism has been adapted as a molecular
technology developed to allow for testing the effects of loss of a target on cellular
function. As a molecular tool, siRNAs are designed to be complementary to a
target mRNA sequence. The siRNA binds to mRNA transcripts of target genes
promoting degradation and preventing translation.

Figure 2.3. Exposure paradigm for E2F1 siRNA transfection after 24 h particulate
Cr(VI) exposure.
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WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for
48 h before siRNA transfection. Transfections were carried out per the
manufacturer’s suggestions with slight modifications. Dharmafect transfection
reagent 1 (Dharmacon, Lafayette, CO) and E2F1 ON-TARGET plus siRNA #09
(Dharmacon;

J-003259-09-0005),

E2F1

ON-TAREGET

plus

siRNA

#10

(Dharmacon;

J-003259-10-0005),

E2F1

ON-TARGET

plus

siRNA

#11

(Dharmacon;

J-003259-11-0005),

E2F1

ON-TARGET

plus

siRNA

#12

(Dharmacon; J-003259-12-0005), and ON-TARGET plus non-targeting control
siRNA #1 (Dharmacon; D-001810-01-05) were combined with serum-free and antibiotic free media 5 minutes separately. The siRNAs were then combined with the
Dharmafect 20 minutes and added to the cells with antibiotic-free media. Final
concentrations of Dharmafect and siRNAs were 2 ul/ml, and 25 nM, respectively.
After 24 h media was replaced, and cells were treated with zinc chromate for 24 h
(48 h total transfection time). Cells were harvested for total RNA, whole cell protein,
and immunofluorescence staining.
Sister chromatid exchange assay
The sister chromatid exchange assay is used as an indirect measure of
homologous recombination repair (Sonoda et al 1999). This method involves the
incorporation of 5-bromodeoxyuridine (BrdU) into DNA to visualize the reciprocal
exchange of DNA that occurs during the crossing over of sister chromatids in
homologous recombination repair. As a result, cells that have gone through two
rounds of replication have chromosomes with one sister chromatid with BrdU
incorporation. When these cells are stained the BrdU sister chromatid is visually
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light while the sister chromatid without BrdU is stained visibly dark resulting in
harlequin staining. If homologous recombination occurred there is reciprocal
exchange of DNA between the two chromatids. This method has been validated
as a measure of homologous recombination repair, although it does not represent
all possible repair products of homologous recombination repair due to variations
in the resolution of holiday junctions.
For 24 h treatments PDGC9-1LU cells were seeded in 100 mm dishes with
0.6 ug/ml BrdU. Cells were allowed to rest for 48 h before replacing the media with
fresh, warm media (with 0.6 ug/ml BrdU also added fresh) and treating with 0, 0.1,
0.15, 0.2, 0.3, and 0.4 ug/cm2 zinc chromate. For 120 h treatments PDGC9-1LU
cells were seeded in 100 mm dishes and allowed to rest 48 h before replacing
media with fresh, warm media and treating with 0, 0.1 0.15, 0.2, and 0.3 ug/cm 2
zinc chromate. No metaphases were observed at 0.4 ug/cm 2 zinc chromate after
120 h exposure and so was not included. BrdU (0.6 ug/ml) was added 72 h (0, 0.1
and 0.15 ug/cm2 zinc chromate) and 96 h (0.2 and 0.3 ug/cm2 zinc chromate)
before the end of treatment due to slowed growth rate at the higher concentrations.
Four hours before the end of the treatment time demecolcine was added to
arrest cells in metaphase. At harvest, the media was collected to avoid loss of any
loosely attached mitotic cells. Cells were washed with PBS (without calcium and
magnesium) and trypsin was added to lift cells off the dishes. Cells were collected
and centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant was aspirated,
and the cell pellet was resuspended with 10 ml of 0.75 M KCl for 17 minutes. One
ml fixative (methanol:acetic acid; 3:1) was added and the cells were pelleted again
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by centrifugation 5 minutes at 4°C and 1000 rpm. The pellet was resuspended in
10 ml fixative 20 minutes at room temperature, the fixative was changed twice, and
cells were dropped onto wet microscope slides. Slides were dried overnight,
soaked in PBS 5 minutes, and stained with 0.5 ug/ml Hoechst 33258
trihydrochloride trihydrate solution (Sigma Aldrich) for 10 minutes at room
temperature. Excess solution was tapped off and several drops of 25 ug/ml
Hoechst 33258 trihydrochloride trihydrate solution was added and a coverslip was
added. Slides were incubated under fluorescent lights (27 W) for 10-12 hours in a
humidified chamber 5 cm from the light source. At the end of the incubation the
coverslips were washed off with distilled water and incubated in 2X sodium
chloride/sodium citrate solution 15 minutes at 60°C. Slides were rinsed with
distilled water, stained with 4% Giemsa stain in Gurr’s buffer 6 minutes, and
coverslips were added with mounting medium. The average number of sister
chromatid exchanges per chromosome was analyzed in 50 diploid cells with
harlequin staining per concentration per time point.
Statistics
Results in Aims 1 and 3 are expressed as the mean +/- SEM (standard error
of the mean) of at least 3 independent experiments unless otherwise noted. 2-way
ANOVA with Tukey post-hoc analysis was used to determine the significance of
Cr(VI) concentrations between exposure times (i.e. 24 h 0.1 ug/cm 2 vs. 120 h 0.1
ug/cm2 zinc chromate) or between Cr(VI) concentrations within a single exposure
time (i.e. 24 h 0 ug/cm2 zinc chromate vs. 24 h 0.1 ug/cm2 zinc chromate). When
comparing between only 2 exposure concentrations Sidak’s post-hoc analysis was
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used. Statistical significance was set at p<0.5. Statistical analysis was performed
using GraphPad Prism v8.4.2.
In Aim 2, mean read counts are expressed as the mean of 3 independent
experiments with 4 technical repeats resulting in an n = 12. A linear mixed effect
model was fit in R (https://www.r-project.org/) with the ‘nlme’ package (R core
team, 2013). The Benjamini-Hochberg FDR-controlling method for multiple
hypothesis testing was applied to determine adjusted p-values. Statistical
significance was set at adjusted p-value<0.01. Statistical analysis was performed
in R using the ‘stats’ package.
Total RNA Isolation and qPCR
Quantitative real-time polymerase chain reaction (qPCR) is a technique
used to quantify levels of RNA transcripts in a sample to better understand
changes in expression. This technique requires isolating RNA, which is reverse
transcribed to cDNA. The cDNA is then used in a polymerase chain reaction (PCR)
to amplify the number of cDNA transcripts. One technique to quantitatively assess
this PCR reaction is using Taqman tools. Taqman uses primer-probe assays that
target specific sequences with attached fluorescent probes and a quencher
inhibiting fluorescent signaling. During the amplification process the primer-probe
binds its target sequence and after polymerization the fluorescent probe is cleaved
and separated from the attached quencher resulting in a fluorescent signal. This
signal is then detected by the qPCR machine to quantitate the level of transcripts
present.
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WTHBF-6 cells were seeded and allowed to reenter logarithmic growth for
48h before treating with zinc chromate for 24, 72, or 120 h. Total RNA was isolated
from WTHBF-6 cells using the mirVana™ miRNA Isolation Kit. The protocol for
total RNA was applied. Briefly, cells were lysed directly in the culture plates and
homogenized. RNA was extracted using acid-phenol:chloroform and the aqueous
phase was transferred to filter cartridges. Total RNA was washed several times
using ethanol and eluted into a fresh tube. RNA quality and concentration was
measured using a NanoDrop ND-1000 spectrophotometer.
cDNA synthesis was carried out using a High Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Inc.) per the manufacturer’s instructions with
slight modifications. Briefly, 2X RT master mix was prepared using random
primers, combined with 2 ug total RNA (per 20 ul reaction), and loaded onto a 96well plate. A no reverse transcriptase control and no RNA control were included in
each reverse transcription reaction. Reverse transcription was carried out as
shown in Table 2.1.
Table 2.1. Reverse Transcription Conditions

Temperature
(ºC)
Time

Step 1

Step 2

Step 3

Step 4

25

37

85

4

10 min

120 min

5 min

∞

qPCR analysis was carried out using the TaqMan RNA assays per the
manufacturer’s instructions with slight modifications. Briefly, TaqMan RNA primers
(E2F1- Hs00153451_m1; RAD51- Hs00947967_m1; GAPDH- Hs02786624_g1 or
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Hs02758991_g1) were combined with TaqMan™ Fast Advanced Master Mix
(Thermo Fisher Inc.) and cDNA in triplicate in a 96 well plate. The no RNA and no
reverse transcriptase controls from cDNA synthesis and a no cDNA control were
included in all qPCR runs. qPCR was carried out using a StepOnePlus Real-Time
PCR system (Applied Biosystems) using conditions shown in Table 2.2. The CT
threshold was set by the instrument’s calculations and results are displayed as
∆∆Ct values relative to the untreated (0 ug/cm 2 zinc chromate) control for each
time point, respectively.
Table 2.2. qPCR Conditions

Temperature
(ºC)
Time

Cycle (40 cycles)
Denature
Anneal/Extend

Hold

Hold

50

95

95

60

2 min

10 min

15 sec

60 sec
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CHAPTER 3: RESULTS

Aim 1: Determine if E2F1 modulates the RAD51 response to particulate Cr(VI)
exposure.
Background
Data show chromosome instability is a primary driver of Cr(VI)
carcinogenesis (Chen et al., 2019; Rager et al., 2019; Wise et al., 2018). However,
the mechanisms of Cr(VI)-induced structural chromosome instability are not fully
elucidated. Cr(VI) induces DNA double strand breaks resulting in structural
chromosome instability (Holmes et al., 2008). We showed Cr(VI) inhibits the
effector step of homologous recombination repair by interfering with RAD51 (Qin
et al., 2014; Browning et al., 2016; Browning et al., 2017a). Reduced protein
expression is a key effect of particulate Cr(VI) exposure that at a fundamental level
can affect other particulate Cr(VI)-induced RAD51 phenotypes including loss of
nuclear foci formation. However, mechanisms of RAD51 protein loss after Cr(VI)
exposure are not known.
There are two possible mechanisms for reduced RAD51 protein levels –
increased protein degradation or decreased protein production. Particulate Cr(VI)
can induce increased protein degradation. Indeed, Bruno et al., 2016 found protein
degradation pathways were deregulated following Cr(VI) exposure in BEAS-2B
cells. Particulate Cr(VI) can interfere with protein production by inhibiting
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transcription. Numerous studies show Cr(VI) causes global downregulation of
expression (Andrew et al., 2003; Wetterhahn and Hamilton, 1989; Ye et al., 2001).
Downregulation of factors involved in DNA repair has been observed following
Cr(VI) exposure (Hodges and Chipman, 2002; Hu et al., 2018). For example, Hu
et al., 2018 found Cr(VI) exposure inhibited transcription of MGMT, XRCC1,
ERCC3, and RAD51 in 16HBE cells.
RAD51 expression is tightly regulated in normal cells. Studies show
overexpression of RAD51 can lead to aberrant recombinase activity and RAD51
binding to chromatin resulting in genomic instability (Raderschall et al., 2002).
Meanwhile, adequate RAD51 protein levels must be maintained to enable a
response to DNA double strand breaks from both endogenous and exogenous
insults. Therefore, understanding transcriptional regulation of RAD51 is critical to
understand how Cr(VI) is affecting RAD51 expression.
Hasselbach et al., 2005 characterized the RAD51 promoter and identified
transcription factors ETS1/PEA3, E2F,TP53, EGR1, and STAT5 bind to the
RAD51 promoter. These transcription factors have different numbers of binding
sites and are either activating or repressive (Table 3.1).
Table 3.1. RAD51 transcriptions factor activity
Transcription
Factor
ETS1/PEA3
E2F
p53
EGR1
STAT5

Activating or
Repressive
Activating
Activating
Repressive
Activating
Activating
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Number of
Binding Sites
1
4
3
2
1

RAD51 has a TATA-less and GC-rich promoter that ranges from base pairs -543
to +204 (747 total base pairs) relative to the transcription start site. There are 3
cis-sequence elements responsible for RAD51 transcription, 1 for basal
expression and 2 that limit the expression. The core promoter element is located
from base pairs -204 to -5 and shares a consensus sequence for transcription
factor binding also found in the BRCA1 promoter that is specifically targeted by the
E2F family of transcription factors (Bindra and Glazer 2007; Hegan et al., 2009;
Xie et al., 2013) (Figure 3.1).

Figure 3.1. Working model of the RAD51 promoter. This figure shows
a model of the RAD51 promoter elements that regulate expression
based on data from Hasselbach et al., 2005. It shows 3 cis-regulatory
elements; one that may limit expression (-305 to -204) one that
enhances expression (-204 to -58) and one that limits expression (58 to +204). It also shows the binding sites of each transcription
factor identified.
E2F1 is a transcription factor involved in the expression of RAD51 and in
the recruitment and stability of DNA repair proteins at double strand breaks.
Studies have identified E2F1 as the predominant transcription factor for RAD51
and show knockdown of E2F1 results in loss of RAD51 protein, mRNA, and
nuclear foci (Chen et al., 2011; Choi and Kim, 2019; Wu et al., 2014).
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E2F1 is normally held in a transcriptionally inactive state by the retinoblastoma
(RB) pocket protein. Phosphorylation of RB releases E2F1, which can then
perform its transcriptional function (Liao et al., 2010; Rubin, 2013). In addition to
release from RB, E2F1 is stabilized by post-translational modifications following
genotoxic stress increasing E2F1’s ability to assist in DNA repair through
transcription activation of DNA repair proteins, and direct involvement in the repair
process (Glorian et al 2017; Ianari et al., 2004).
E2F4 is a repressive member of the E2F family of transcription factors and
has been shown to directly compete with E2F1 for promoter binding. Indeed,
Bindra et al., 2007 showed E2F1 and E2F4 bind to the same region of the RAD51
promoter. E2F4 is a part of the DREAM complex, which includes the pocket protein
p130. Hypophospho-p130 binds to E2F4, which then translocates to promoters.
The hypo-phosphorylation of p130 enhances the formation of the DREAM complex
and is facilitated by p53. However, p53 has also been shown to directly repress
RAD51 transcription by binding the promoter itself (Hine et al., 2014; Arias-Lopez
et al., 2005; Hannay et al., 2007). The repressive DREAM complex can displace
the activating E2F1 complex at promoters leading to transcriptional repression,
although this mechanism is not well understood. Studies show the DREAM
complex downregulates DNA repair and facilitates a G2 arrest following DNA
damage (Fischer et al., 2014; Jaber et al., 2016).
Other transcription factors have been less characterized for RAD51
transcription. Hasselbach et al., 2005 reported ETS1/PEA3 was included as a
transcription factor at the RAD51 promoter, but acknowledges this protein is often
a co-enhancer of transcription instead of being the predominant activator. While
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Hasselbach et al., 2005 suggested EGR1 may be inhibitory, Hine et al., 2014 found
deletion of the EGR1 binding site reduced RAD51 expression by 40%. Hine et al.,
2014 also characterized the RAD51 promoter with slightly different results than
Hasselbach et al., 2005. This may be due to the different cell types each used and
preparation of the constructs in their experiments.
Although studies have begun to characterize transcriptional control of the
RAD51 promoter it is still unknown if RAD51 transcription is inhibited following
Cr(VI) exposure. We determined if particulate Cr(VI)-induced reduction of RAD51
protein is due to altered protein half-life or reduced expression (Objective 1).
Because E2F1 is the predominant transcription factor for RAD51 we assessed the
effects of particulate Cr(VI) exposure on E2F1 (Objective 2). Finally, to further
explore the role of E2F1 in the RAD51 response we assessed if E2F1 could
modulate RAD51 after particulate Cr(VI) exposure (Objectives 3-4). All
experiments in this aim were done in WTHBF-6 cells.
Results
Objective 1: Particulate Cr(VI)-induced reduction of RAD51 protein is a result
of inhibited expression
We showed particulate Cr(VI) reduces RAD51 whole cell protein (Browning
et al., 2016). We confirmed this effect using the cell-equivalence western blot
method. Figure 3.2A shows representative western blots of whole cell RAD51
protein. RAD51 whole cell protein is unaffected after 24 h particulate Cr(VI)
exposure, but decreases after prolonged 72 and 120 h exposure in a
concentration- and time-dependent manner (Figure 3.2B) consistent with previous
results. Specifically, 24 h exposure to 0.1, 0.2 and 0.3 ug/cm 2 zinc chromate
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increased then decreased RAD51 whole cell protein to 109, 90, and 81% of
control. RAD51 whole cell protein was decreased to 70, 28, and 11% after 72 h
and further to 40, 20, and 6% of control after 120 h at 0.1, 0.2 and 0.3 ug/cm 2 zinc
chromate, respectively. All zinc chromate concentrations RAD51 protein levels
were significantly reduced compared to the control after prolonged 72 and 120 h
exposure (p<0.0001). However, the small reductions observed after 24 h zinc
chromate exposure were not statistically significant.
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B.

0 ug/cm² zinc chromate
0.1 ug/cm² zinc chromate
0.2 ug/cm² zinc chromate
0.3 ug/cm² zinc chromate

RAD51 Whole Cell Protein
Expression
(Relative to Control)

1.4
1.2

1

*

0.8
0.6

***

0.4

***

***
***

0.2

***

0
24

72

120

Time (h)

Figure 3.2. Prolonged exposure to particulate Cr(VI) reduces RAD51
whole cell protein expression. This figure shows (A) representative
western blot images of whole cell RAD51 and (B) RAD51 whole cell
protein (relative to control) decreased with concentration and time
after 72 and 120 h, but not 24 h exposure. GAPDH was used as a
loading control. When comparing zinc chromate concentrations
between time points all concentrations were statistically significant
(p<0.01) between 24 and 72 h or 24 and 120 h exposure. Data
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represent the mean of three experiments. Error bars = standard error
of the mean. Statistically different from the control: *p<0.05;
***p<0.0001.
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RAD51 protein reduction after particulate Cr(VI) exposure could be due to
an increase in protein degradation. One component of assessing protein
degradation is protein half-life. To assess if Cr(VI) affects RAD51 protein half-life
cells were treated with 0 or 0.2 ug/cm 2 zinc chromate for 24 or 120 h and at the
end of treatment a protein translation inhibitor, cycloheximide (CHX), was added
and a 12 h time course was performed to harvest protein. Figure 3.3A shows a
representative western blot for RAD51 whole cell protein after 24 or 120 h zinc
chromate exposure and a 12 h CHX treatment time course. RAD51 whole cell
protein levels decreased significantly beginning at 4 h after the addition of CHX
after 24 h 0 and 0.2 ug/cm2 zinc chromate exposure compared to the 0 h time point
(Figure 3.3B). RAD51 protein was significantly reduced 4 and 6 h hours after the
addition of CHX in 0 and 0.2 ug/cm 2 zinc chromate treated cells, respectively
(Figure 3.3C). There was no difference in RAD51 protein half-life comparing 0.2
ug/cm2 zinc chromate to the control or between exposure time points. Table 3.2
shows the calculated half-life of RAD51 after 24 or 120 h zinc chromate exposure
compared to the controls and confirms Cr(VI) has little effect on RAD51 protein
half-life.
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Figure 3.3. Particulate Cr(VI) has little effect on RAD51 protein halflife. This figure shows (A) representative images of RAD51 whole cell
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protein (relative to the 0 h CHX control for either the 0 or 0.2 ug/cm 2
zinc chromate condition) after 24 and 120 h zinc chromate exposure
and 12 h CHX exposure. Data represent the mean of three
experiments. Error bars = standard error of the mean. Exposure to
(B) 24 and (C) 120 h zinc chromate has little effect on RAD51 protein
half-life. GAPDH was used as a loading control. RAD51 whole cell
protein significantly decreased compared to 0 h CHX following the
addition of CHX in all conditions. Statistically different compared to 0
h CHX: **p<0.01; ***p<0.0001.
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Table 3.2. RAD51 protein half-life
Zinc chromate
conc. (ug/cm2)

24 h

120 h

0

5.17 h

5.59 h

0.2

4.35 h

5.92 h

Table 3.2. shows RAD51 protein half-life in hours after 24 or 120 h
exposure to 0 or 0.2 ug/cm2 zinc chromate.
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The RAD51 protein half-life data indicates protein degradation is not
significantly contributing to the reduction of RAD51 protein observed after
prolonged particulate Cr(VI) exposure suggesting the effect is on protein
production. To test this possibility, we measured RAD51 mRNA levels using qPCR.
Particulate Cr(VI) inhibited RAD51 mRNA moderately after 24 h 0.1, 0.2, and 0.3
ug/cm2 zinc chromate exposure to 83, 73, and 62% compared to control although
none were significant (Figure 3.4). Prolonged exposure of 72 and 120 h 0.1, 0.2
and 0.3 ug/cm2 zinc chromate reduced RAD51 mRNA to 49, 31, and 16% and 53,
21 and 24% of control, respectively. After prolonged exposure of both 72 and 120
h RAD51 mRNA was significantly reduced at all concentrations compared to
control and compared to the respective concentration after 24 h exposure.
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Relative RAD51 mRNA Expression
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Figure 3.4. Particulate Cr(VI) inhibits RAD51 mRNA. This figure
shows after prolonged 72 and 120 h exposure zinc chromate inhibits
RAD51 mRNA levels. GAPD was used to normalize RAD51 mRNA
levels. RAD51 mRNA level was significantly reduced at all
concentrations after 72 and 120 h exposure compared to control
(*p<0.05; ***p<0.0001). RAD51 mRNA at all zinc chromate-treated
concentrations was significantly decreased after 72 and 120 h
compared to the respective concentration at 24 h exposure. Data
represent the mean of three experiments. Error bars = standard error
of the mean.
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Objective 2: Particulate Cr(VI) inhibits E2F1 expression
The combination of protein half-life and qPCR data suggests the reduction
of RAD51 protein following particulate Cr(VI) exposure is primarily a result of
inhibited transcription. We sought to further investigate how Cr(VI) inhibits RAD51
expression. We chose to focus on E2F1, the predominant transcription factor for
RAD51, to assess how particulate Cr(VI) exposure affects E2F1 expression.
Figure 3.5A shows representative E2F1 whole cell western blots. Similar to the
effects on RAD51, particulate Cr(VI) did not affect E2F1 whole cell protein levels
after 24 h exposure (84, 103 and 88% of control), but decreased levels to 57, 48,
and 41% and 43, 47, and 55 % after 72 and 120 h 0.1, 0.2, and 0.3 ug/cm 2 zinc
chromate exposure, respectively (Figure 3.5B). E2F1 whole cell protein was
decreased significantly compared to the control after 72 h 0.3 ug/cm 2 and 120 h
0.1 ug/cm2 zinc chromate, however all zinc chromate treated concentrations are
clearly repressed compared to control at these time points.
E2F1 self-regulates its own transcription and we found prolonged
particulate Cr(VI) exposure inhibits E2F1 protein expression (Johnson et al., 1994).
We tested if particulate Cr(VI) inhibits E2F1 mRNA levels using qPCR following
particulate Cr(VI) exposure. Particulate Cr(VI) inhibited E2F1 mRNA levels after
24, 72, and 120 h exposure (Figure 3.6). After 24 h E2F1 mRNA was reduced to
82, 55, and 56% of control following 0.1, 0.2, and 0.3 ug/cm 2 zinc chromate, and
further decreased to 45, 28, and 18% of control after 72 and h. E2F1 mRNA
remained low after 120 h decreasing to 55, 26, and 36% of control. At all time
points each concentration was significantly decreased compared to control except
24h 0.1 ug/cm2 zinc chromate. All concentrations after prolonged exposure of 72
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and 120 h were significantly decreased compared to the respective acute 24 h
concentration.
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Figure 3.5. Prolonged particulate Cr(VI) inhibits E2F1 whole cell
protein. This figure shows E2F1 whole cell protein is reduces after
prolonged 72 and 120 h exposure to zinc chromate. Data represent
the mean of three experiments. Error bars = standard error of the
mean. (A) Representative images of E2F1 whole cell protein western
blots. GAPDH was used as a loading control. (B) E2F1 whole cell
protein (relative to control). Statistically significant compared to
control: *p<0.05.
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Figure 3.6. Particulate Cr(VI) inhibits E2F1 mRNA levels. This figure
shows 24, 72 and 120 h zinc chromate exposure inhibits E2F1
mRNA levels. GAPD was used as to normalize E2F1 mRNA levels.
E2F1 mRNA level was significantly reduced at all concentrations
compared to control except 24 h 0.1 ug/cm 2 zinc chromate
(***p<0.0001).
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concentrations was significantly decreased after 72 and 120 h
compared to the respective concentration at 24 h exposure. Data
represent the mean of three experiments. Error bars = standard error
of the mean.
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Objective 3: E2F1 overexpression does not rescue Cr(VI)-induced RAD51
failure
Particulate Cr(VI) induces a normal RAD51 response after acute 24 h
exposure and an abnormal response after 120 h exposure characterized by
inhibited protein expression and RAD51 nuclear foci formation and increased
RAD51 cytoplasmic accumulation (Browning et al., 2016; Qin et al., 2014). Here,
we show particulate Cr(VI) inhibits RAD51 mRNA indicating RAD51 expression
specifically is impaired following exposure (Figure 3.4). We also showed the
expression of the predominant transcription factor for RAD51, E2F1, was also
suppressed following particulate Cr(VI) exposure (Figure 3.6). Therefore, we
wanted to connect the correlating data between RAD51 and E2F1 impairment
following particulate Cr(VI) exposure. We sought to determine if overexpression of
E2F1 could offset the Cr(VI-reduced E2E1 protein levels to rescue Cr(VI)-induced
RAD51 failure after 120 h exposure. To test this connection, cells were treated with
zinc chromate for 120 h. For the last 48 h of exposure cells were transfected with
either a plasmid vector control (CMV500) or E2F1 overexpression plasmid. At
harvest, cells were collected for protein or fixed for immunofluorescence staining.
Figure 3.7 shows E2F1 was successfully transfected into WTHBF-6 cells. After
120 h exposure to 0 and 0.2 ug/cm2 zinc chromate E2F1 protein was 6220 and
5630 percent of the untransfected control.
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Figure 3.7. Transfection with E2F1 overexpression plasmid
increases E2F1 whole cell protein. This figure shows E2F1 protein
increases following transfection with E2F1 overexpression plasmid
compared to untransfected cells and the transfection control plasmid
(CMV500). E2F1 protein was normalized to GAPDH as a loading
control. Data represent the mean of two experiments. Error bars =
standard error of the mean.

83

RAD51 cytoplasmic accumulation is a key phenotype observed after
prolonged exposure to particulate Cr(VI), however, the function of RAD51 is in the
nucleus. (Browning et al., 2016; Qin et al. ,2014). The mislocalization of RAD51 in
the cytoplasm may inhibit RAD51 from participating in homologous recombination
repair. We used immunofluorescence staining and confocal microscopy to analyze
RAD51 cytoplasmic accumulation following 120 h particulate chromium exposure
and E2F1 overexpression.
Figure 3.8A shows representative images of WTHBF-6 cells exposed to 120
h 0 or 0.2 ug/cm2 zinc chromate with or without transfection. Cells were considered
positive for cytoplasmic accumulation if the cytoplasmic intensity was greater than
95% of control cells. All conditions were compared to the untransfected 0 ug/cm 2
zinc chromate control. Following 120 h exposure to 0.2 ug/cm2 zinc chromate 43%
of cells were positive for RAD51 cytoplasmic accumulation consistent with
previously published data (Browning et al., 2016)(Figure 3.8B). If E2F1 rescued
particulate Cr(VI)-induced RAD51 cytoplasmic accumulation we would expect to
see lower cytoplasmic accumulation levels in the E2F1 overexpression-transfected
cells compared to the CMV500 transfection control. However, the percent of cells
with RAD51 cytoplasmic accumulation was decreased in both the CMV500 control
and E2F1-transfected cells. Additionally, there was no difference between control
and 0.2 ug/cm2 zinc chromate treated cells in either transfection condition. This
indicates the transfection procedure itself, not E2F1 overexpression caused the
reduction in RAD51 cytoplasmic accumulation after 120 h particulate Cr(VI)
exposure.
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Figure 3.8. E2F1 overexpression does not prevent particulate Cr(VI)induced RAD51 cytoplasmic accumulation. This figures shows E2F1
does not rescue particulate Cr(VI)-induced RAD51 cytoplasmic
accumulation. (A) Representative images of RAD51 subcellular
localization. The yellow arrow points to a cytoplasmic RAD51
aggregate. (B) Exposure to 120 h 0.2 ug/cm 2 zinc chromate induces
cytoplasmic accumulation of RAD51 in untransfected cells. However,
no cytoplasmic accumulation was observed in the CMV500
transfection control or E2F1 overexpression conditions. Data
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represent the mean of three experiments. Error bars = standard error
of the mean. No statistical significance was observed.
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RAD51 foci formation is an indicator of RAD51 function in homologous
recombination repair at double strand breaks. Previous studies show RAD51
nuclear foci formation is inhibited following prolonged but not acute exposure to
particulate Cr(VI) (Browning et al., 2016; Qin et al., 2014). We tested if E2F1
overexpression could rescue the loss of RAD51 nuclear foci following 120 h
exposure to particulate Cr(VI). The baseline level of RAD51 nuclear foci is set at
5% of cells with more than 10 foci per cell based on previous studies (Browning et
al., 2016; Qin et al., 2014). In untransfected cells we saw the expected response
finding RAD51 nuclear foci formation is inhibited after 120 h exposure to 0.2 ug/cm 2
zinc chromate consistent with our previous work (Browning et al., 2016; Qin et al.,
2014) (Figure 3.9). If E2F1 overexpression rescues particulate Cr(VI)-inhibited
RAD51 nuclear foci formation we would expect those levels to increase. However,
in both the CMV500 transfection control and E2F1-transfected cells, RAD51 foci
remain below baseline level.
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Figure 3.9. Particulate Cr(VI)-inhibited RAD51 nuclear foci is not
rescued by E2F1 overexpression. This figure shows after 120 h
particulate Cr(VI) exposure E2F1 overexpression does not increase
RAD51 nuclear foci formation. The untransfected control has
inhibited RAD51 nuclear foci formation following exposure to 0.2
ug/cm2 zinc chromate, and similar levels of RAD51 nuclear foci were
observed in the CMV500 transfection control and E2F1-transfected
cells. The horizontal dashed grey line at 5 percent of cells with more
than 10 RAD51 foci represents baseline levels normally observed in
untreated cells. Data represent the mean of three experiments. Error
bars = standard error of the mean. No statistical significance was
observed.
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The literature suggests the primary role of E2F1 in RAD51 regulation is
currently as a transcription factor for RAD51 expression. There may be many
mechanisms affecting the localization of RAD51 unrelated to E2F1. Although we
did not find E2F1 overexpression rescues Cr(VI)-induced RAD51 mislocalization
we wanted to test if RAD51 protein levels could be restored by overexpressing
E2F1 after 120 h particulate Cr(VI) exposure. Figure 3.10A shows representative
western blot images of E2F1 and RAD51 following 120 h exposure to 0.2 ug/cm 2
zinc chromate with or without transfection. In untransfected cells, particulate Cr(VI)
reduced RAD51 whole cell protein levels to 50% of control after 120 h exposure to
0.2 ug/cm2 zinc chromate consistent with our previous work (Browning et al., 2016;
Qin et al., 2014) (Figure 3.10B). However, E2F1 overexpression did not increase
RAD51 protein levels following 0 or 0.2 ug/cm 2 zinc chromate exposure. RAD51
protein increases slightly in E2F1-transfected cells compared to the CMV500
transfection control (40% to 60%, respectively) in 0 ug/cm 2 zinc chromate controls,
but there was no difference after exposure to 0.2 ug/cm 2 zinc chromate (both 30%
of control).
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Figure 3.10. E2F1 overexpression does not rescue particulate
Cr(VI)-inhibited RAD51 protein expression. This figure shows
RAD51 whole cell protein is inhibited following 120 h exposure to 0.2
ug/cm2 zinc chromate in untransfected cells and this phenotype is
not rescued by E2F1 overexpression. GAPDH was used as a loading
control. (A) Representative western blot images. (B) RAD51 whole
cell protein expression (all conditions are relative to the
untransfected 0 ug/cm2 zinc chromate control). Data represent the
mean of two experiments. Error bars = standard error of the mean.
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Objective 4: Loss of E2F1 does not induce RAD51 failure after acute 24 h
particulate Cr(VI) exposure
E2F1 overexpression did not rescue RAD51 failure following prolonged 120
h particulate Cr(VI) exposure. However, we also wanted to test the possible
connection by determining if knocking down E2F1 could inhibit RAD51 following
acute 24 h particulate Cr(VI) exposure to recapitulate the 120 h exposure
outcomes. RAD51 has a normal response following 24 h particulate Cr(VI)
exposure characterized by unaffected protein expression, and increased nuclear
localization, and foci formation at double strand breaks (Browning et al., 2016;
Tamblyn et al., 2009; Qin et al., 2014). Studies show loss of E2F1 results in
reduced RAD51 protein levels, nuclear foci formation and inhibited homologous
recombination repair (Chen et al., 2011; Choi and Kim, 2019; Wu et al., 2014). We
transfected cells with E2F1 siRNA for 48 h and treated with 0.2 ug/cm 2 zinc
chromate the last 24 h of the transfection. Cells were harvested for
immunofluorescence staining, protein, and RNA.
Figure 3.11 shows E2F1 was successfully knocked down following
transfection with four different E2F1 siRNAs after 24 h exposure to 0 and 0.2
ug/cm2 zinc chromate. This analysis was performed two ways. The observed
effects of the transfection procedure on E2F1 expression, all conditions were
normalized to the untransfected 0 ug/cm2 zinc chromate control. The transfection
procedure reduced E2F1 protein levels (60%) compared to the untransfected 0
ug/cm2 zinc chromate control (Figure 3.11A). However, 0.2 ug/cm 2 zinc chromate
reduced E2F1 expression to 70% in both the untransfected and non-targeting
siRNA control compared to 0 ug/cm 2 zinc chromate, respectively (Figure 3.11A91

B). This reduction is the result we would expect after 24 h particulate Cr(VI)
exposure. E2F1 protein was decreased significantly in all E2F1 siRNA conditions
compared to the untransfected and non-targeting siRNA control. E2F1 was
knocked down to 30% or less compared to the non-targeting control.
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Figure 3.11. Knockdown of E2F1 inhibits E2F1 protein levels. This
figure shows E2F1 knockdown for 48 h leads to reduced E2F1
protein levels. Data represent the mean of at least 5 experiments.
Error bars = standard error of the mean. (A) E2F1 whole cell protein
levels relative to the 0 ug/cm2 zinc chromate untransfected control.
E2F1 decreased significantly after 0.2 ug/cm 2 zinc chromate
compared to 0 ug/cm2 zinc chromate in both the untransfected and
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non-targeting

siRNA

conditions

(***p<0.0001),

however,

no

difference in this comparison was observed in E2F1 siRNA
conditions. E2F1 levels were significantly decreased in all E2F1
siRNA conditions compared to the untransfected and non-targeting
siRNA control (#p<.0.0001) (B) E2F1 protein levels relative to the 0
ug/cm2 zinc chromate non-targeting siRNA control. E2F1 decreased
in all E2F1 siRNA conditions compared to the non-targeting siRNA
control.
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We analyzed RAD51 cytoplasmic accumulation after E2F1 knockdown and
24 h particulate Cr(VI) exposure. The same measures used in the E2F1
overexpression experiments for RAD51 cytoplasmic accumulation were applied.
After 24 h particulate Cr(VI) exposure we would expect a normal RAD51 response
and no increase in RAD51 cytoplasmic accumulation in untransfected cells. This
outcome is confirmed in the results which show 0.2 ug/cm 2 zinc chromate control
did not increase RAD51 cytoplasmic accumulation in the untransfected control
(Figure 3.12). We also observed no increase in RAD51 cytoplasmic accumulation
in the E2F1 knockdown conditions after either 0 ug/cm 2 or 0.2 ug/cm2 zinc
chromate exposure. The highest level of RAD51 cytoplasmic accumulation in any
condition was 12% compared to 4% in the control (Figure 3.12) and 43%, which
was observed in untransfected cells exposed to 120 h 0.2 ug/cm 2 zinc chromate
(Figure 3.8).
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Figure 3.12. E2F1 knockdown does not induce RAD51 cytoplasmic
accumulation after 24 h particulate Cr(VI) exposure. This figure
shows RAD51 cytoplasmic accumulation did not increase following
E2F1 knockdown and 24 h particulate Cr(VI) exposure. Data
represent the mean of three experiments for all conditions (E2F1 #9
and #10; n=1). Error bars = standard error of the mean. No statistical
significance was observed.
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Since E2F1 knockdown did not induce cytoplasmic accumulation of RAD51,
RAD51 protein may still be available in the nucleus to form foci at DNA double
strand breaks. We measured RAD51 nuclear foci after E2F1 knockdown and 24 h
particulate Cr(VI) exposure to test this possibility. Exposure to 24 h 0.2 ug/cm2 zinc
chromate increased RAD51 foci in all conditions (Figure 3.13). These increases
were significant in the untransfected and non-targeting siRNA control (21 and 26%
of cells, respectively), and these results are consistent with our previous work
(Browning et al., 2016; Qin et al., 2014). One of the four E2F1 siRNA conditions
also had a significant increase in RAD51 foci (E2F1 #10, 15% of cells). There was
no difference in RAD51 foci level in cells with no zinc chromate exposure across
all conditions. This outcome is expected because untreated RAD51 foci levels are
already below baseline level and without a stimulus to induce RAD51 foci formation
no change would be observable. However, when comparing RAD51 foci levels
after 0.2 ug/cm2 zinc chromate exposure, the percent of cells with RAD51 foci was
significantly decreased in all E2F1 knockdown conditions (except E2F1 #10)
compared to the non-targeting siRNA control. These data indicate loss of E2F1
inhibited RAD51 foci formation after acute 24 h particulate Cr(VI) exposure.
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Figure 3.13. E2F1 knockdown decreases RAD51 nuclear foci after
acute particulate Cr(VI) exposure. This figure shows the percent of
cells with more than 10 RAD51 foci per cell following 24 h particulate
Cr(VI) exposure and E2F1 knockdown (untransfected 0 ug/cm 2 zinc
chromate controls subtracted). Exposure to 24 h 0.2 ug/cm 2 zinc
chromate significantly increased RAD51 foci in the untransfected
and non-targeting siRNA controls and the E2F1 #10 siRNA condition
(*p<0.05; ***p,0.0001). RAD51 foci were significantly decreased in
all E2F1 siRNA conditions (except E2F1 #10) after exposure to 0.2
ug/cm2 zinc chromate compared to the non-targeting siRNA control
(#p<0.05). Data represent the mean of at least 3 experiments (E2F1
#11 and 12; n=2). Error bars = standard error of the mean.
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We are proposing E2F1’s transcription factor function would inhibit RAD51
expression. Less RAD51 protein may also explain the inhibited RAD51 nuclear foci
response to acute 24 h particulate Cr(VI) exposure after E2F1 knockdown. To
determine if RAD51 protein is suppressed following E2F1 knockdown and acute
24 h particulate Cr(VI) exposure we measured RAD51 protein. Figure 3.14 shows
representative western blot images of E2F1 and RAD51 after E2F1 knockdown
and 24 h exposure to particulate Cr(VI). We assessed the effect of the transfection
on RAD51 protein expression and found while the transfection decreased RAD51
protein to 70% in the non-targeting siRNA condition compared to the untransfected
condition, it was not significant (Figure 3.14B). In the untransfected and nontargeting control we saw the expected result of no difference in RAD51 protein
level between 0 and 0.2 ug/cm 2 zinc chromate. When we compared the E2F1
knockdown conditions to the non-targeting siRNA control only E2F1 #9 reduced
RAD51 protein levels (50% of control), and only in the 0 ug/cm 2 zinc chromate
condition. These data indicate E2F1 knockdown does not affect RAD51 protein
levels.
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Figure 3.14. E2F1 knockdown does not inhibit RAD51 protein after
24 h particulate Cr(VI) exposure. This figure shows E2F1 knockdown
for 48 h does not affect RAD51 protein levels. Data represent the
mean of at least 5 experiments. Error bars = standard error of the
mean. (A) Representative image of E2F1 and RAD51 western blots.
(B) RAD51 whole cell protein levels relative to the 0 ug/cm 2 zinc
chromate untransfected control. There was no change in RAD51
protein level between 0 and 0.2 ug/cm 2 zinc chromate in any of the
conditions. RAD51 protein was decreased to 70% in the nontargeting siRNA control compared to the untransfected control, but
this was not significant. (C) RAD51 protein levels relative to the 0
ug/cm2 zinc chromate non-targeting siRNA control. RAD51 protein
level only decreased in one E2F1 siRNA condition (E2F1 #9;
***p<0.001) compared to the non-targeting siRNA control, and only
in the 0 ug/cm2 zinc chromate condition.
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It is possible E2F1 knockdown inhibits RAD51 transcription, but not protein
levels. To test this possibility, we determined the effect of E2F1 knockdown on
RAD51 mRNA levels using qPCR. We confirmed E2F1 knockdown inhibits E2F1
mRNA (Figure 3.15A). E2F1 mRNA was significantly inhibited in all E2F1
knockdown conditions compared to the non-targeting siRNA control except E2F1
#10 after 0.2 ug/cm2 zinc chromate exposure. Exposure to 24 h 0.2 ug/cm 2 zinc
chromate also decreased E2F1 mRNA in all conditions, although only significantly
in the untransfected control. The E2F1 mRNA reduction is consistent with our
previous results (Figure 3.6).
Next, we evaluated RAD51 mRNA levels following E2F1 knockdown. Figure
3.15B shows RAD51 mRNA is decreased by 24 h exposure to 0.2 ug/cm 2 zinc
chromate however, none of the changes in these levels are significant. For
example, 0.2 ug/cm2 zinc chromate reduced RAD51 mRNA to 64% compared to
control similar to our previous experiments evaluating RAD51 mRNA after
particulate Cr(VI) exposure (Figure 3.4). RAD51 mRNA was reduced by E2F1
siRNA #9 compared to the non-targeting control, but this reduction was not
significant. E2F1 #10 increased RAD51 mRNA slightly compared to the nontargeting control.
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Figure 3.15. E2F1 knockdown does not consistently RAD51 mRNA
expression. This figure shows E2F1 knockdown does not inhibit
RAD51 mRNA expression after acute 24 h particulate Cr(VI)
exposure. Data represent the mean of three experiments. Error bars
= standard error of the mean. (A) E2F1 mRNA were successfully
reduced following E2F1 knockdown (#p<0.05). Particulate Cr(VI)
reduced E2F1 mRNA levels in all conditions, but was only significant
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in the untransfected control (***p<0.0001). (B) RAD51 mRNA was
unaffected by 0.2 ug/cm2 zinc chromate exposure or E2F1
knockdown. GAPD was used as to normalize E2F1 and RAD51
mRNA levels.
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Alternative hypotheses for reduced RAD51 expression
The literature shows loss of E2F1 results in RAD51 impairment after
induction of DNA double strand breaks (Chen et al., 2011; Choi and Kim, 2019;
Wu et al., 2014). It is well known exposure to particulate Cr(VI) induces DNA
double strand breaks and the canonical repair of those breaks occurs through
homologous recombination (Bryant et al., 2006; Gastaldo et al., 2007; Helleday et
al., 2000; Stackpole et al., 2007). However, the data in objective 3 and 4 indicate
E2F1 does not modulate the RAD51 response to particulate Cr(VI). We began to
develop alternative hypotheses that may explain this outcome. Although we
showed E2F1 whole cell protein was significantly inhibited following prolonged
exposure to particulate Cr(VI) it is possible in this case available protein is
accumulated in the nucleus in order to preserve critical functions. Therefore, we
measured E2F1 nuclear protein levels following particulate Cr(VI) exposure.
Figure 3.16A shows representative western lots of E2F1 nuclear protein.
Particulate Cr(VI) had no effect on E2F1 nuclear protein levels after 24, 72, or 120
h exposure. For example, exposure to 0.2 ug/cm 2 zinc chromate resulted in
nuclear E2F1 protein levels of 94, 92, and 65 % of control after 24, 72, and 120 h,
respectively. E2F1 nuclear protein decreased with concentration after 120 h
exposure resulting in 85, 65, and 55 % of control following 0.1, 0.2, 0.3 ug/cm2 zinc
chromate, however these levels were not significant compared to control or each
other. These data suggest although total levels of E2F1 are significantly
suppressed following exposure to prolonged particulate Cr(VI) the levels of E2F1
protein remaining are sequestered in the nucleus.
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Figure 3.16. Particulate Cr(VI) does not affect E2F1 nuclear protein
levels. This figure shows E2F1 nuclear protein is unaffected by
exposure to particulate Cr(VI). (A) Representative western blots of
E2F1 nuclear protein. (B) E2F1 nuclear protein levels (relative to
control) are unaffected following exposure to 24, 72, and 120 h
particulate Cr(VI). H3 was used as loading control. Data represent
the mean of three experiments. Error bars = standard error of the
mean. No statistical significance was observed.
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RAD51 expression is tightly regulated by a balance of transcriptional
activators and repressors. We wanted to investigate if other transcription factors
involved in RAD51 expression were affected by particulate Cr(VI) exposure. We
considered another transcriptional activator of RAD51 transcription, EGR1. Figure
3.17A shows representative western blots of whole cell EGR1 protein. EGR1
whole cell protein is unaffected by acute 24 h exposure to particulate Cr(VI) but
decreases after 120 h exposure with concentration (Figure 3.17). For example,
EGR1 protein is only reduced to 87% of control after 24 h exposure to 0.3 ug/cm 2
zinc chromate but to 81, 76, 65% of control after 120 h exposure to 0.1, 0.2 and
0.2 ug/cm2 zinc chromate; these levels are not significant. These data indicate
another activator of RAD51 expression is suppressed following prolonged
particulate Cr(VI) exposure.
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Figure 3.17. Prolonged particulate Cr(VI) exposure decreases EGR1
whole cell protein expression. This figure shows prolonged 120 h
exposure to particulate Cr(VI) decreases whole cell EGR1 protein
(relative to control). (A) Representative western blot images of whole
cell EGR1 protein. (B) EGR1 whole cell protein expression after
acute 24 and prolonged 120 h exposure to particulate Cr(VI)
exposure. GAPDH was used as a loading control. Data represent the
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mean of three experiments. Error bars = standard error of the mean.
No statistical significance was observed.
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Loss of the tumor suppressor p53 is commonly associated with
carcinogenic mechanisms (Hamadeh et al., 1999; Shen et al., 2008; Wang, 1999).
As previously mentioned p53 suppresses RAD51 transcription through at least two
mechanisms. It indirectly suppresses RAD51 through the DREAM complex
(Engeland et al., 2018). Second, p53 can directly bind to the RAD51 promoter
repressing transcription (Hine et al., 2014; Arias-Lopez et al., 2005; Hannay et al.,
2007). We measured total p53 and phospho-p53 (Ser15), which indicates p53
stabilization associated with DNA damage (Canman et al., 1997; Shieh et al.,
1997). Figure 3.18A shows representative of p53 western blots. Particulate Cr(VI)
exposure increased total p53 expression after 24 h exposure and decreased
expression after 120 h exposure (Figure 13.18B). For example, 24 h exposure to
0.1, 0.2, and 0.3 ug/cm2 zinc chromate increased p53 total protein to 114, 139, and
144% of control while 120 h reduced total p53 protein to 92, 79, and 69% of control.
Neither the increase after 24 h nor the decrease after 120 h exposure were
significant compared to control. Figure 3.18C shows while particulate Cr(VI)
slightly alters total p53, phospho-p53 (Ser15) is unaffected. For example, 0.2
ug/cm2 zinc chromate altered p-p53 protein to 107 and 77% of control after 24 and
120 h, respectively. These data suggest p53 stabilization is unaffected by
particulate Cr(VI) exposure, and the minimal effect of Cr(VI) on p53 may not be a
major contributor to the reduction of RAD51 expression.
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Figure 3.18. Particulate Cr(VI) does not affect p53. This figure shows
particulate Cr(VI) exposure does not affect p53 or phospho-p53. (A)
Representative western blot images of total p53 and phospho-p53
(Ser15). (B) Particulate Cr(VI) modulates total p53 levels differently
after 24 and 120 h exposure, however no statistical significance was
observed. (B) Phospho-p53 (Ser15) was unaffected by exposure to
acute 24 h or prolonged 120 h exposure to particulate Cr(VI). No
statistical significance was observed. GAPDH was used as a loading
control. Data represent the mean of four experiments. Error bars =
standard error of the mean.
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One mechanism of p53 repression of RAD51 expression is through the
DREAM complex. We found p53 was not inhibited significantly by particulate Cr(VI)
exposure. Downstream of p53 in the DREAM pathway p130 binds with E2F4
resulting in repressed transcription (Engeland et al., 2018). Hypo-phosphorylation
of p130 facilitates p130 binding E2F4, and this process is mediated by p53. We
assessed total and phospho-p130 expression following particulate Cr(VI)
exposure.
Figure 3.19 shows representative western blot images of total and phosphop130. Particulate Cr(VI) decreased total p130 protein levels after 24 h and further
decreases after 120 h exposure (Figure 3.19B). For example, exposure to 0.2
ug/cm2 zinc chromate decreased total p130 protein levels to 85 and 51% of control
after 24 and 120 h, respectively. Although total p130 was decreased following
exposure to particulate Cr(VI) the hypo-phosphorylation of p130 facilitates its
binding with the transcriptional repressor E2F4. Therefore, we also measured
phospho-p130 levels following exposure to particulate Cr(VI). Figure 3.19C shows
exposure to particulate Cr(VI) reduces phospho-p130 after 24 and 120 h. For
example, exposure to 0.3 ug/cm2 zinc chromate reduces to 40 and 47% of control
after 24 and 120 h, respectively. These data indicate, of the total p130 available
after particulate Cr(VI) exposure less is phosphorylated.
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Figure 3.19. Particulate Cr(VI) decreases total and phospho-p130
protein levels. This figure shows particulate Cr(VI) inhibits total and
phospho-p130 whole cell protein levels. (A) Representative western
blot images of total and phospho-p130 whole cell protein. Particulate
Cr(VI) inhibits (B) p130 and (C) phospho-p130 after 24 h and further
after 120 h exposure. GAPDH was used a loading control. Data
represent the mean of two experiments. Error bars = standard error
of the mean.
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Less phosphorylation increases the interaction of p130 with E2F4. E2F4 is
a repressive transcription factor that directly competes with E2F1 for the same
binding site at the RAD51 promoter. To begin to test if E2F4-induced suppression
may play a role in the repression of E2F1-mediated transcription we measured
E2F4 protein levels following particulate Cr(VI) exposure. Figure 3.20 shows
representative western blots of E2F4 whole cell protein. Particulate Cr(VI) had no
effect on E2F4 protein level after 24 or 120 h exposure. For example, E2F4 levels
after 0.3 ug/cm2 zinc chromate were 104 and 110% of control (Figure 3.20B).
These data show while exposure to particulate Cr(VI) inhibits E2F1 protein after
prolonged exposure (Figure 3.5) E2F4 protein levels are unaffected. Engeland et
al 2018 suggests the balance of activating E2F1 and repressive E2F4 controls
expression. Specifically, Bindra et al., 2007 showed E2F1 and E2F4 compete for
the same binding sequence on the RAD51 promoter. We looked at the ratio of
E2F4 to E2F1 after acute and prolonged particulate Cr(VI) exposure. Figure 3.20C
shows after 24 h there is no change in the ratio of E2F4 to E2F1, however, after
120 h exposure the ratio increases. These data indicate the increase in the ratio
of E2F4 to E2F1 after prolonged exposure to particulate Cr(VI) may inhibit E2F1mediated expression of RAD51.
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Figure 3.20. Particulate Cr(VI) increases the ratio of E2F4 to E2F1.
This figure shows particulate Cr(VI) does not affect E2F4 protein
levels after particulate Cr(VI) exposure, but increases the ratio of
E2F4 to E2F1 after prolonged exposure. Data represent the mean of
three experiments. Error bars = standard error of the mean. (A)
Representative western blot images of E2F4. (B) E2F4 whole cell
protein levels (relative to control) are unaffected by acute 24 or
prolonged 120 h exposure to particulate Cr(VI). GAPDH was used
as a loading control. No statistical significance was observed. (C)
The ratio of E2F4 to E2F1 increases after exposure to 120 h
particulate Cr(VI).
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Summary
In this Aim, we show the reduction in RAD51 protein after particulate Cr(VI)
exposure is primarily a result of decreased transcription. We found RAD51 mRNA
levels begin to decrease after 24 h exposure to particulate Cr(VI) and further
decrease after 72 and 120 h. However, we did not find any considerable difference
in RAD51 protein half-life after 24 or 120 h exposure. Considering the reduction of
RAD51 protein is due to a transcriptional issue we investigated the effects of
particulate Cr(VI) on E2F1, the predominant transcription factor for RAD51. We
found particulate Cr(VI) decreased E2F1 whole cell protein levels after prolonged
72 and 120 h exposure, and mRNA decreased beginning after 24 h and continued
to decrease after 72 and 120 h.
To connect the loss of E2F1 and RAD51 after particulate Cr(VI) exposure
we tested if overexpressing E2F1 could rescue RAD51 failure induced by
prolonged particulate Cr(VI) exposure. We analyzed three endpoints to assess
RAD51 failure: RAD51 cytoplasmic accumulation, nuclear foci formation, and
RAD51 whole cell protein expression. We found E2F1 overexpression did not
inhibit RAD51 cytoplasmic accumulation or restore RAD51 nuclear foci and protein
levels after prolonged particulate Cr(VI) exposure.
We also tried to confirm the connection by recapitulating 120 exposure
outcomes after 24 h exposure. We knocked down E2F1 after acute particulate
Cr(VI) exposure to test if loss of E2F1 could inhibit the RAD51 response to
particulate Cr(VI) when the RAD51 response is usually normal. We found loss of
E2F1 did not induce RAD51 cytoplasmic accumulation and did not reduce RAD51
protein or mRNA levels after acute particulate Cr(VI) exposure and so E2F1
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inhibition did not recapitulate most 120 h exposure outcomes. However, we did
find loss of E2F1 inhibited RAD51 foci formation after 24 h particulate Cr(VI)
exposure when foci formation usually increases.
We demonstrated the reduction of RAD51 protein is due to a transcriptional
issue, however, RAD51 expression was not modulated by E2F1 in response to
particulate Cr(VI). Therefore, we explored alternative hypotheses. While
particulate Cr(VI) knocked down E2F1 whole cell protein we found nuclear protein
was unaffected potentially explaining the results of our E2F1 overexpression and
knockdown experiments. We also assessed how other mediators of RAD51
transcription were affected by particulate Cr(VI) exposure. The transcriptional
activator, EGR1, was slightly decreased by particulate Cr(VI) exposure after 24 h
exposure and further decreased after 120 h exposure. The transcriptional
repressor p53 increased slightly after 24 h and decreased after 120 h exposure,
however, p53 stability was unaffected. Finally, we assessed the transcriptional
repressor, E2F4, and its binding partner p130 and found while p130 levels
decreased after particulate Cr(VI) exposure, phosphorylation also decreased.
E2F4 protein was unaffected by particulate Cr(VI) exposure, and this resulted in
an increase in the ratio of E2F4 to E2F1 following prolonged particulate Cr(VI)
exposure. This result, in part, may explain inhibited RAD51 expression following
prolonged particulate Cr(VI) exposure.

120

Aim 2: Identify particulate Cr(VI)-altered miRNAs involved in RAD51
regulation and homologous recombination repair
Background
Cr(VI) causes permanent-heritable phenotypes, but induces low rates of
mutations in key oncogenes and tumor suppressors (Ewis et al., 2001; Wetterhahn
and Hamilton, 1989; Katabami et al., 2000; Kondo et al., 1997; Wise et al., 2018).
Additionally, Cr(VI) is known to alter global gene expression, however, the
mechanisms of this effect are unknown (Andrew et al., 2003; Izzotti et al., 2002;
Ye and Shi, 2001). The field of Cr(VI) research is increasingly finding epigenetic
modifications may play a significant role in Cr(VI) carcinogenesis contributing to
the permanent-heritable phenotypes and global changes in gene expression
following Cr(VI) exposure (Rager et al., 2019).
Specifically related to our study, Cr(VI) has been shown to downregulate
expression of DNA repair genes (Andrew et al., 2003; Clancy et al., 2012, Wu et
al., 2012). Aim 1 shows RAD51 transcription is decreased following particulate
Cr(VI) exposure. Aim 1 also shows the primary transcription factor of RAD51,
E2F1, does not modulate RAD51 expression following particulate Cr(VI) exposure.
Additionally, while alternative transcription factors of RAD51 were investigated,
they cannot fully explain particulate Cr(VI)-inhibited RAD51 expression. Based on
these data and the general consensus from the literature that epigenetic
mechanisms play a role in altered gene expression and Cr(VI) carcinogenesis, we
investigated how miRNAs may play a role in inhibited RAD51.
miRNAs are short non-coding RNA sequences with an average 22 base
pairs in length. miRNAs are transcribed into primary-miRNA (pri-miRNA) and then
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exported out of the nucleus to the cytoplasm where they are processed to
precursor-miRNA (pre-miRNA) before finally being converted into mature miRNA
(O’Brien et al., 2018; Perron, 2008). Mature miRNAs target mRNA sequences to
regulate expression through the RNA-induced silencing complex (RISC)
(MacFarlane and Murphy, 2010). miRNAs usually target to the 3’ UTR site of
mRNA (Ha and Kim, 2014). The binding location on the mRNA transcript and the
homology of the sequence of the miRNA to the mRNA transcript play a role in the
effectiveness of the miRNA effect on either target degradation or translation
inhibition (Finnegan and Matzke, 2003; McGeary et al., 2019). For example,
miRNAs with perfect sequence matches in the 3’ UTR region of an mRNA
transcript leads to mRNA degradation (Rhoades et al., 2002). However, imperfect
matches have been shown to only inhibit translation of an mRNA transcript, which
may only delay the translation process, or have no effect (Martin et al., 2014;
Saxena et al., 2003). These, perfect and imperfect matches mostly refer to the
seed region of the 3’ UTR of an mRNA target. However, they can also bind to other
regions of the mRNA transcript contributing to the complexity of miRNA-mRNA
target analysis (Betel et al., 2010; Broughton et al., 2016).
Single miRNAs may target mRNA transcripts from many different genes,
and any given mRNA transcript may be regulated by many different miRNAs. It
has been challenging to determine how the balance of miRNAs may affect the
expression of specific genes. One approach to understanding how the altered
balance of miRNAs plays a role in gene expression is using RNAseq analysis.
RNAseq analysis provides global analysis of the expression of RNAs. Using
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RNAseq to evaluate miRNAs provides hypothesis-driving data about how miRNAs
may contribute to a pathogenic endpoint.
Studies have evaluated the effects of Cr(VI) exposure on limited miRNAs,
but none considered particulate Cr(VI) (Chandra et al., 2015; He et al., 2013; Li et
al., 2014; Li et al., 2016; Pratheeshkumar et al., 2017; Wang et al., 2019, Wang et
al., 2020; Zhang et al., 2020). Cr(VI)-altered miRNAs have specifically been linked
to DNA damage in cell culture and epidemiology studies (Chandra et al., 2016; Li
et al., 2014). For example, Li et al., 2014 found miR-3940-5p was associated with
genetic damage in the blood of workers exposed to Cr(VI).
To date, five studies have evaluated miRNAs in lung cells after Cr(VI)
exposure (He et al., 2013; Li et al., 2016; Pratheeshkumar et al., 2017; Wang et
al., 2019; Wang et al., 2020). However, only one evaluated miRNAs in relation to
DNA repair (Li et al., 2016). In general, there is very limited data available on the
effects of miRNAs on pathways of Cr(VI) carcinogenesis. This is partly due to the
fact only one genome-wide study has been done to evaluate Cr(VI)-altered miRNA
expression, and this was done in the radish plant (Raphanus sativus L.) (Liu et al.,
2015). No global expression data is available to evaluate Cr(VI) altered miRNAs in
humans, let alone in the lung, which is the primary target of Cr(VI) exposure.
In Aim 2 we performed a global analysis of miRNA expression using
RNAseq in human lung cells following particulate Cr(VI) exposure. We
characterized particulate Cr(VI)-altered miRNA expression patterns to assess how
particulate Cr(VI) up- or down-regulates miRNA expression (Objective 1). We are
specifically interested in how miRNAs affect pathways of Cr(VI) carcinogenesis.
We applied the RNAseq analysis of differentially expressed miRNAs to identify
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Cr(VI)-altered miRNAs involved in pathways of Cr(VI) carcinogenesis (Objective
2). To focus more closely on homologous recombination repair and RAD51 we
identified Cr(VI)-altered miRNAs that specifically regulate targets in the
homologous recombination pathway and RAD51 (Objective 3).
Results
Objective 1: Particulate Cr(VI) alters global expression of miRNAs
This is the first study to evaluate global miRNA expression after Cr(VI)
exposure in human cells. The primary target of particulate Cr(VI) exposure is the
lung. We evaluated how particulate Cr(VI) altered miRNA expression in human
lung cells after acute and prolonged exposures. Our first goal was to assess
changes in miRNA expression patters after particulate Cr(VI) exposure. In our
analysis, 956 unique miRNAs were identified across all conditions. Of these, table
3.4 shows the total number of significantly altered (adjusted p-value<0.01) miRNAs
affected by particulate Cr(VI) exposure. In Table 3.3 the numbers of upregulated
and downregulated miRNAs are included. In some conditions, a miRNA was only
expressed in a treated condition indicating that miRNA was ‘turned on’, or
alternatively a miRNA may only have been expressed in the control and therefore,
‘turned off’. miRNAs that were turned off or on are listed distinctly from the up- or
down-regulated miRNAs in Table 3.4 and combined together as another measure.
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Table 3.3 Distribution of significantly altered miRNAs by particulate Cr(VI)
exposure.
24h
Zinc Chromate
Concentration (ug/cm²)
Upregulated
Downregulated
Turned on
Turned off
Total upregulated
Total downregulated
Total altered

0.1

0.2
20
12
3
3
23
15
38

146
46
8
9
154
55
209

72h
0.3

0.1

63
46
2
1
65
47
112

0.2
17
69
2
1
19
70
89

17
99
2
1
19
100
119

120h
0.3
51
105
4
2
55
107
162

0.1
33
110
2
0
35
110
145

0.2
48
122
4
1
52
123
175

Table 3.3 shows the number of significantly (adjusted p-value<0.01)
up- or down-regulated miRNAs, the number of miRNAs turned on or
off, and the total for each (Total Upregulated = upregulated + turned
on; total downregulated = downregulated + turned off). For each
condition the total number of miRNAs significantly altered by
particulate Cr(VI) exposure is listed as the “Total altered” for each
column. Data represent the mean of three independent experiments
and four technical replicates.
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0.3
47
136
7
2
54
138
192

To determine trends in expression changes after particulate Cr(VI)
exposure we visualized the data in Table 3.3 as bar graphs in Figure 3.21. Figure
3.21A shows higher concentrations of particulate Cr(VI) increase the number of
upregulated miRNAs at all time points. However, there is a spike in upregulated
miRNA after 24 h exposure to 0.2 ug/cm 2 zinc chromate. Figure 3.14B shows the
number of downregulated miRNAs increase with time and concentration after
exposure to particulate Cr(VI). For example, exposure to 0.2 ug/cm 2 zinc chromate
resulted in a total of 55, 100, and 138 miRNAs downregulated after 24, 72 and 120
h exposure, respectively. It is also notable more miRNAs were downregulated
compared to those that were upregulated. For example, after 120 h exposure to
0.3 ug/cm

2

zinc chromate only 54 miRNAs were upregulated while 138 miRNAs

were downregulated. Downregulation of protein-coding gene expression is
associated with Cr(VI) exposure. These data show for the first time Cr(VI) also
downregulates global miRNA expression.
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Figure

3.21.

Particulate

Cr(VI)

exposure

increases

global

downregulation of miRNAs. This figure shows particulate Cr(VI)
significantly (adjusted p-value<0.01) upregulated or downregulated
miRNAs compared to control. Data represent the mean of three
independent experiments and four technical

replicates. (A)

Particulate Cr(VI) significantly upregulated miRNAs at all zinc
chromate concentrations compared to the control, though there was
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a spike after 24 h exposure to 0.2 ug/cm2 zinc chromate. (B)
Particulate Cr(VI) significantly downregulated miRNAs in a time-and
concentration-associated manner.
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We visualized these data using volcano plots to assess the distribution and
scattering of miRNAs according to two measures: significance and fold change. All
956 miRNAs were included in each analysis. The volcano plots visualize the
distribution of up- or -downregulated miRNAs, their significance, and whether the
fold change was greater than two (Figure 3.22). The fold change parameter was
set to provide some biological relevance to the changes in expression in this global
analysis. It is notable that under each condition there are miRNAs with a fold
change greater than 2 that did not reach our significance cut-off of an adjusted pvalue<0.01. In addition, there were also changes is expression that were
significant, but were less than 2-fold that are also not included. From these data
we can see the number of significantly up- or -downregulated miRNAs with a fold
change greater than two for each condition. These values are listed in table 3.4.
For example, 0.3 ug/cm2 zinc chromate resulted in 12, 18 and 45 miRNAs
downregulated and 14, 30 and 19 miRNAs upregulated after 24, 72, and 120 h
exposure, respectively.
These data are presented as bar graphs in Figure 3.23 to assess trends
across concentrations and time. There is a spike in significantly upregulated
miRNAs (fold change >2) after 24 h exposure to 0.2 ug/cm 2 zinc chromate, which
reflects the spike seen in all upregulated miRNAs under this condition (Figure
3.21). There is also a large increase in upregulated miRNAs after 72 h exposure
to 0.3 ug/cm2 zinc chromate (30 miRNAs) compared to 0.1 and 0.2 ug/cm 2 zinc
chromate, which only had 7 significantly upregulated miRNAs with a fold change
greater than 2 each. After 120 h the number of significantly upregulated miRNAs
with a fold change greater than 2 increases with concentration. For example, after
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0.1, 0.2 and 0.3 ug/cm2 zinc chromate 8, 17, and 19 miRNAs were upregulated,
respectively. Figure 3.21B shows particulate Cr(VI) increased the number of
downregulated miRNAs in a concentration and time-associated manner after
prolonged exposure (72 and 120 h) For example, 120 h exposure to 0.1, 0.2 and
0.3 ug/cm2 zinc chromate resulted in 15, 37 and 45 significantly downregulated
miRNAs (fold change >2), respectively. Notably, after 24 h exposure there was a
spike in significantly downregulated miRNAs (fold change >2) after 0.2 ug/cm 2 zinc
chromate (29 miRNAs) compared to 0.1 and 0.2 ug/cm 2 zinc chromate (11 and 12
miRNAs, respectively).
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Figure 3.22. Particulate Cr(VI) alters the expression of miRNAs. This
figure shows the -Log10(adjusted p-value) and Log2(fold change) of
all miRNAs identified in the RNAseq analysis after 24 h (A, B, C - 0.1,
0.2, and 0.3 ug/cm2 zinc chromate compared to control),
respectively, 72 h (D, E, F - 0.1, 0.2, and 0.3 ug/cm2 zinc chromate
compared to control, respectively), and 120 h (G, H, I - 0.1, 0.2, and
0.3 ug/cm2 zinc chromate compared to control, respectively). All
miRNAs above the grey horizontal grey dashed line were
significantly affected by particulate Cr(VI) exposure (adjusted p131

value<0.01). These miRNAs are signified by orange or red dots. All
miRNAs to the right of the vertical grey dashed line on the x-axis set
at 1 were upregulated with a fold change greater than 2. All miRNA
to the left of the vertical grey dashed line set at -1 were
downregulated with a fold change greater than 2. Data represent the
mean of three independent experiments and four technical
replicates.
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Table 3.4 Number of significantly up- or down-regulated miRNAs with a fold
change greater than 2 after particulate Cr(VI) exposure.
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Figure 3.23. miRNAs significantly altered by particulate Cr(VI) with a
fold change greater than 2. This figure shows particulate Cr(VI)
increases the number of miRNAs significantly up- or down-regulated
(adjusted p-value<0.01) with a fold change greater than 2 compared
to control. Data represent the mean of three independent
experiments and four technical replicates. (A) miRNAs upregulated
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by particulate Cr(VI) exposure relative to control. (B) miRNAs
downregulated by particulate Cr(VI) exposure relative to control.

135

This broad general view of particulate Cr(VI) altered miRNAs in Table 3.5
and Figure 3.23 does not indicate how many of the same miRNAs were affected
between conditions. To better understand the number of miRNAs upregulated or
downregulated by particulate Cr(VI) exposure across concentrations we visualized
the data using Venn diagrams. Each Venn diagram shows the crossover of
miRNAs significantly affected (either up- or down-regulated) by particulate Cr(VI)
within a time point (Figure 3.22). Very few of the same miRNAs were significantly
upregulated (fold change >2) in both the 0.1 and 0.3 ug/cm 2 zinc chromate
conditions at all time points. For example, no significantly upregulated miRNAs
were the same between 0.1 and 0.3 ug/cm 2 zinc chromate after 24 and 72 h,
respectively, and only 0 and 1 downregulated miRNAs were shared between these
two time points. However, after 120 h exposure there were 5 downregulated and
21 upregulated miRNAs shared between 0.2 and 0.3 ug/cm 2 zinc chromate,
respectively.
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Figure 3.24. Venn diagrams of up- and down-regulated miRNAs
across particulate Cr(VI) concentrations. This figure shows how
many miRNAs were significantly up- or down-regulated (fold change
>2) after particulate Cr(VI) exposure between concentrations
compared to control. Data represent the mean of three independent
experiments and four technical replicates. A, B, and C show Venn
diagrams of miRNAs upregulated by 0.1, 0.2 and 0.3 ug/cm 2 zinc
chromate after 24, 72, and 120 h exposure, respectively. D, E, and
F show Venn diagrams of miRNAs downregulated by 0.1, 0.2 and
0.3 ug/cm2 zinc chromate after 24, 72, and 120 h, respectively
compared to control.

137

To better understand how particulate Cr(VI) affected expression across
different miRNAs we generated heatmaps using fold change data. Figure 3.25
shows Euclidean hierarchical clustering of miRNAs after 24 (A), 72 (B), and 120 h
(C) exposure to particulate Cr(VI). These heatmaps cluster together miRNAs using
the Euclidean hierarchical model, which clusters units based on direct lines of
relatedness. In this case, the closer in color of the unit, the more similar the fold
change of the miRNA compared to the control. For example, after 120 h exposure
miR-200A, miR-194-1 and miR-194-2 clustered closely to one another and were
all significantly upregulated. We can see distinct clustering of up- or downregulated miRNAs in these heatmaps, but this clustering is especially prominent
after prolonged 72 and 120 h exposure where the top halves of the heatmaps are
almost exclusively orange (upregulated) and the bottom halves are almost
exclusively blue (downregulated). This distinction is less obvious after 24 h
exposure to particulate Cr(VI). The difference between the 24 h and 72 or 120 h
distinctions in clustering reflects our other data that show the 24 h response to
particulate Cr(VI) is different than the 72 and 120 h responses. Additionally, the
larger number of miRNAs in the 24 h heatmap shows more miRNAs were
significantly affected (fold change >2) than after 72 or 120 h exposure. However,
this likely reflects the spike of upregulated miRNAs after 24 h exposure to 0.2
ug/cm2 zinc chromate presented earlier (Figure 3.23). It is noteworthy that of the
large number of miRNAs in the 24 h heatmap many of them have light-colored
units (white correlating to a fold change of 0) indicating a low fold change in
expression. The heatmaps were also clustered using k-clustering to show
relatedness between miRNA expression changes. Figure 3.26 shows heatmaps of
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the miRNAs using Euclidean k-clustering. A k-cluster n = 3 was used in the
analysis, and clearly clusters the miRNAs by expression patterns. In Figure 3.26A
we can clearly see the distinction between miRNAs with higher fold change
patterns and those with low fold change. There is also a stronger distinction across
all the time points between the clusters of up- and down-regulated miRNAs. Similar
to the hierarchical clustering, the 72 and 120 h heatmaps are more distinct than
the 24 h heatmap.

139

140

Figure 3.25. Euclidean hierarchical clustering of miRNAs altered by
particulate Cr(VI) exposure. This figure shows hierarchical clustering
of significantly altered miRNAs after particulate Cr(VI) exposure
compared to control. Data represent the mean of three independent
experiments and four technical replicates. Clustering of miRNAs was
performed after 24 (A), 72 (B), and 120 h (C) exposure to particulate
Cr(VI). The average linkage method was applied. Data are
represented as fold change relative to control. miRNAs were
included if they were significantly affected (adjusted p-value<0.01,
fold change >2) in at least one condition for each individual time point
compared to control. Upregulated miRNAs are coded orange while
downregulated miRNAs are coded blue.
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Figure 3.26. K-clustering of miRNAs altered by particulate Cr(VI)
exposure. This figure shows the k-clustering of miRNAs significantly
affected by particulate Cr(VI) exposure compared to control. Data
represent the mean of three independent experiments and four
technical replicates. K-clustering of miRNAs was performed after 24
(A), 72 (B), and 120 h (C) exposure to particulate Cr(VI). The average
linkage method was applied. Data are represented as fold change
relative to control. miRNAs were included if they were significantly
affected (adjusted p-value<0.01, fold change >2) in at least one
condition for each individual time point. Upregulated miRNAs are
coded orange while downregulated miRNAs are coded blue. A kcluster of 3 was applied and grouped the miRNAs by red, orange, or
white for each distinct cluster.
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Objective 2: Particulate Cr(VI) alters miRNAs involved in pathways of Cr(VI)
carcinogenesis
The data in Objective 1 provide the first analysis of global miRNA
expression after Cr(VI) exposure in human cells. We found particulate Cr(VI)
increased the number of miRNAs significantly up- or down-regulated and identified
trends in the analyses. We are specifically interested in the role of miRNAs in
Cr(VI) carcinogenesis. While the global analysis is informative about trends of
Cr(VI)-altered miRNAs we wanted to know how they may be involved in the
mechanisms of Cr(VI) carcinogenesis. We performed a literature search for recent
review papers on Cr(VI) to identify pathways proposed to be involved in Cr(VI)
carcinogenesis. We identified 9 recent articles (Table 3.5) for this purpose.
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Table 3.5. Articles used to populate pathways of Cr(VI) carcinogenesis.
Paper Title

Citation

Molecular and epigenetic mechanisms of Cr(VI)-induced
carcinogenesis

Chen et al., 2019

Oxidative stress and metabolic reprogramming in Cr(VI)
carcinogenesis

Clementino et al., 2018

Mechanisms of chromium-induced toxicity

DesMarias and Costa, 2019

Imbalance of oxidative and reductive species involved in
chromium(VI)-induced toxic effects

Hu et al., 2017

Review of transcriptomic responses to hexavalent
chromium exposure in lung cells supports a role of
epigenetic mediators in carcinogenesis

Rager et al., 2019

Current status on chromium research and its implications
for health and risk assessment

Speer and Wise, 2018

Metal carcinogen exposure induces cancer stem cell-like
property through epigenetic reprograming: A novel
mechanism of metal carcinogenesis

Wang and Yang, 2019

Carcinogenicity of chromium and chemoprevention: a brief
update

Wang et al., 2017

Metal carcinogenesis and DNA damage: A case study
using hexavalent chromium

Wise and Wise, 2018
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We correlated the pathways of Cr(VI) carcinogenesis identified in the
literature with pathways in the KEGG database. We identified 5 networks and 13
sub-networks that pathways of Cr(VI) carcinogenesis applied to (Table 3.6). The 5
networks include 4 involved in cell mechanisms, and 1 related to human disease.
All the human disease sub-networks are related to cancer. Of those networks
related to cellular mechanisms, 3 are related to environmental information
processing, genetic information processing, and metabolism while one is related
to cellular processes. Upon looking at the sub-networks many are expectedly
associated

with

carcinogenesis

including

signaling

transduction,

energy

metabolism, and replication and repair. Thirty-six distinct KEGG pathways were
identified within these networks to be involved in Cr(VI) carcinogenesis. These are
presented in the data below.
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Table 3.6. KEGG networks of Cr(VI) carcinogenesis.
Network

Sub-Network

Cellular Processes

Cell growth and death

Environmental information processing

Transport and catabolism

Environmental information processing

Signal transduction

Environmental information processing

Signaling molecules and interactions

Genetic information processing

Folding, sorting, degradation

Genetic information processing

Replication and repair

Genetic information processing

Transcription

Metabolism

Carbohydrate metabolism

Metabolism

Energy Metabolism

Metabolism

Xenobiotics biodegradation and metabolism

Human disease

Cancer: overview

Human disease

Cancer: specific types

Human disease

Drug resistance: antineoplastic
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We populated lists of significantly up-or down-regulated miRNAs (fold
change >2) for each condition and uploaded them to the web-based analysis
system mirPath, which identified KEGG pathways affected by sets of miRNAs
(Vlachos et al .,2015). These pathways were then cross-referenced with the KEGG
pathways identified through our Cr(VI) literature search to determine how many
genes within a pathway was affected by particualte Cr(VI)-upregulated miRNAs
and how many miRNAs targeted each pathway. We focused on upregulated
miRNAs because upregulation of miRNAs leads to the downregulation of gene
expression. We partitioned the pathways by their relevance to one another
resulting in 4 groupings: Cancer related (Table 3.7A-B), signaling (Table 3.8A-B),
cellular processes (Table 3.9A-B), and DNA repair (Table 3.10A-B). We can see
the number of particulate Cr(VI)-upregulated miRNAs predicted to target pathways
of Cr(VI) carcinogenesis and the number of genes targeted increase with time or
concentration. For example, the number of predicted genes targeted by particulate
Cr(VI)-upregulated miRNAs in the pathways in cancer pathway are 64, 87, and 93
after 24, 72, and 120 h. In all these tables, we can see an increase after 24 h 0.2
ug/cm2 zinc chromate consistent with the earlier data showing a spike at under this
condition (Figure 3.23). Of all of the pathways involved in signaling the PI3K-AKT
pathway had the most predicted genes targeted by Cr(VI)-upregulated miRNAs.
Of the ‘cellular processes’ pathways, apoptosis, cell cycle, and ubiquitin-mediated
proteolysis were the most targeted. For example, 10, 20 and 23 genes in the cell
cycle pathway were predicted to be targeted by particulate Cr(VI)-upregulated
miRNAs after 0.3 ug/cm2 zinc chromate after 24 , 72, and 120 h, respectively. The
DNA repair pathways had similar numbers of genes predicted to be targeted by
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particulate Cr(VI)-upregulated miRNAs and the number of miRNAs that targeted
those pathways. For example, the fanconi anemia pathway, nucleotide excision
repair, and homologous recombination had 8, 7, and 5 genes predicted to be
targeted by particulate Cr(VI)-upregulated miRNAs, after 24 , 72, and 120 h
exposure to 0.3 ug/cm2 zinc chromate, respectively.
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Table 3.7A. Number of genes targeted by Cr(VI)-upregulated miRNAs in cancer
related pathways.

Table 3.7B. Number of Cr(VI)-upreguated miRNAs targeting genes in cancer
related pathways.

Table 3.8A. Number of genes targeted by Cr(VI)-upregulated miRNAs in signaling
pathways.
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Table 3.8B. Number of Cr(VI)-upreguated miRNAs targeting genes in signaling.

Table 3.9A. Number of genes targeted by Cr(VI)-upregulated miRNAs in cellular
processes pathways.

Table 3.9B. Number of Cr(VI)-upreguated miRNAs targeting genes in cellular
processes pathways.
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Table 3.10A. Number of genes targeted by Cr(VI)-upregulated miRNAs in DNA
repair pathways.

Table 3.10B. Number of Cr(VI)-upreguated miRNAs targeting genes in DNA
repair pathways.
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We compared how many genes were predicted to be targeted by particulate
Cr(VI) up- or down-regulated miRNAs using 0.3 ug/cm 2 zinc chromate as a
representative concentration (Figure 3.27). For most pathways the number of
genes predicted to be targeted by downregulated miRNAs was lower than the
number of genes predicted to be targeted by upregulated miRNAs (24h: 9 out of
29, 72h: 6 out of 29, 120h: 18 out of 29). The increase of genes predicted to be
targeted by particulate Cr(VI)-downregulated miRNAs after 120 h reflects the
global downregulation of miRNA expression induced by particulate Cr(VI)
exposure. It is noteworthy, although particulate Cr(VI) induces downregulation of
more miRNAs than those that are upregulated, genes in more pathways of Cr(VI)
carcinogenesis are targeted by particulate Cr(VI)-upregulated miRNAs.
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Figure 3.27. Comparison of the number of genes targeted by
particulate Cr(VI)-up or down-regulated miRNAs in pathways of
Cr(VI) carcinogenesis. This figure shows the number genes targeted
by up- or down-regulated miRNAs in pathways of Cr(VI)
carcinogenesis after exposure to 0.3 ug/cm2 zinc chromate
compared to control (adjusted p-value<0.01, fold change >2). Data
represent the mean of three independent experiments and four
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technical replicates. Genes targeted after 24 (A), 72 (h), and 120 h
(C) exposure to particulate Cr(VI) exposure are shown.
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Similarly, in Figure 3.28 we show the numbers of particulate Cr(VI) up- and
down-regulated miRNAs predicted to target genes in pathways of Cr(VI)
carcinogenesis. We found for most pathways the number of downregulated
miRNAs affected by particulate Cr(VI) exposure was relatively low after 24 h (10
out of 29 pathways) and 72 h (5 out of 29). However, after 120 h 24 out of 29
pathways had more miRNAs downregulated by particulate Cr(VI) exposure than
those that were upregulated. This accurately reflects the global downregulation of
miRNAs by particulate Cr(VI) exposure we showed earlier (Figure 3.23). After 120
h exposure to particulate Cr(VI) only the apoptosis, non-homologous end joining,
mismatch repair, and oxidative phosphorylation pathways had more miRNAs
upregulated than downregulated. It is notable after 24 and 72 h exposure the
number of upregulated miRNAs in the ubiquitin mediated proteolysis pathway is 6
and 7 times higher than the number of downregulated miRNAs in that pathway,
respectively (Figure 3.28A-B).
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Figure 3.28. Comparison of the number of particulate Cr(VI)-up or
down-regulated miRNAs targeting genes in pathways of Cr(VI)
carcinogenesis. This figure shows the number of up- or downregulated

miRNAs targeting

genes in

pathways

of

Cr(VI)

carcinogenesis after exposure to 0.3 ug/cm 2 zinc chromate
compared to control (adjusted p-value<0.01, fold change >2). Data
represent the mean of three independent experiments and four
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technical replicates. miRNAs altered after 24 (A), 72 (h), and 120 h
(C) exposure to particulate Cr(VI) exposure are shown.
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Objective 3: Particulate Cr(VI) alters miRNAs that target homologous
recombination and regulate RAD51 expression
In Objective 2 of Aim 2 we began to investigate Cr(VI)-altered miRNAs
involved in pathways of Cr(VI) carcinogenesis. To further narrow down the focus,
we wanted to look closer at how miRNAs significantly induced by particulate Cr(VI)
affect the homologous recombination pathway, and ultimately, RAD51. We further
analyzed the mirPath data correlating significantly particulate Cr(VI)-upregulated
miRNAs (fold change >2) with the KEGG pathway of homologous recombination.
For each particulate Cr(VI)-upregulated miRNA at each condition we identified
gene targets in the homologous recombination pathway. Table 3.11 shows the
specific particulate Cr(VI)-upregulated miRNAs and their predicted targets in the
homologous recombination pathway. Comparing across time points miRNAs
targeting RPA2 and RPA1 are upregulated. After 24 h exposure miRNAs predicted
to target XRCC3 were upregulated at all concentrations. Similarly, after 72 h
miRNAs predicted to target RPA1 and RPA2 were upregulated after 0.1 and 0.3
ug/cm2 zinc chromate (none were observed after 0.2 ug/cm 2 zinc chromate). After
120 h exposure miRNAs predicted to target RPA2 and RAD52 were upregulated
at all concentrations.
This breakdown also allows us to see which miRNAs were significantly
upregulated under all 9 of the conditions (3 time points and 3 concentrations). After
24 and 72 h no miRNAs were upregulated at all concentrations. However, after
120 h exposure miR-210-5p and miR-210-3p were upregulated at all
concentrations. miR-210-3p is also upregulated after 72 h exposure to 0.3 ug/cm 2
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zinc chromate, and miR-210-3p and miR-210-5p were upregulated after 24 h
exposure to 0.2 ug/cm2 zinc chromate.
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Table 3.11. Particulate Cr(VI)-upregulated miRNAs and their targets in the
homologous recombination pathway.

miRNAs found to
target pathway
miR-3064-5p
miR-3136-3p
miR-3193
miR-3689c
miR-4695-5p
miR-6824-5p
miR-6827-5p
miR-210-5p
miR-6789-3p
miR-7108-3p
miR-4786-3p
miR-6840-3p
miR-210-3p
miR-4642
miR-1913
miR-3665
miR-6089
miR-1275
miR-4497
miR-4634
miR-3195
miR-1538
miR-665
miR-3187-5p
miR-3657
miR-4472
miR-6087
miR-6881

24 h

72 h

0.1 ZC

0.1 ZC
miRNAs found to
target pathway
miR-6797-5p
miR-2276-5p
miR-6882-3p
0.2 ZC
None
0.3 ZC
miR-7109-5p
miR-210-5p
miR-7846-3p
miR-210-3p
miR-6089
miR-3195
miR-6087

Gene Targeted
XRCC3
RPA3
MUS81
RAD51B
0.2 ZC
XRCC2
RPA1
POLD4
RPA2
TOP3A
POLD1, XRCC3
POLD3
MRE11A
RAD52
BLM
RPA1, EME1, RPA2
TOP3A, TOP3B
TOP3A
MUS81
RAD51C
XRCC2
RAD51D
TOP3A, TOP3B, XRCC3
EME1, RAD51D
0.3 ZC
TOP3A
XRCC3, MRE11A
RPA1
RAD51C
BLM
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120 h
Gene
Targeted
RPA1
RPA2
RAD54B

RPA1
RPA2
RAD52
RAD52
TOP3A
RAD51D
RAD51C

0.1 ZC
miRNAs found to
target pathway Gene Targeted
miR-210-5p
RPA2
miR-210-3p
RAD52
0.2 ZC
miR-6880-5p
POLD3
miR-6880-3p
TOP3A
miR-210-5p
RPA2
miR-210-3p
RAD52
miR-1249-5p
RPA1
0.3 ZC
miR-6825-5p
RAD51B, SSBP1
miR-486-3p
POLD1
miR-210-5p
RPA2
miR-210-3p
RAD52

Regulators of RAD51 and RAD51 homologs were predicted to be targeted
by miRNAs significantly upregulated by particulate Cr(VI) exposure (fold change
>2). However, we did not want to overlook particulate Cr(VI)-upregulated miRNAs
predicted to target RAD51. In our next analysis we included all miRNAs
significantly upregulated by particulate Cr(VI) exposure (adjusted p-value<0.01).
We used an online database called mirSystem to identify miRNAs predicted to
target RAD51 (Lu et al., 2012). Using this platform, 126 miRNAs were identified
that target RAD51. Then we cross-referenced RAD51 targeting miRNAs with
significantly upregulated miRNAs in our RNAseq dataset. We found particulate
Cr(VI) upregulated 37 unique miRNAs out of the 126 that target RAD51. Figure
3.29 shows the total number of particulate Cr(VI) upregulated miRNAs that target
RAD51. We can see the number of particulate Cr(VI) upregulated miRNAs
increased to 24 and 14 after 24 h exposure after 0.2 and 0.3 ug/cm 2 zinc chromate,
respectively. After 72 h exposure to 0.3 ug/cm 2 zinc chromate there were 11
upregulated miRNAs that target RAD51 and this level remained elevated after 120
h exposure.
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Total Number of Upregulated
miRNAs Targeting RAD51

25

0.1 ug/cm² zinc chromate
0.2 ug/cm² zinc chromate
0.3 ug/cm² zinc chromate

20
15
10
5
0
24

72
Time (h)

120

Figure 3.29. Particulate Cr(VI) upregulates miRNAs that target
RAD51. This figure shows the number of significantly (adjusted pvalue<0.01) upregulated miRNAs that target RAD51 after particulate
Cr(VI) exposure compared to control. Upregulated miRNA targeting
RAD51 increase after 24, 72 and 120 h exposure. Data represent the
mean of three independent experiments and four technical
replicates.
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We considered each miRNA that targets RAD51 to see if there were any
trends in the upregulation across concentration or time. Figure 3.30 shows the
RAD51-targeting miRNAs and under each condition they were significantly
upregulated. Several miRNAs were significantly upregulated after 24 h exposure
to 0.2 and 0.3 ug/cm2 zinc chromate including miR-320a, miR-134-5p, miR-1365p, and miR-432-5p. miR-134-5p was also upregulated at all concentrations after
72 and 120 h exposure. miR432-5p and miR-194-5p were significantly upregulated
after 72h exposure to 0.2 and 0.3 ug/cm 2 zinc chromate and at all concentrations
after 120 h exposure. miR-26b-5p was significantly upregulated after 72 h
exposure to the highest concentration and the two highest concentrations after 120
h exposure. miR-411-5p and miR-30b-5p were significantly upregulated after both
72 and 120 h at the highest concentration. All these miRNAs show either a trend
in concentration or time and should be further considered in the regulation of
RAD51 expression after particulate Cr(VI) exposure.
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24 h

72 h

120 h

Figure 3.30. This figure shows trends in the fold change of
expression of miRNAs predicted to target RAD51 altered by
particulate Cr(VI) exposure. miRNAs were included if at least one
miRNA was significantly upregulated at any condition. The color
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scheme represents the Log2(fold change). Units with black boarders
represent conditions with significantly upregulated miRNAs.
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We find particulate Cr(VI) significantly upregulates miRNAs predicted to
target the RAD51 mRNA transcript. However, studies show the quality of the
binding between a miRNA and its target mRNA plays a role in the efficacy and fate
of these interactions (Martin et al., 2014; Rhoades et al., 2002; Saxena et al.,
2003). We evaluated the binding characteristics of the miRNAs predicted to target
RAD51 significantly upregulated by particulate Cr(VI) exposure. This analysis was
done using microRNA.org which is an online database that allows you to search
for an mRNA target and view the binding location, mirSVR score, and exact
nucleotide pairing of each miRNA that binds it. Table 3.13 shows the total number
of binding sites for each miRNA on the mRNA transcript, their mirSVR score, and
the number of nucleotides in the 3’ UTR region the miRNA had a perfect match to
on the RAD51 mRNA transcript. The mirSVR score is assigned based on a
regression model to determine the likelihood of mRNA target downregulation and
the lower the score, the more likely it is the miRNA will result in the downregulation
of a target (Betel et al., 2010). All the miRNAs on the list have mirSVR scores less
than -1 except 2 indicating the likelihood of binding is high. However, we found
several miRNAs have more than one predicted binding site to RAD51 mRNA. For
example, miR-130b-3p has 2 predicted binding sites, while miR-148b-5p has 4
predicted binding sites.
For those miRNAs with more than one prediced binding site, one is
preferable over the others. For example, the first binding site of miR-130b-3p has
a mirSVR score of -0.005 and has 6mer binding compared to the second binding
site with a mirSVR of -0.0933 which has 8mer binding. A 6mer is a perfect 6
nucleotide match in the seed region and is considered the strongest followed by
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7mer and 8mer binding (Grimson et al., 2007). We can see all the miRNA binding
sites with the lowest mirSVR scores are 6mers. For example, the 6mers miR-5323p and miR-30b-5p have mirSVR score of -0.0007 and -0.0015, respectively while
8mers miR-130a-3p and miR-320a have mirSVR scores of -0.1015 and -1.0068,
respectively. The miRNAs with perfect 6mer binding and low mirSVR scores are
the best candidates for targeting RAD51 mRNA for degradation. We found 17 of
the 37 miRNAs significantly upregulated by particulate Cr(VI) exposure have a
6mer binding site. These data suggest RAD51 targeting miRNAs significantly
upregulated by particulate Cr(VI) exposure are likely to bind the RAD51 mRNA
transcript interfering with expression.
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Table 3.12. RAD51 mRNA binding site information of significantly upregulated
miRNAs by particulate Cr(VI) exposure.

Table 3.12 shows significantly upregulated (adjusted p-value<0.01) miRNAs by
particulate Cr(VI) exposure that target RAD51. The total binding sites are shown
as well as the mirSVR score and number of nucleotides that match perfectly to the
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3’ UTR of RAD51 for all binding sites for each miRNA. Numbers in parenthesis
(i.e. 7 (1)) indicate a mis-match in the 3’ UTR binding sequence.
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Summary
In Aim 2 we present the first study to evaluate global expression of miRNAs
after Cr(VI) exposure in human cells. We show particulate Cr(VI) significantly alters
the expression of miRNAs. The number of significantly increased miRNAs
increased with particulate Cr(VI) exposure at all time points, and these levels were
higher at higher concentrations of zinc chromate. We also observed when
comparing the number of significantly upregulated miRNAs to the number of
downregulated miRNAs at each condition, more miRNAs were downregulated by
particulate Cr(VI) exposure. These are the first data to show Cr(VI) alters global
miRNA expression, and more miRNAs are downregulated.
We also compared the altered expression of miRNAs after particulate Cr(VI)
expression by narrowing the parameters by evaluating significantly altered
miRNAs with a fold change greater than 2. Such a large dataset allowed us to
focus on miRNAs that may have the largest biological relevance for global effect
analysis. We visualized the scattering of miRNAs based on these criteria using
volcano plots and found not all miRNAs with a fold change greater than 2 were
significant (adjusted p-value<2). We also found the number of significantly
upregulated miRNAs (fold change >2) increased almost 7-fold after 24 h exposure
to 0.2 ug/cm2 zinc chromate compared to 0.1 0r 0.3 ug/cm 2 zinc chromate at this
this time point. After 72 and 120 h more miRNAs were significantly upregulated at
higher zinc chromate concentrations. The number of significantly downregulated
miRNAs (fold change >2) also increased with concentration and time, although
there was a spike in the 24 h 0.2 ug/cm2 zinc chromate condition. We also included
analysis of the overlap of miRNAs significantly expressed across zinc chromate
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concentration. This analysis was also used to generate heat maps showing the
clustering of miRNAs based on their fold change values to better understand how
patterns of miRNA expression altered by particulate Cr(VI) exposure.
In Objective 2 we focused the analysis on particulate Cr(VI)-altered miRNAs
that target genes in pathways of Cr(VI) carcinogenesis. We generated a list of
KEGG pathways involved in Cr(VI) carcinogenesis and performed analysis
comparing the KEGG pathways list with KEGG pathways targeted by particulate
Cr(VI)-altered miRNAs at each of our conditions. We found particulate Cr(VI)altered miRNAs target pathways of Cr(VI) carcinogenesis. We further analyzed
these data to compared the number of up- or down-regulated miRNAs that target
each pathway of Cr(VI) carcinogenesis and the number of genes targeted by
miRNAs up- or down-regulated by particulate Cr(VI) exposure.
In Objective 3 we focused in on how particulate Cr(VI)-upregulated miRNAs
affect the homologous recombination pathway and specifically RAD51. We
identified miRNAs at each time point and particulate Cr(VI) concentration that
target specific proteins in the homologous recombination pathway. We found
trends in predicted target genes and the miRNAs that affect their expression.
Finally, we analyzed all significantly up-regulated miRNAs from the RNAseq
analysis that predicted to target RAD51. Using an online database 126 miRNAs
were predicted to target the RAD51 mRNA transcript. Of those 37 unique miRNAs
were upregulated by particulate Cr(VI) exposure. We evaluated each of these 37
miRNAs under each treatment condition and identified trends in expression
associated with time and concentration. Lastly, we assessed the quality of each
predicted binding site of these miRNAs to determine the likeliness that they would
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result in a biological effect. We found all but two of the Cr(VI)-upregulated miRNAs
have a high likelihood of binding and 17 out of the 37 had perfect match binding in
the seed region.
Aim 3: Characterize the effects of particulate Cr(VI) on homologous
recombination in leatherback sea turtle lung cells.
Background
Cr(VI) is a global environmental pollutant and can affect both humans and
wildlife. The One Environmental Health approach is a research perspective that
incorporates human, wildlife, and ecosystem health to better understand how
toxicants affect the overall health of the environment (Perez and Wise, 2018). We
are investigating the effects of particulate Cr(VI) cells from both human and wildlife
species. We showed particulate Cr(VI) does not induce the same response to
particulate Cr(VI) in whale cells that is observed in human cells (Browning et al.,
2017; Li Chen et al., 2009a; Li Chen et al., 2009b; Li Chen et al., 2012; Wise et al.
2015). In this study we focus on another marine species, leatherback sea turtles.
Leatherback sea turtles are a large (up to 1200 lbs) and long-lived (~45
years) marine reptile that spend the entirety of their lives in the ocean. The
extended amount of time leatherbacks spend in the ocean exposes them to
pollutants and contaminants in the water, air, or food sources (Godley et al., 1999;
Guirlet et al., 2008; Perrault et al., 2013; Storelli and Marcotrigiano, 2003). These
exposures may lead to detrimental health impacts including immune and
reproductive failure (Guirlet et al., 2010; Stewart et al., 2011a). Furthermore,
leatherbacks may bioaccumulate environmental contaminants exacerbating health
issues caused by even low levels of exposure.
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Several studies have investigated metal levels in leatherback sea turtles
around the world and found their tissues may accumulate metals such as mercury,
cadmium, lead, and arsenic (Guirlet et al., 2010; Kunito et al., 2008; Stewart et al.,
2011b). To our knowledge only one study has investigated Cr levels in
leatherbacks but did not measure Cr levels in lung tissue (Poppi et al., 2012).
However, one study showed in tissues of adult and young loggerhead sea turtles
(Caretta caretta) Cr accumulated in the highest concentrations in the lung (Storelli
et al., 1998). These studies demonstrate leatherbacks are exposed to Cr(VI) in the
environment.
It is important to study the potential effects of environmental contaminants
such as Cr(VI) in leatherbacks to understand the potential impact on the health of
their population, the health of the environment, and to gain insight into human
health. Previously, we have shown particulate and soluble Cr(VI) is cytotoxic and
genotoxic in leatherback sea turtle lung cells (Speer et al., 2017). Additionally, we
found human and leatherback lung cells has similar levels of cytotoxicity and
genotoxicity although there were some observable differences between the two
species (Speer et al., 2018). No studies have investigated DNA damage or repair
in leatherbacks, and it is unknown how Cr(VI) causes genotoxicity in leatherback
cells.
In Aims 1 and 2 of this dissertation we investigated mechanisms of
particulate Cr(VI) induced loss of homologous recombination repair in human lung
cells. In Aim 3 we investigate key endpoints of particulate Cr(VI) exposure in
leatherback lung cells to begin to understand the mechanisms of particulate Cr(VI)
toxicity in this species. We hypothesize particulate Cr(VI) will induce DNA damage
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in leatherback cells and impair DNA repair based on our previous studies of Cr(VI)
in leatherback lung cells. We tested this hypothesis my measuring DNA double
strand breaks and homologous recombination repair in primary leatherback lung
cells.
Results
Objective 1: Particulate Cr(VI) induces DNA damage in leatherback lung cells.
We observed particulate Cr(VI) induced genotoxicity in leatherback lung
cells after acute and prolonged exposure as a measure of structural chromosome
instability (Speer et al., 2017; Speer et al., 2018). Induction of DNA double strand
breaks is a primary driver of structural chromosome instability. We measured DNA
double strand breaks in leatherback lung cells using two measures. We used the
neutral comet assay to measure of DNA double strand breaks in leatherback lung
cells. We found particulate Cr(VI) did not increase comet tail intensity in
leatherback lung cells after 24 or 120 h exposure (Figure 3.31). For example, 24 h
exposure to 0.1 or 0.4 ug/cm2 zinc chromate resulted in a tail intensity of 1 and 1.2
relative to control, respectively, while 120 h exposure resulted in a tail intensity of
0.9 and 1.4 relative to control, respectively.
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B. 1.8

24 h
120 h

Tail Intensity
(Relative to Control)

1.6
1.4
1.2
1.0
0.8
0.6

0.4
0.2

0.0
0

0.1

0.2

0.3

0.4

Zinc Chromate Concentration (ug/cm2)

Figure 3.31. Particulate Cr(VI) does not increase DNA damage. This
figure shows tail intensity as a measure of DNA double strand breaks
does not increase after 24 or 120 h exposure to particulate Cr(VI).
Data represent the mean of at least 3 independent experiments.
Error bars = standard error of the mean. No statistical significance
was observed. (A) Representative images of comets after exposure
to particulate Cr(VI) in leatherback lung cells. (B) Particulate Cr(VI)
does not increase comet tail intensity in leatherback lung cells after
24 or 120 h exposure.
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We also measured DNA double strand breaks using gamma-H2AX nuclear
foci. The histone variant, H2AX is phosphorylated (gamma-H2AX) in response to
DNA double strand breaks as a signaling method to initiate repair (Khanna and
Jackson, 2001).
Figure 3.32A shows representative images of gamma-H2AX foci in leatherback
lung cells. We found particulate Cr(VI) increased the percent of cells with >10 foci
after 24 and 120 h exposure (Figure 3.32B). For example, 24 h exposure to 0.1 or
0.4 ug/cm2 zinc chromate resulted in 8.7 and 27.3 percent of cell with >10 gammaH2AX foci, respectively, while 120 h exposure resulted in 11.3 and 24.7 percent of
cells with >10 gamma-H2AX foci, respectively. Only 24 h exposure to 0.4 ug/cm 2
zinc chromate was significant from control (*p<0.05), but there is a clear increasing
trend in the percent of cells with >10 gamma-H2AX foci after 24 h exposure. We
observed similar levels of gamma-H2AX foci after both 24 and 120 h exposure.
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Figure 3.32. Particulate Cr(VI) increases gamma-H2AX foci in
leatherback lung cells. This figure shows the percent of leatherback
lung cells with >10 gamma-H2AX foci increases with concentration
after 24 and 120 h exposure. Data represent the mean of three
independent experiments. Error bars = standard error of the mean.
(A) Representative images of gamma-H2AX foci in leatherback lung
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cells. The nucleus is stained blue with DAPI. gamma-H2AX foci are
stained pink. (B) The percent of cells with >10 gamma-H2AX foci
after 24 and 120 h exposure increased with increasing zinc chromate
concentrations. The percent of cells with >10 gamma-H2AX foci was
significantly higher after 24 h exposure to 0.4 ug/cm 2 zinc chromate
compared to control (*p<0.05). The percent of cells with >10 gammaH2AX foci increased after 120 h exposure to 0.1, 0.3, and 0.4 ug/cm 2
zinc chromate compared to control.
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Objective 2: RAD51 but not homologous recombination is impaired after prolonged
particulate Cr(VI) exposure
In Objective 1 we found induction of DNA double strand breaks increased
after particulate Cr(VI) exposure in leatherback lung cells using gamma-H2AX as
a measure. However, there appeared to be no increase in DNA double strand
breaks in the comet assay analysis. To better understand this result and to
determine if particulate Cr(VI) affects DNA repair in leatherback lung cells we first
assessed homologous recombination repair by measuring RAD51 nuclear foci.
Figure 3.33A shows representative images of RAD51 foci in leatherback lung cells.
We found RAD51 nuclear foci increase after 24 h exposure to particulate Cr(VI)
(Figure 3.33B). For example, exposure to 0.1, 0.2, 0.3, and 0.4 ug/cm 2 zinc
chromate resulted in 9.3 15.3, 18, and 18.3% of cells with >10 RAD51 foci. The
0.2, 0.3 and 0.4 ug/cm2 concentrations were significant compared to control
(*p<0.05 and **p<0.01). However, after 120 h exposure to particulate Cr(VI)
RAD51 nuclear foci increase at lower concentrations and then decreased at the
higher concentrations. For example, 0.1 and 0.2 ug/cm2 zinc chromate increase
the percent of cells with >10 RAD51 foci to 8 and 11, respectively, while after 0.3
and 0.4 ug/cm2 zinc chromate the percent of cells with >10 RAD51 foci is only 2.8
and 1.5, respectively. The increase was only significant after 0.2 ug/cm2 zinc
chromate (*p<0.5). The percent of cells with >10 RAD51 foci was significantly
lower after 120 h exposure to 0.3 and 0.4 ug/cm 2 zinc chromate compared to 24 h
(#p<0.05; ##p<0.01).
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Figure 3.33. RAD51 nuclear foci increase after acute but not
prolonged particulate Cr(VI) exposure in leatherback lung cells. Data
represent the mean of at least three independent experiments. Error
bars = standard error of the mean. (A) Representative images of
RAD51 foci in leatherback lung cells. The nucleus is stained blue
with DAPI. yH2AX foci are stained red. (B) The percent of cells with
>10 RAD51 foci (controls subtracted) in leatherback lung cells.
Particulate Cr(VI) increases the percent of cells with >10 RAD51 foci
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after 24 h in leatherback lung cells compared to control (*p<0.05,
**p<0.01). While the percent of cells with >10 RAD51 foci increases
after 120h exposure to 0.1 and 0.2 ug/cm 2 zinc chromate (*p<0.05)
it decreases after 0.3 and 0.4 ug/cm 2 zinc chromate. The percent of
cells with >10 RAD51 foci is significantly lower after 120 h compared
to 24 h at 0.3 and 0.4 ug/cm2 zinc chromate (#p<0.05; (##p<0.01).
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RAD51 nuclear foci were decreased after 120 h exposure to particulate
Cr(VI) compared to 24 h. Sister chromatid exchanges were used as a measure of
homologous recombination repair in leatherback lung cells. Figure 3.34A shows
representative images of leatherback lung cells metaphases with sister chromatid
exchanges. We found the ratio of sister chromatid exchanges to chromosome
number increased significantly after 24 and 120 h exposure to all concentrations
of particulate Cr(VI) (**p<0.01; ***p<0.001). For example, 24 h exposure to 0.1 and
0.3 ug/cm2 zinc chromate increased the ratio of sister chromatid exchanges to
chromosome number to 0.1 and 0.2, respectively. This ratio was higher after 120
h exposure resulting in a ratio of 0.2 and 0.4 after exposure to 0.1 and 0.4 ug/cm2
zinc chromate, respectively. The ratio of sister chromatid exchanges to
chromosome number was significantly higher after 120 h exposure to 0.15, 0.2,
and 0.3 ug/cm2 zinc chromate compared to 24 h ( ###p<0.001). No metaphases
were observed after 120 h exposure to 0.4 ug/cm 2 zinc chromate consistent with
previous data (Speer et al., 2019).
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Figure 3.34. Particulate Cr(VI) induces sister chromatid exchanges
in leatherback lung cells. This figure shows after 24 and 120 h
exposure sister chromatid exchanges increase with particulate
Cr(VI) concentration. (A) Representative images of sister chromatid
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exchanges in leatherback lung cells. (B) Ratio of sister chromatid
exchanges to chromosome number. Sister chromatid exchanges
were increased in each zinc chromate concentration (**p<0.01;
***p<0.001). Sister chromatid exchanges were significantly higher
after 120 h exposure to 0.15, 0.2, and 0.3 ug/cm 2 zinc chromate
(###p<0.001). After 120 h exposure to 0.4 ug/cm 2 zinc chromate no
metaphases (NM) were observed. Results represent the mean of at
least three independent experiments. Error bars = standard error of
the mean.
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Summary
In objective 2 we investigated DNA damage and repair in leatherback lung
cells after acute and prolonged exposure to particulate Cr(VI). We found DNA
double strand breaks did not increase with particulate Cr(VI) concentration after
24 or 120 h exposure using the comet assay. However, gamma-H2AX foci
increased with concentration to similar levels after both 24 and 120 h particulate
Cr(VI) exposure. The difference between the comet assay and gamma-H2AX foci
analysis could be the result of differences in the two measurements or signify
double strand breaks are being partially repaired in leatherback lung cells after
exposure to particulate Cr(VI).
After measuring DNA repair in leatherback lung cells we saw prolonged
exposure to particulate Cr(VI) inhibited RAD51 foci at higher concentrations of
particulate Cr(VI), but homologous recombination repair was not inhibited. These
data indicate while RAD51 may be inhibited after prolonged exposure, homologous
recombination is still available to leatherback lung cells and may be partially
protective.
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CHAPTER 4: DISCUSSION
Overview
Homologous recombination is a high-fidelity DNA repair mechanism critical
in maintaining genomic stability (Bryant et al., 2006; Stackpole et al., 2007).
Studies show the homologous recombination pathway is involved in the repair of
DNA double strand breaks induced by several metals including Cr(VI), arsenic,
cadmium, lead, and nickel (Bryant et al., 2006; Gastaldo et al., 2007; Helleday et
al., 2000; Stackpole et al., 2007). When homologous recombination repair is
unavailable the cell must resort to low-fidelity repair mechanisms increasing the
rate of chromosome instability. Indeed, we have shown Cr(VI) induces DNA double
strand breaks while inhibiting homologous recombination repair resulting in
chromosome instability (Browning et al., 2016, Qin et al., 2014; Wise et al., 2003;
Wise et al., 2002; Xie et al., 2009)
A critical factor in homologous recombination repair is the protein RAD51,
which is involved in carrying out the effector step in this pathway. RAD51 is
inhibited after prolonged exposure to particulate Cr(VI) illustrated by inhibited
RAD51 monofilament formation and nuclear foci, cytoplasmic accumulation of
RAD51 protein, and inhibited RAD51 protein expression (Browning et al., 2016;
Qin et al., 2014). Decreased RAD51 protein is a key event that may underlie the
other RAD51 phenotypes observed after prolonged Cr(VI) exposure. The
transcription factor, E2F1, is predominantly responsible for RAD51 expression,
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and studies show loss of E2F1 inhibits RAD51 expression and foci formation as
well as homologous recombination repair (Chen et al., 2011; Choi and Kim, 2019;
Wu et al., 2014). However, there are no studies investigating RAD51 expression
and the mechanisms controlling RAD51 expression after Cr(VI) exposure.
In Aim 1 we tested if E2F1 mediates the RAD51 response to particulate
Cr(VI) exposure. We demonstrated the decrease in RAD51 protein is likely due to
inhibited expression and not protein degradation. We focused on the predominant
transcription factor for RAD51, E2F1, to determine if E2F1 was critical for
expression of RAD51 after particulate Cr(VI) exposure. We found E2F1
overexpression does not rescue RAD51 failure induced by prolonged particulate
Cr(VI) exposure. This result indicates E2F1 alone does not modulate the RAD51
response to particulate Cr(VI). This conclusion was supported by our data that
shows knocking down E2F1 does not inhibit RAD51 expression. While we began
to investigate the potential role of alternative transcription factors in particulate
Cr(VI)-inhibited RAD51 expression, these results could not fully explain the
decrease of RAD51 expression.
In Aim 2 we performed a global RNAseq analysis to investigate how
particulate Cr(VI) alters the expression of miRNAs. miRNAs are key regulators of
gene expression, and studies show Cr(VI) causes global changes in gene
expression. However, limited studies have evaluated changes in miRNA
expression following Cr(VI) exposure, and none focused on homologous
recombination repair or RAD51. We investigated the effects of acute and
prolonged exposure to particulate Cr(VI) on miRNAs and characterized their
expression profiles. We found particulate Cr(VI) significantly altered miRNA
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expression and caused global down regulation of miRNAs. Additionally, we found
miRNAs altered by particulate Cr(VI) target genes in pathways of Cr(VI)
carcinogenesis. RAD51 expression is a focus of this study and we characterized
which particulate Cr(VI)-altered miRNAs predicted to target RAD51 and the
likelihood of their potential to bind to the RAD51 mRNA transcript. Together these
data provide insight into how particulate Cr(VI) alters global expression of miRNAs
and how they may play a role in pathways of Cr(VI) carcinogenesis.
To complement our investigation in the mechanisms of particulate Cr(VI)induced homologous recombination failure we applied the One Environmental
Health approach by evaluating key endpoints in leatherback sea turtle lung cells.
Previous studies using this approach have identified differences in the response
to Cr(VI) exposure that may serve as protective mechanisms in one species over
another (Browning et al., 2017a; Li Chen et al., 2009a; Li Chen et al., 2009b; Li
Chen et al., 2012; Wise et al. 2015). Therefore, in aim 3 we investigated DNA
damage and repair in leatherback lung cells. Using the comet assay we found
particulate Cr(VI) did not induce DNA damage. However, when we measured
gamma-H2AX foci, there was an increase after acute and prolonged particulate
Cr(VI) exposure. When we investigated repair, we found RAD51 foci increased
after 24 h, but was inhibited after 120 h exposure indicating RAD51 is impaired.
Alternatively, the breaks could be resolved. Even though RAD51 was decreased,
homologous recombination repair was active indicated by the increase of sister
chromatid exchanges. These data indicate homologous recombination repair is
available in leatherback lung cells to repair double strand breaks.
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The conclusions of these aims are supported by the data in this dissertation.
Below, we discuss the results in detail.
Particulate Cr(VI) inhibits expression of RAD51 and E2F1
RAD51, the key protein in the effector step of homologous recombination,
is impaired after prolonged exposure to particulate Cr(VI) while earlier steps in the
pathway remain functional (Qin et al., 2014). Loss of RAD51 was characterized by
inhibited nuclear foci and monofilament formation, increased cytoplasmic
accumulation, and inhibited protein expression (Browning et al., 2016; Qin et al.,
2014). Browning et al., 2017a further investigated mechanisms of cytoplasmic
accumulation of RAD51 after prolonged Cr(VI) exposure, however how particulate
Cr(VI) inhibits RAD51 protein expression is unknown and was a major focus of this
investigation.
We confirmed RAD51 protein expression decreased following prolonged,
but not acute particulate Cr(VI) exposure consistent with previous studies
(Browning et al., 2014, Qin et al., 2014). Decreased levels of protein could result
from either increased protein degradation or decreased production of the protein.
Bruno et al., 2016 characterized ubiquitin-mediated protein degradation as an
important pathway of Cr(VI) exposure leading to deleterious cellular effects.
However, our data show particulate Cr(VI) exposure had minimal effect on RAD51
protein half-life indicating protein degradation likely plays a minor role in the
decrease of RAD51 protein levels. We did not apply additional methods to
investigate RAD51 protein degradation in our analysis, however, it is unlikely to be
a major contributor based on our protein half-life results. Thus, degradation may

194

be an overall important pathway for Cr(VI), but it does not appear to have a major
contribution to this specific protein.
By contrast, we did find a reduction in processes underlying protein
production, specifically RAD51 transcription. RAD51 mRNA expression decreased
slightly after 24 h (not significant) but notably, and significantly decreased after 72
and remained low after 120 h exposure to particulate Cr(VI). While Bruno et al.,
2016, suggests protein degradation is increased following Cr(VI) exposure our
mRNA expression data suggest inhibited transcription is the primary mechanism
responsible for the decrease of RAD51 protein, specifically. This result is
supported by Manning and Patierno, 1992 who demonstrated Cr(VI) inhibits
transcription. Our data are the first to describe RAD51 mRNA expression following
Cr(VI) exposure, for both particulate and soluble Cr(VI) compounds. These results
are consistent with studies showing Cr(VI) downregulates expression of DNA
repair genes and correlate with the trend in RAD51 protein levels previously
reported after acute and prolonged Cr(VI) exposure (Browning et al., 2016; Hodges
et al., 2002; Hu et al., 2018; Pritchard et al., 2007; Qin e al., 2014; Takahashi et
al., 2004).
Although we found decreased levels of RAD51 mRNA it is possible RAD51
protein reduction after prolonged particulate Cr(VI) exposure is also due to
inhibited translation. Several studies have shown Cr(VI) inhibits protein translation
(Blankenship et al., 1994; Gunaratnam and Grant, 2008; Shumilla and
Barchowsky, 1999) Gunaratnam and Grant, 2008 showed Cr(VI) inhibited DNA,
RNA, and protein synthesis, but the most significant effect was on protein
synthesis. It is possible the decreased protein synthesis caused by Cr(VI) is the
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result of several mechanisms including inhibited transcription, RNA degradation,
and inhibited translation as the end product of gene expression. Specific
mechanisms of inhibited protein translation involving transcriptional machinery
after Cr(VI) exposure have not been investigated. However, one emerging
mechanism is the involvement of miRNAs in mRNA degradation and inhibited
translation. We will discuss this possibility further below.
RAD51 is a key protein in homologous recombination repair and thus its
transcriptional control has been investigated. Control of RAD51 expression is
tightly regulated. E2F1 is the predominant transcription factor for RAD51 and loss
of E2F1 inhibits RAD51 protein and nuclear foci formation (Chen et al., 2011; Choi
and Kim, 2019; Wu et al., 2014). These results correlate with the RAD51 response
after prolonged particulate Cr(VI) exposure. Studies show E2F1 is inhibited
following exposure to other metals including arsenic and cadmium (Lam et al.,
2014; Lam et al., 2015; Li et al., 2008; Wu et al., 2013). However, only one study
investigated E2F1 after Cr(VI) exposure and found 24 h exposure increased E2F1
expression (Permenter et al., 2011). Prolonged exposures have not been
investigated. We investigated the effects of particulate Cr(VI) on E2F1 to determine
if particulate Cr(VI)-induced loss of E2F1 may underlie reduced RAD51
expression. Our data show E2F1 protein expression is unaffected after 24
exposure but decreases after 72 and 120 h exposure. We observe significant
decrease of RAD51 mRNA after prolonged exposures correlating with prolonged
Cr(VI)-inhibited E2F1 protein expression. E2F1 mRNA also decreased after 24 h
and further decreased after 72 and 120 h exposure to particulate Cr(VI) consistent
with the E2F1 protein levels. E2F1 self regulates its own transcription. Therefore,
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the loss of E2F1 protein after prolonged exposure may explain reduced E2F1
mRNA. RAD51 and E2F1 mRNA begin to decrease after 24 h suggesting
transcription may be inhibited earlier than the decrease in protein is detected and
indicates there may more than one mechanism for decreased mRNA levels at this
time point. The mechanism underlying the loss of mRNA is currently unknown.
One possible mechanism that may explain our results is miRNAs target the mRNA
for degradation, and we will address this possibility below. miRNA-induced loss of
mRNA does not explain why RAD51 and E2F1 protein levels are not affected after
24 h particulate Cr(VI) exposure. One explanation is the cell recognizes the need
for RAD51 and E2F1 protein after acute particulate Cr(VI)-induced DNA damage
and protects available protein. Indeed, studies show E2F1 protein is stabilized
following DNA damage (Biwas and Johnson, 2012; Ianari et al., 2004; Lin et al.,
2001).
E2F1 does not mediate the RAD51 response to particulate Cr(VI)
We observed particulate Cr(VI) affected RAD51 and E2F1 mRNA and
protein expression in a similar temporal manner suggesting loss of E2F1 after
prolonged particulate Cr(VI) exposure may be responsible for loss of RAD51. To
confirm this connection, we attempted to rescue the RAD51 response by
overexpressing E2F1 after prolonged particulate Cr(VI) exposure. We found
overexpression of E2F1 did not rescue RAD51 as the reduced protein levels,
inhibited foci formation and aberrant cytoplasmic accumulation remained despite
elevated E2F1 levels. RAD51 protein levels were inhibited in our untransfected
control after 120 h exposure to particulate Cr(VI) consistent with previous data
(Browning et al., 2016; Qin et al., 2014). However, while RAD51 protein levels
197

increased after E2F1 overexpression in the cells untreated with particulate Cr(VI),
after 120 h exposure to 0.2 ug.cm 2 zinc chromate RAD51 protein did not increase
compared to the transfection control. These data show that while E2F1
overexpression may increase RAD51 protein levels, it does not rescue prolonged
particulate Cr(VI)-induced reduction in RAD51 protein. When we examined RAD51
nuclear foci we did not find E2F1 rescued prolonged particulate Cr(VI)-inhibited
RAD51 foci formation observed in our untransfected control. This result indicates
E2F1 may not directly affect RAD51 nuclear foci formation. One explanation for
this result may be E2F1 overexpression does not abrogate prolonged particulate
Cr(VI)-induced RAD51 cytoplasmic accumulation and RAD51 is not available in
the nucleus. However, when we examined RAD51 cytoplasmic accumulation after
E2F1 overexpression we did not find RAD51 cytoplasmic accumulation was
inhibited after prolonged particulate Cr(VI) exposure. These data suggest E2F1 is
not involved in RAD51 nuclear localization.
The regulation of RAD51 expression and localization in the cell are
controlled by complex mechanisms. Our data showing E2F1 increased RAD51
protein expression in cells untreated with particulate Cr(VI) is consistent with the
literature. However, RAD51 protein levels were not modulated by E2F1 after
particulate Cr(VI) exposure. Alternative repressive mechanisms may prevent the
excess amount of E2F1 in the cells from expressing RAD51 explaining this result.
Failure of E2F1 overexpression to rescue particulate Cr(VI)-inhibited RAD51 foci
formation may be explained by the fact that RAD51 protein was not restored.
Alternatively, RAD51 nuclear foci are formed as a result of RAD51 loading onto
single-stranded DNA at sites of DNA double strand breaks in part by BRCA2 and
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RAD51C, and this process may be unaffected by E2F1 (Amunugama et al., 2013;
Forget and Kowalczykowski, 2010; Jensen et al., 2010).
Inhibited RAD51 nuclear foci may also be attributed to our result showing
E2F1 overexpression did not abrogate particulate Cr(IV)-induced RAD51
cytoplasmic accumulation rendering RAD51 unavailable in the nucleus. This
outcome was unexpected as Ketchap et al., 2010 found histone deacetylase
inhibitors affected RAD51 through E2F1-mediated mechanisms. One endpoint
they confirmed was the induction of RAD51 cytoplasmic accumulation. The
difference in our results may be due to the histone deacetylase inhibitors
themselves used in Katchap et al., 2010 and not the loss of E2F1 directly. Katchap
et al., 2010 used a histone deacetylase inhibitor that targets both class I and class
II histone deacetylases, which can target non-histone proteins (Glozak et al.,
2005). It is possible the inhibitor in this study affected post-translational
modifications on proteins important for RAD51 localization.
RAD51 has no nuclear localization signal and thus must bind to other
proteins, BRCA2 and RAD51C, to be transported into the nucleus (Gildemeister et
al., 2009; Jeyasekharan et al., 2013). These proteins interact with nuclear pore
complexes to mediate transport of RAD51 into the nucleus (Christie et al., 2016).
Indeed, Browning et al., 2017a showed RAD51 nuclear transport mediated by
BRCA2 and RAD51C was inhibited. It is possible E2F1 does not affect these
mechanisms and that is why we did not see E2F1 overexpression rescue RAD51
cytoplasmic accumulation of RAD51 after prolonged particulate Cr(VI) exposure.
It is notable that RAD51 cytoplasmic accumulation was decreased to low levels in
the transfection control of our experiment. This result makes it difficult compare
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any observable effect of E2F1 overexpression and may have artifactually masked
the result. This result indicates the transfection procedure itself affected RAD51
cytoplasmic accumulation, although the mechanisms underlying this possibility
have not been investigated.
An alternative explanation for why E2F1 overexpression did not rescue any
particulate Cr(VI)-induced RAD51 phenotypes is due to off-target effects directly
related to E2F1 overexpression. Previously, overexpression of E2F1 was found to
lead to activation of cell death pathways in fibroblasts (Kowalik et al., 1995).
Therefore, it is possible E2F1 overexpression induced off-target effects that
interfered with normal DNA repair mechanisms. Although we did not measure cell
death, if cell death pathways were activated after E2F1 overexpression, it is likely
less resources would be allocated to DNA repair mechanisms. This points to the
delicate balance of factors in the cell and how they respond to genotoxic insult.
It may be that complications of the E2F1 overexpression paradigm
prevented us from determining if E2F1 mediates the RAD51 response to
particulate Cr(VI). Therefore, we tried to connect E2F1 with the RAD51 response
by knocking down E2F1 after acute exposure to particulate Cr(VI) when RAD51 is
normally active to try an recapitulate the prolonged exposure response. Previous
studies were successful showing loss of E2F1 inhibits RAD51 (Chen et al., 2011;
Choi and Kim, 2019; Wu et al., 2014). We found knockdown of E2F1 did not inhibit
RAD51 mRNA or protein expression or induce RAD51 cytoplasmic accumulation
but did inhibit RAD51 nuclear foci formation. RAD51 protein levels were unaffected
by E2F1 knockdown in three out of the four E2F1 siRNAs tested after exposure to
acute 24 h particulate Cr(VI). Although one E2F1 siRNA inhibited RAD51 protein
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levels, it is possible this siRNA has an off-target effect on RAD51 expression
inconsistent with the other siRNAs. These data indicate E2F1 does not modulate
RAD51 protein levels in WTHBF-6 cells in response to particulate Cr(VI) consistent
with our E2F1 overexpression data. Similarly, when we investigated RAD51 mRNA
after E2F1 knockdown we found RAD51 mRNA were not consistently affected.
While RAD51 mRNA was decreased slightly after E2F1 knockdown with one
siRNA, it was slightly increased by another siRNA correlating with the RAD51
protein data after E2F1 knockdown. When we examined RAD51 localization, we
found E2F1 knockdown did not induce RAD51 cytoplasmic accumulation observed
after prolonged particulate Cr(VI) exposure indicating E2F1 does is not involved in
mechanisms regulated RAD51 nuclear localization. These data are consistent with
our E2F1 overexpression analysis. The cytoplasmic accumulation result is
contrary to our finding that E2F1 knockdown inhibited RAD51 nuclear foci
formation after only acute 24 h exposure to particulate Cr(VI). This result suggests
E2F1 may affect RAD51 localization or stability at DNA double strand breaks but
not nuclear localization.
The results of our E2F1 knockdown experiments may be explained by the
complex nature of the involvement of E2F1 in RAD51 expression and function.
Only one of the four E2F1 siRNA transfection resulted in decreased RAD51 protein
expression and was only significant in the condition with no particulate Cr(VI)
exposure. An explanation for this result may be that in this condition E2F1 was
knocked down to 10% while the other E2F1 knockdowns E2F1 was only knocked
down to between 20-30%. This difference could explain why we do not observe
the decrease of RAD51 reported by others in the literature. However, within our
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study mechanism, particulate Cr(VI) does not reduce E2F1 protein to these levels.
In fact, the largest effect on E2F1 protein loss is after 72 h exposure to 0.3 ug/cm 2
zinc chromate resulting in 41% E2F1 protein levels relative to control. Therefore,
it may be possible E2F1 knockdown inhibits RAD51, but only at levels not reached
after particulate Cr(VI) exposure.
E2F1 is responsible for the transcription of RAD51. However, we found
E2F1 knockdown did not inhibit RAD51 mRNA expression consistently after acute
particulate Cr(VI) exposure. Other studies have found E2F1 knockdown inhibits
RAD51 mRNA expression (Choi and Kim, 2019; Wu et al., 2014). These papers
are inconsistent with our results showing E2F1 knockdown did not significantly
impact RAD51 mRNA. The levels of E2F1 in our study may not low enough to
induce the RAD51 effect observed in other studies. Similar to the RAD51 protein
expression results the E2F1 siRNA condition where E2F1 was knocked down to
10% reduced RAD51 mRNA, while in the other E2F1 siRNA condition E2F1 was
knocked down to 20-30% and slightly increased RAD51 mRNA. An alternative
explanation is we found nuclear E2F1 protein levels only decreased after 120 h
exposure. Although total E2F1 protein is significantly decreased after 72 and 120
h particulate Cr(VI) exposure, it appears what E2F1 protein is available is shuttled
into the nucleus. Another explanation is alternative transcription factors may be
compensating for the loss of E2F1 in the expression of RAD51. Consistent with
these results and our E2F1 overexpression data we found E2F1 knockdown did
not induce RAD51 cytoplasmic accumulation after only acute exposure to
particulate Cr(VI). This result may be because E2F1 simply is not involved in the
nuclear localization of RAD51 as discussed above.
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It is also possible the timing of the experiment did not allow for the
development of RAD51 cytoplasmic accumulation or the reduction in RAD51
mRNA and protein. For example, we knocked down E2F1 for a total of 48 h and
treated with particulate Cr(VI) the last 24 h of the transfection. In initial testing, we
found WTHBF-6 cells did not tolerate longer E2F1 knockdown transfection times
well. This timing issue may have inhibited our ability to detect the RAD51
phenotypes investigated that may require longer to develop. It is also possible
knocking down E2F1 had off-target effects in the cells that affected these
endpoints.
Although RAD51 protein and mRNA expression and cytoplasmic
accumulation were unaffected by E2F1 knockdown, we did find RAD51 nuclear
foci were inhibited. This result is consistent with studies showing loss of E2F1
reduces RAD51 nuclear foci at double strand breaks and inhibits DNA repair. For
example, Chen et al., 2011 showed E2F1 knockout cells had increased DNA
damage and inhibited repair indicated by the comet assay and gamma-H2AX foci
while also reducing RAD51 nuclear foci. RAD51 nuclear foci normally increase in
response to acute particulate Cr(VI) exposure (Browning et al., 2014; Qin et al.,
2014). Our data show loss of E2F1 inhibited RAD51 nuclear foci formation after
acute particulate Cr(VI) exposure. These data indicate E2F1 may play a role in
RAD51 loading onto single-stranded DNA at double strand breaks, or affect
proteins involved in this process. E2F1 can localize to DNA double strand breaks
and plays a role in the signaling and stability of DNA repair proteins (Chen et al.,
2011; Choi and Kim, 2019; Liao et al., 2010; Lin et al., 2001). It is possible E2F1
facilitates RAD51 nuclear foci formation directly or through the regulation of
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mediator proteins. This direct involvement at DNA double strand breaks may
explain why E2F1 knockdown affected RAD51 nuclear foci but not the other
endpoints we assessed. This result does not explain why we did not see E2F1
overexpression rescue prolonged particulate Cr(VI)-inhibited RAD51 nuclear foci
formation. However, as previously discussed the overexpression procedure may
have had off-target effects affecting the result. Further work is required to
determine the role of E2F1 in RAD51 foci formation after particulate Cr(VI)
exposure.
Alternative RAD51 transcription factors may play a role in RAD51 expression
after particulate Cr(VI) exposure
While we found E2F1 may affect RAD51 nuclear foci formation, RAD51
expression was unaffected by modulating E2F1. We explored alternative
mechanisms that may explain these results focusing on alternate proteins involved
in RAD51 transcription however there is little data on the regulation of RAD51 by
other transcription factors. EGR1 is a proposed transcriptional activator of RAD51
(Hine et al., 2014). We found EGR1 was unaffected after 24 h but had a modest
decrease after 120 h exposure. For example, 120 h exposure to 0.1, 0.2, and 0.3
ug/cm2 zinc chromate decreased EGR1 to 81, 76, and 64% of control, respectively,
although these results were not significant. We have not investigated the modest
decrease in EGR1 after prolonged particulate Cr(VI) exposure thus far and how it
may contribute to loss of RAD51 expression.
We considered the opposite scenario, that rather than RAD51 activators
being decreases, perhaps transcription was low because inhibitors were
increased. It is possible transcriptional repressors modulate RAD51 expression
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after particulate Cr(VI) exposure. Indeed, Engeland, 2018 suggests the balance of
activating and repressive complexes are important in gene expression. P53 is a
direct and indirect transcriptional repressor of RAD51 (Buchop, 1997; Toledo,
1998). However, we found p53 protein increased after 24 h and decreased slightly
after 120h exposure to particulate Cr(VI), which does not support a conclusion that
p53 was repressing RAD51 transcription. We further found p53 stabilization was
not altered. These data suggest p53 may not play a significant direct role in the
expression of RAD51 after particulate Cr(VI) exposure. Our observations that
stability is unaffected would allow p53 to participate in indirect regulation of RAD51
expression. For example, p53 facilitates hypo-phosphorylation of p130, and hypop130 binds to E2F4 facilitation the formation of the repressive DREAM complex
(Engeland, 2018).
The DREAM complex is thought to displace activating complexes
containing E2F1. Indeed, Bindra et al., 2007 showed E2F1 and E2F4 compete for
the same binding location at the RAD51 promoter. We found while p130 protein
decreased after particulate Cr(VI) exposure, phospho-p130 was further deceased.
These data indicate of the p130 available after particulate Cr(VI) exposure, more
is in the hypo-phosphorylated form, which may then complex with E2F4. We found
E2F4 protein to be slightly elevated level after acute and prolonged exposure to
particulate Cr(VI).

This outcome indicates while E2F1 is inhibited following

particulate Cr(VI) exposure E2F4 is unaffected, which would shift the balance of
the two transcription factors towards the repressive E2F4. Based on the literature
this imbalance may be responsible for the repressed RAD51 expression (Bindra
et al., 2007; Schwentner et al., 2015). Our data showing E2F1 overexpression
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might initially seem to contradict the hypothesis that the balance of E2F1 to E2F4
is responsible for RAD51 repression after particulate Cr(VI) exposure. However,
the complexity of this process may need to be further investigated to better
delineate the mechanism. Indeed, there is not much known about how the
repressive DREAM complex displaces the transcriptional activating complex
containing E2F1.
Particulate Cr(VI) upregulates miRNAs targeting RAD51 expression
Our data exploring transcriptional control of RAD51 do not fully explain loss
of RAD51 mRNA and protein after particulate Cr(VI) exposure. miRNAs play a
significant role in regulating gene expression by targeting mRNA for degradation
or inhibition of translation. Only a few studies have evaluated changes in miRNAs
after Cr(VI) expression, however, these only focused on a few miRNAs each, and
none in connection to RAD51 (Chandra et al., 2015; Li et al., 2014; Li et al., 2016).
We performed a global analysis of miRNAs using RNAseq after exposure to acute
and prolonged particulate Cr(VI) exposure in human lung cells and identified
miRNAs upregulated by particulate Cr(VI) that target RAD51.
We found particulate Cr(VI) upregulated miRNAs targeting RAD51 mRNA.
Of the 126 miRNAs predicted to target RAD51, we found 37 to be significantly
upregulated by particulate Cr(VI) exposure. Thirty-five of these miRNAs targeted
RAD51 with high likelihood of binding according to their mirSVR scores. Seventeen
out of the 37 total miRNA targeting RAD51 had perfect 6mer binding, which
indicates many of the particulate Cr(VI) upregulated miRNAs targeting RAD51
have a high likelihood of binding and having an effect on RAD51 expression.
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We observed trends in concentration and time associated with several
miRNAs. For example, miR-432-5p and miR-194-5p were upregulated after 72 and
120 h exposure at all concentrations of particulate Cr(VI). These miRNAs have
7mer binding to the RAD51 mRNA transcript. miR-30b was significantly
upregulated after 120 h exposure at the highest concentration and has perfect
6mer binding to the RAD51 mRNA transcript. We observed significant upregulation
of RAD51-targeting miR-186 after 24 h exposure to particulate Cr(VI) with 3
predicted binding sites on the RAD51 mRNA transcript (one with a perfect 6mer
match). This miRNA was also found to induce chromosome instability following
arsenic exposure although this study did not consider the implications of miR-186
targeting RAD51 in their analysis (Wu et al., 2019). miR-186 and those RAD51targeting miRNAs upregulated after prolonged exposure would be excellent
candidates for further evaluation of their effect on RAD51 expression and
chromosome instability after particulate Cr(IV) exposure.
No previous studies evaluated miRNAs altered by Cr(VI) in relation to
RAD51. However, RAD51 itself has been the target of therapeutic studies for
interference by miRNAs. For example, Huang et al., targeted RAD51 using miR103 and miR-107 although we did not see these miRNAs affected by particulate
Cr(VI) exposure. Several other studies also identified RAD51-targeting miRNAs in
relation to cancers or therapeutic use, but none overlapped with particulate Cr(VI)upregulated miRNAs targeting RAD51 in our results (Lai et al., 2016; Gasparini et
al., 2014; Li et al., 2016).

207

Particulate

Cr(VI)

upregulates

miRNAs

that

target

homologous

recombination genes
RAD51 is a key protein in the homologous recombination pathway and we
found particulate Cr(VI) upregulated miRNAs predicted to target RAD51. However,
Cr(VI) may upregulate miRNAs targeting additional proteins in the homologous
recombination pathway affecting RAD51. We identified individual miRNAs
significantly upregulated (fold change >2) by particulate Cr(VI) under each
experimental condition and their gene targets in the homologous recombination
pathway. It is notable RAD51 was not included in this list. This is because of our
stringent cut-off of a fold change >2 for this specific analysis. However, the analysis
shows many of the genes targeted are RAD51 homologs or involved in loading
RAD51 onto the single-stranded DNA at double strand breaks. For example,
XRCC2, RAD52, RAD51D, RAD51C, and RAD51B were all targeted by particulate
Cr(VI)-upregulated miRNAs. Specifically, we observed several trends across
concentration and time including miR-210 (which targets RAD52), which was
upregulated at all time points. RAD52 is involved in loading RAD51 onto the singlestranded DNA at double strand breaks. Few genes in the earlier steps of
homologous recombination repair were affected consistent with our previous
reports showing it is the downstream steps in homologous recombination affected
by particulate Cr(VI) exposure (Browning et al., 2016; Browning et al., 2017a; Qin
et al., 2014). For example, early proteins in the homologous recombination
pathway RAD50, ATM, and NBS1 were not predicted to be targeted by particulate
Cr(VI)-upregulated miRNAs. We have not investigated the effect of Cr(VI) on NBS1
specifically, however, MRE11 which is a part of the sensing DNA double strand
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breaks with NBS1 (MRN complex) was unaffected by prolonged Cr(VI) exposure
(Qin et al., 2014). The MRN complex is important for signaling of DNA double
strand breaks, and our previous study also shows downstream signaling by ATM
remains functional after prolonged Cr(VI) exposure (Qin et al., 2014). This is
consistent with the RNAseq data showing ATM was not a predicted target by
particulate Cr(VI) upregulated miRNAs. In contrast, RPA proteins, which coat
single-stranded DNA were targeted under all particulate Cr(VI) conditions. RPA
nuclear foci levels are decreased after prolonged particulate Cr(VI) exposure
compared to acute exposure indicating a possible inhibitory effect correlating with
our RNAseq data (data not published, Cynthia Browning). However, RPA
expression has not been measured. RPA is involved in many processes including
cell cycle, DNA damage checkpoints, DNA replication, and most DNA repair
pathways (Zou et al., 2006). Further work is needed to understand if the miRNAs
predicted to target RPA in our analysis have a significant impact on homologous
recombination repair.
Particulate

Cr(VI)

alters

miRNAs

that

target

pathways

of

Cr(VI)

carcinogenesis
We identified particulate Cr(VI)-upregulated miRNAs that target RAD51 and
other proteins involved in homologous recombination repair, which is known to be
an important in the mechanism of Cr(VI) carcinogenesis. Carcinogenesis is a
complex process and involves many different pathways, and it is unknown how
Cr(VI)-altered miRNAs affect other pathways of Cr(VI) carcinogenesis. To date this
is the only study to evaluate global changes in miRNAs after Cr(VI) exposure.
Therefore, we considered the broader implications of particulate Cr(VI)-altered
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miRNAs. To address this gap in the literature, we identified up- or down-regulated
miRNAs significantly affected by particulate Cr(VI) exposure then assessed them
in the context of pathways of Cr(VI) carcinogenesis.
Particulate Cr(VI) increased the number of significantly (adjusted pvalue<0.01) up- and down-regulated miRNAs compared to the control in all
conditions. Increased expression of miRNAs is often associated with decreased
translation of their mRNA targets. Therefore the upregulation of miRNAs by
particulate Cr(VI) may increase the chance of those miRNAs binding to their target
mRNA transcripts resulting in downregulation of translation. Conversely, the
downregulation of miRNAs by particulate Cr(VI) may result in increased translation
of their target mRNAs. The balance of up-and down-regulated miRNAs is a
complex process. For example, the upregulation of a miRNA targeting an activator
of a pathway may decrease activity in that pathway. Alternatively, the
downregulation of a miRNA targeting a repressor may result in increased activity
of that repressor’s target.
In our analysis we observed a significantly higher number of miRNAs
upregulated after 24 h exposure to 0.2 ug/cm 2 zinc chromate compared to all other
particulate Cr(VI) concentrations at any time point. In our previous studies on
particulate Cr(VI) exposure we have found a different response after 24 h
compared to prolonged 72 or 120 h exposure (Browning et al., 2016; Browning et
al., 2017a; Holmes et al., 2006; Martino et al., 2015; Qin et al., 2014). However,
the reason for the specific concentration effect after 24 h exposure to 0.2 ug/cm 2
zinc chromate is unknown. Apart from this anomaly, we found the total number of
downregulated miRNAs under each condition was greater than the number of
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upregulated miRNAs. For example, after 120 h exposure particulate Cr(VI)
downregulated more than twice the number of miRNAs that were upregulated. This
result suggests Cr(VI) causes more downregulation than upregulation of miRNAs
and is the first assessment to show global expression of non-coding RNAs affected
by Cr(VI) exposure. Indeed, studies show exposure to Cr(VI) alters global gene
expression (Andrew et al., 2003; Izzotti et al., 2002; Wetterhahn and Hamilton,
1989; Ye and Shi, 2001). One explanation for how Cr(VI) alters global expression
may be Cr(VI) affects miRNAs targeting the transcriptional machinery in cells,
however, further investigation of this possibility is required.
Due to the large dataset we characterized the miRNAs significantly
(adjusted p-value<0.01) affected by particulate Cr(VI) exposure. A stringent foldchange cut-off of 2 was applied to focus on miRNAs that may have a more
impactful biological responses in the cell. Analysis of miRNAs shared between
treatment concentrations of up- or down-regulated revealed not many miRNAs
were shared between the lowest and highest particulate Cr(VI) concentrations
tested. This result indicates different concentrations of particulate Cr(VI) modulate
expression of different sets of miRNAs. There are no studies addressing the impact
of this effect. However, this result could have implications in the mixture of miRNAs
available at any given concentration of particulate Cr(VI) exposure and affect how
cells respond.
Using Euclidean clustering to create heatmaps, we determined which
miRNAs were up- or down-regulated with similar patterns across particulate Cr(VI)
exposure conditions. We found strong clustering between miRNAs similarly
affected by particulate Cr(VI) exposure. One endpoint considered was how the
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miRNAs clustered after acute or prolonged particulate Cr(VI) exposure. When
comparing the 24 h clustering to the 72 or 120 h clustering the 24 h clustering looks
less similar to the 72 and 120 h clustering. This difference seems to be in part due
to a large number of miRNAs with low fold change values in the 24 h data indicating
they may not have a significant impact. It is also notable in the 24 h data there are
more miRNAs included in the heatmap than 72 or 120 h, however, this likely
reflects the spike in the total number of upregulated miRNAs after 24 h exposure
to 0.2 ug/cm2 zinc chromate previously discussed. We also observed miRNAs in
the 24 h data with a switch in expression patterns that was only observed in one
miRNA in the 72 h dataset and not at all in the 120 h data set. For example,
miRNAs went from being upregulated at 0.1 ug/cm 2 zinc chromate to
downregulated at 0.2 ug/cm2 zinc chromate, and then upregulated again at 0.3
ug/cm2 zinc chromate or vice versa. These data indicate the trends in
concentration-response were stronger after prolonged 72 and 120 h exposure than
after 24 h exposure to particulate Cr(VI). This difference in the analysis at 24 h
compared to prolonged 72 or 120 h exposure is consistent with trends in our
previous data and highlights the different effects of acute verses prolonged Cr(VI)
exposure (Browning et al., 2016; Browning et al., 2017a; Holmes et al., 2006;
Martino et al., 2015; Qin et al., 2014).
When we used this analysis to look closer at specific miRNA effects we
found miR-194-1 was significantly upregulated after 72 h and after 120 h exposure
had the highest fold change increase at that time point. Upregulation of miR-1941 was also reported in the liver of rats treated with arsenic although gene targets
may differ between species (Ren et al., 2015). In general metals are known to
212

share similar mechanisms of carcinogenesis (Chen et al., 2019). Studies have
begun to investigate how carcinogenic metals such as cadmium and arsenic alter
global miRNA expression, but none have been done following Cr(VI) exposure (Liu
et al., 2015; Ren et al., 2015). Hou et al., 2011 summarized a set of studies
evaluating the effect of environmental chemicals including cadmium, arsenic,
cigarette smoke, and metal-rich particulate matter on miRNA expression and found
miR-210 was downregulated by arsenic trioxide (Cao et al., 2011). We also found
miR-210 was downregulated after 24 h exposure to 0.3 ug/cm 2 zinc chromate in
our study. Additional studies comparing how metals alter miRNA expression may
be insightful to their role in carcinogenesis.
We used this differential miRNA expression data to identify and characterize
pathways of Cr(VI) carcinogenesis targeted by particulate Cr(VI)-altered miRNAs.
Pathways of Cr(VI) carcinogenesis were identified through a literature search of
recent papers on this topic and aligning those pathways with pathways in the
KEGG database. We noted trends in the number of genes predicted to be targeted
by Cr(VI)-altered miRNAs in each pathway and identified which pathways were
targeted by the most Cr(VI)-altered miRNAs. Of the cellular processes pathways
cell cycle and apoptosis were two of the pathways predicted to have the most
targeted genes. Cr(VI) is known to alter cell cycle and cell death mechanisms
contributing to carcinogenesis (Gavin et al., 2007; O’Brien et al., 2002; Russo et
al., 2005; Wise et al., 2006b). For example, Wise et al., 2006b showed prolonged
exposure to particulate lead chromate induced spindle assembly checkpoint
bypass altering cell cycle in WTHBF-6 cells. These cells also exhibited numerical
chromosome instability, a hallmark of lung cancers. Russo et al., 2005 showed
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Cr(VI) increased pro-apoptotic genes, however, this was only after acute 24 h
exposure to high concentrations of soluble Cr(VI). It is currently unclear how
subsets of Cr(VI)-exposure cells evade apoptosis to develop into malignant cells.
Our miRNA analysis may provide insight into this mechanism.
The pathway analysis also shows which pathways have bigger differences
in the number of genes per pathway targeted by up- or down-regulated miRNAs
and the total number of up- or down-regulated miRNAs predicted to target each
pathway. For example, in the ubiquitin mediated proteolysis pathway after 24 h
exposure to 0.3 ug/cm2 zinc chromate 16 genes were predicted to be targeted by
downregulated miRNAs and 20 genes were targeted by upregulated miRNAs while
only 2 downregulated miRNAs targeted genes in this pathway and 12 upregulated
miRNAs targeted genes in this pathway. One consideration is that the number of
predicted targets identified in any given KEGG pathways may play a role in our
analysis. For example, we observed the PI3K-AKT pathway had the most genes
targeted my Cr(VI)-upregulated miRNAs (13, 20, and 18 after 24, 72, and 120 h
exposure to 0.3 ug/cm2 zinc chromate, respectively). While the PI3K-AKT pathway
is extensive (354 genes), it is still worth noting this result to investigate further. This
analysis demonstrates the complex dynamics of the relationship between miRNAs
and their targets and highlights the need to better understand how miRNAregulated gene expression is controlled.
Pathway analysis revealed correlations between these results and those of
several studies that have investigated smaller sets of miRNAs. For example, Li et
al., 2014 identified miR-3940-5p was altered by Cr(VI) exposure in human plasma
and associated it with regulation of a gene in involved in homologous
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recombination repair, a pathway targeted by Cr(VI)-altered miRNAs. However, we
found miR-3940 was significantly increased, but only after 24 h exposure.
Similarly, miR-4741 and miR-590 were reported as significantly down- and upregulated, respectively, in the Cr(VI) plasma study. In our RNAseq results we found
miR-4741 was also downregulated after 24 h exposure to particulate Cr(VI)
consistent with the plasma miRNA report. However, miR-590 was upregulated
after 120 h exposure in our RNAseq data set contrary to being upregulated by
Cr(VI) exposure in the blood. These results may be due to many factors including
the source of the miRNAs (human plasma of people exposed to potassium
chromate vs. cultured lung cells exposed to zinc chromate) and different study
methods (microarray vs. RNAseq). In future studies these analyses can be used
to further investigate miRNAs involved in pathways of Cr(VI) carcinogenesis
providing a road map of affected targets.
Our data support a recent analysis of pathways of Cr(VI) carcinogenesis
suggesting Cr(VI)-altered epigenetic mechanisms lead to genomic instability as a
key driver of Cr(VI) carcinogenesis (Rager et al., 2019). This hypothesis is
supported by data showing Cr(VI) induces low-rates of point mutations while
causing inheritable phenotypes (Ewis et al., 2001; DeFlora and Wetterhahn, 1989;
Katabami et al., 2000; Kondo et al., 1997; Wise et al., 2018). Specifically, Cr(VI)altered miRNAs have been proposed to downregulate DNA repair factors
ultimately leading to genomic instability. Our data support this hypothesis and it
will be important to investigate how miRNAs contribute to the multiple mechanisms
of genomic instability.
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Leatherback lung cells are resistant to particulate Cr(VI)-inhibited
homologous recombination repair
Leatherback sea turtles are an excellent candidate for the One
Environmental Health approach. Leatherbacks are a large marine reptile with a
long lifespan and may be exposed to environmental contaminants throughout their
life. Few studies have evaluated Cr levels in tissues of leatherback (Guzman et al,.
2020; Perrault et al., 2019; Poppi et al., 2012). However, Guzman et al., 2020
found Cr levels in leatherback eggs considered unsafe for humans. Cr was
measured in another marine species, sperm whales (Physeter macrocephalus)
and their tissues had Cr levels as high as levels found in human lung tissue from
workers who died of chromate-induced lung cancer (Wise et al., 2009). These
studies confirm Cr is a threat to marine species.
While Cr(VI) induces chromosome instability in whale cells, the levels are
far lower than those observed in human cells demonstrating a difference in
response (Li Chen et al., 2009a; Li Chen et al., 2009b). We used this same
approach to show Cr(VI) induces chromosome instability in leatherback sea turtle
lung cells at similar levels to those observed in human lung cells although some
differences in response were observed (Speer et al., 2018; Speer et al., 2019).
Browning et al., 2017b began to investigate the mechanisms of chromosome
instability in whale cells and showed RAD51 increases after both acute and
prolonged Cr(VI) exposure in whale cells, but these levels were higher after acute
Cr(VI) exposure. RAD51 and homologous recombination repair have not been
investigated in leatherbacks.
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We measured RAD51 foci after acute and prolonged exposure to particulate
Cr(VI) in leatherback lung cells. We found RAD51 nuclear foci increased after
acute 24 h exposure to particulate Cr(VI). However, after prolonged 120 h
exposure RAD51 nuclear foci increased at lower concentrations slightly, then
decreased to baseline levels at the higher concentrations. These data suggest
RAD51 is inhibited after prolonged exposure to particulate Cr(VI) in leatherback
lung cells and are consistent with results in human data (Browning et al., 2016; Qin
et al., 2014).
Homologous recombination repair is protective against Cr(VI)-induced
genomic instability in human cells (Bryant et al., 2006; Stackpole et al., 2007). As
we found RAD51 foci were decreased after prolonged particulate Cr(VI) exposure,
we also assessed homologous recombination repair using the sister chromatid
exchange assay. We found sister chromatid exchanges increase after 24 h with
increasing particulate Cr(VI) concentration and increase further after prolonged
120 h exposure. This result suggests homologous recombination repair is available
to repair DNA double strand breaks after both acute and prolonged particulate
Cr(VI) exposure.
This result initially seems contradictory to our RAD51 outcomes we
observed in turtle cells. It is tempting to suggest that Cr(VI) might be inducing sister
chromatid exchanges not by inducing homologous recombination repair, but
instead by inhibiting topoisomerase II. Historically, some data in the literature
suggest topoisomerase II inhibitors can increase sister chromatid exchanges
(Dillehay et al., 1989; Pommier et al., 1988). However, this possibility seems is
unlikely to be a major contributor to our effect. First, the hypothesis that
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topoisomerase inhibitors induce sister chromatid exchanges is controversial many
reports show they do not increase sister chromatid exchanges (Fantini et al., 1998;
Lim et al., 1986). Secondly, topoisomerase II inhibitors ultimately cause DNA
double strand breaks and these breaks can be repaired by homologous
recombination repair. Thus, the most likely explanation for topoisomerase II inhibitinduced sister chromatid exchanges is the induction of homologous recombination
repair and not some homologous recombination repair-independent mechanism.
Furthermore, the breaks after topoisomerase II inhibitors are predominately
repaired by non-homologous recombination repair (Adachi et al., 2003, Kantidze
and Razin, 2006; Terasawa et al., 2014). If Cr(VI) was inhibiting topoisomerase II,
one would expect the breaks to be repaired by non-homologous end joining
resulting in reduced sister chromatid exchanges and reduced RAD51 foci, but we
did not find this outcome. Therefore, it seems unlikely that topoisomerase II
inhibitions would explain this outcome.
Another explanation for the difference between the RAD51 foci and sister
chromatid exchange data is that homologous recombination repair in leatherbacks
may differ than that in human cells where RAD51 is necessary for successful
repair. RAD51 is highly conserved across species (Khoo et al., 2009). However, it
is possible slight differences in the RAD51 protein may have affected the sensitivity
of human RAD51 antibodies in the leatherback cells. Browning et al., 2017b also
found RAD51 nuclear foci increased to lower levels after prolonged exposure then
was observed after acute exposure, however, sister chromatid exchanges
increased). This is consistent with the pattern of our result in leatherback lung cells.
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Structural chromosome instability increases with Cr(VI) exposure in
leatherback lung cells (Speer et al., 2018; Speer et al., 2019). Induction of DNA
double strand breaks is a key event of structural chromosome instability, however,
we found homologous recombination repair was active after prolonged particulate
Cr(VI) exposure in leatherback lung cells. When we investigated DNA damage in
leatherback lung cells we found no increase in DNA double strand breaks after 24
or 120 h exposure to particulate Cr(VI) using the neutral comet assay in
leatherback lung cells. However, we did observe an increase in gamma-H2AX foci
after both 24 and 120 h exposure to particulate Cr(VI). The gamma-H2AX data
indicate particulate Cr(VI) induces DNA double strand breaks after both acute and
prolonged exposure, but these data do not correlate with our sister chromatid
exchange data showing an increase in homologous recombination repair after
acute and prolonged exposure to particulate Cr(VI). In contrast, our comet analysis
does support the sister chromatid exchange data. There are several explanations
that may explain the difference between the comet assay analysis and gammaH2AX data. One explanation may be due to assay sensitivity. The sensitivity of the
comet analysis may not have been high enough to detect a significant change in
DNA double strand breaks after particulate Cr(VI) exposure. In contrast, at least
25% of cells had elevated levels of gamma-H2AX foci after the highest
concentration of particulate Cr(VI) at both time points. Alternatively, the timing of
the detection of gamma-H2AX compared to the detection of double strand breaks
by comet assay may play a role in the different response. Future investigation is
necessary to assess DNA repair dynamics in leatherbacks to determine how the
timing of repair in leatherbacks may affect our results.
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These data do not fully explain the increase in chromosome damage seen
after prolonged particulate Cr exposure in leatherback lung cells (Speer et al.,
2019). Chromosome breakage during mitosis can induce structural chromosome
instability contributing to higher levels of chromosome damage however, this
mechanism has not been investigated after Cr(VI) exposure (Bayani et al., 2007).
In conclusion, we have shown RAD51 was inhibited after prolonged exposure,
however homologous recombination repair is uninhibited by prolonged particulate
Cr(VI) exposure demonstrated by our sister chromatid exchange data. These
results provide the first mechanistic data on how Cr(VI) causes chromosome
instability in leatherback sea turtle cells.
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FUTURE DIRECTIONS
This study provides data contributing to the mechanistic insight of Cr(VI)induced carcinogenesis. It provides the first analysis of transcriptional regulation
of RAD51 following Cr(VI) exposure and the role of E2F1 in this process. We also
present the first global analysis of miRNAs after Cr(VI) exposure in human cells
using RNAseq analysis. These data were applied to identify miRNAs targeting
pathways of Cr(VI) carcinogenesis, and specifically homologous recombination
and RAD51. We also demonstrated for the first-time mechanisms involved in DNA
repair in leatherback cells. However, these data generated many new ideas and
hypotheses to investigate in the future.
First, while we showed E2F1 did not modulate RAD51 expression after
particulate Cr(VI) exposure directly it would be important to test E2F1 binding the
RAD51 promotor and its ability to transcribe the RAD51 gene. Investigating this
possibility could be accomplished using the ChIP assay and a gene reporter
system. It is possible other proteins involved in E2F1-mediated transcription are
affected by Cr(VI) exposure, and thus, are required for successful expression of
RAD51. Specifically, the release of E2F1 from the retinoblastoma protein is
required for E2F1 to perform its transcriptional function. E2F1 must also associate
with its dimerization protein to enhance transcription. These functions could be
tested using proximity ligation assay as well as the ChIP assay. In lung cells E2F1
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may be more important for RAD51 localization at double strand breaks than
transcription. This hypothesis could be tested using immunofluorescence assays.
Knocking down E2F1 in a direct repeat green fluorescent protein (DR-GFP)
reporter system for homologous recombination repair may elucidate if E2F1 is
essential for homologous recombination repair after Cr(VI) exposure. Additionally,
we showed E2F4 may play a role in RAD51 repression. It would be interesting to
pursue this hypothesis by overexpressing E2F4 or knocking it down to test the
effect on RAD51 and homologous recombination repair. Using the ChIP assay to
investigate if Cr(VI) displaces E2F1 with E2F4 would provide insight into regulation
of RAD51 transcription specifically.
In Aim 2, we provided extensive hypothesis-driving data. It will be interesting
to compare the results of Cr(VI)-altered miRNAs with miRNAs altered by other
metals to better understand mechanisms of metal carcinogenesis. Additionally,
looking closer at the miRNAs with the highest fold-change in expression and their
targets in more detail warrant further investigation. Validation of some of the
differentially expressed miRNAs identified in the RNAseq analysis using qPCR
would confirm their change in expression after particulate Cr(VI) exposure.
Additionally, using miRNA mimics of specific miRNAs from the analysis can be
used to confirm effects on targets of select miRNAs, and specifically of RAD51.
While we investigated specific genes in the homologous recombination pathway
predicted to be targeted by Cr(VI)-upregulated miRNAs this type of analysis would
be insightful for other pathways in Cr(VI) carcinogenesis as well.
Finally, further investigation into the mechanisms of genotoxicity in
leatherback lung cells warrant further investigation to elucidate differences in DNA
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damage and repair. It will be important to perform cell cycle analysis to determine
if Cr(VI) induces cell cycle arrest. Additionally, measuring RAD51 using western
blot analysis may provide a more clear image of how Cr(VI) affects RAD51 in
leatherback lung cells. Additionally, performing time course analysis of DNA repair
to characterize the time it takes for leatherback lung cells to repair double strand
breaks would be insightful to the dynamics of repair. These data might also explain
the results of this study in better detail.
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research.” Rochester Institute of Technology and Rochester General
Hospital, Rochester, NY.

2012

2012

Fellowships and Awards
2020 Celebrating Women in Toxicology Award, Women in Toxicology Special Interest
Group, Society of Toxicology
2020 Graduate Student Travel Award, University of Louisville, for travel to the 59th
annual meeting of the Society of Toxicology.
2020

Doctoral Dissertation Completion Award, competitive stipend award to complete
degree, University of Louisville, Louisville, KY.

2019-2020

Graduate Research Fellowship, NIEHS R01 award to Dr. John Wise

2019 Ph.D. Poster Award, First Place, Ohio Valley Regional Chapter of the Society of
Toxicology (OVSOT) Annual Meeting, Cincinnati, OH.
2019 Tox on the Clock Presentation Award, Third Place, Ohio Valley Regional Chapter
of the Society of Toxicology (OVSOT) Annual Meeting, Cincinnati, OH.
2019 K.C. Huang Outstanding Graduate Student Award, Department of Pharmacology
and Toxicology, University of Louisville, Louisville, KY.
2019 Graduate Student Travel Award, Society of Toxicology, for travel to the 58th annual
meeting of the Society of Toxicology, Baltimore, MD.
2019 Graduate Student Travel Award, University of Louisville, for travel to the
International Sea Turtle Symposium, Charleston, SC.
2017-2019
T32 Environmental Health Sciences Predoctoral Training Grant, National
Institute of Environmental Health Sciences.
2018 Ph.D. Poster Award, Second Place, Ohio Valley Society of Toxicology Regional
Meeting, Louisville, KY.
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2018 Graduate Student Oral Presentation Award, 20th Annual Midwest DNA Repair
Symposium, Columbus, OH.
2018 Graduate Student Travel Award, University of Louisville, for travel to the 10th
Conference on Metal Toxicity & Carcinogenesis, Albuquerque, NM.
2018 Graduate Student Travel Award, University of Louisville, for travel to the 57th
annual meeting of the Society of Toxicology.
2018 Graduate Student Council Research Award, University of Louisville, and $500
award for RNAseq analysis.
2017

Graduate Dean’s Citation Award, University of Louisville.

2017 Graduate Student Travel Award, University of Louisville, for travel to the 56th
annual meeting of the Society of Toxicology.
2016 Graduate Student Council Research Award, University of Louisville, and $500
award for ICP-MS analysis of leatherback sea turtle samples.
2015 Master’s Basic Science Graduate Student Award, Second
Research!Louisville poster presentation, University of Louisville.

place

for

2015 Graduate Student Award, Second place for the 54th annual meeting of the Society
of Toxicology from the Northeast Regional Chapter of the Society of Toxicology.
2015 Graduate Student Travel Support Award for travel to the 54th Annual Meeting of
the Society of Toxicology from the Maine Economic Improvement Fund, University
of Southern Maine.
Publications
1. Speer, R.M., The, T., Xie, H., Liou, L., Adam, R., Wise, J.P., Sr. (2017) Cytotoxicity
and Genotoxicity of Particulate and Soluble Cobalt in Human Urothelial Cells. Biological
and Trace Element Research. 180: 48. doi: 10.1007/s12011-017-0989-z.
2. Browning, C.L., Speer, R.M., and Wise, J.P., Sr. (2017) “Molecular Mechanisms of
Chromium-Induced Carcinogenesis,” in Mudipalli, A., Zelikoff, J.T. (Eds) Essential and
Non- Essential Metals: Carcinogenesis, Prevention and Therapeutics, Springer, UK, ISBN
978-3-319-55448-8.
3. Speer, R.M., Wise, C.W., Young, J.L., Aboueissa, A.M., Martin Bras, M., Barandiarin,
M., Bermúdez E., Marquez-D’Acunti, L., Wise, J.P., Sr. (2018) The Cytotoxicity and
Genotoxicity of Particulate and Soluble Hexavalent Chromium in Leatherback Sea Turtle
Lung Cells. Aquatic Toxicology. 198:149-157. doi: 10.1016/j.aquatox.2018.03.003.
4. Speer, R.M., Wise, J.P., Sr. (2018) Current Status on Chromium Research and its
Implications for Health and Risk Assessment. Chemistry Molecular Sciences and
Chemical Engineering. 1-16. doi.org/10.1016/B978-0-12-409547-2.14283-0.
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5. Wise Jr., J.P., Croom-Perez, T.J., Meaza Isusi, I., Aboueissa, A.M., Lopez Montalvo,
C.A., Martin Bras, M., Speer, R.M., Bonilla Garzon, N.A., Urban, J.R., Perkins, C., Wise
Sr., J.P. (2019) A Whale of a Tale: A One Environmental Health Approach to Study Metal
Pollution in the Sea of Cortez. Toxicology and Applied Pharmacology. 376: 58-69.
https://doi.org/10.1016/j.taap.2019.05.005.
6. Speer, R.M., Wise, S.S., Croom-Perez, T.J., Aboueissa, A.M., Martin Bras, M.,
Barandiaran, M., Bermúdez, E., Wise, J.P., Sr. (2019) A Comparison of Particulate
Hexavalent Chromium Cytotoxicity and Genotoxicity in Human and Leatherback Sea
Turtle Lung Cells from a One Environmental Health Perspective. Toxicology and Applied
Pharmacology. 376: 70-81. https://doi.org/10.1016/j.taap.2019.05.013.
7. Meaza, I., Speer, R.M., Toyoda, J.H., Lu, H., Wise, S.S., Croom-Perez, T.J., Aboueissa,
A., and Wise, J.P., Sr. (2020) Prolonged exposure to particulate Cr(VI) is cytotoxic and
genotoxic to fin whale cells. Journal of Trace Elements in Medicine and Biology.
https://doi.org/10.1016/j.jtemb.2020.126562.
Abstracts
1. Speer, R.M., The, T., and Wise, Sr., J.P. The Cytotoxicity and Genotoxicity of
Particulate and Soluble Cobalt in Human Urothelial Cells. Toxicological Sciences, 144: 75,
2015.
2. Speer, R.M., The, T., and Wise, Sr., J.P. Comparison of the Cytotoxicity and
Genotoxicity of Particulate and Soluble Hexavalent Chromium in Human and Leatherback
Sea Turtle (Dermochelys coriacea) Skin Cells Toxicological Sciences, 150(1): 154 LB,
2016.
3. Speer, R.M., Young, J.L., Martin Bras, M., Barandiarin, M., Marquez, L., and Wise, Sr.,
J.P. A Comparison of the Cytotoxicity and Genotoxicity of Particulate and Soluble
Hexavalent Chromium in Human and Leatherback Sea Turtle (Dermochelys coriacea)
Skin Cells. Proceedings of the Annual Meeting of the International Association of Aquatic
Animal Medicine (IAAAM), 2016.
4. Speer, R.M., Young, J.L., Martin Bras, M., Barandiaran, M., Marquez-D’Acunti, L., and
Wise, Sr., J.P. A Comparison of the Cytotoxicity and Genotoxicity of Particulate and
Soluble Hexavalent Chromium in Human and Leatherback sea Turtle (Dermochelys
coriacea) Lung Cells. Proceedings of the 9th Conference on Metal Toxicity and
Carcinogenesis, 4, 2016, Lexington, KY.
5. Young, J.L., Wise, S.S., Wise, C.F., Speer, R.M., Raph, S.M. Lowers, R., Hall, C.,
Phillipps, L., Guillette, Jr., L.J., and Wise, Sr., J.P. Using the American alligator (Alligator
mississippiensis) as a Representative Species to Study Environmental Toxicology using
a One Environmental Health Approach at Kennedy Space Center. Proceedings of the 3 rd
Biennial Symposium on the Biology and Ecotoxicology of the American Alligator, 2016.
6. Speer, R.M., Young, J.L., Martin Bras, M., Barandiaran, M., Marquez-D’Acunti, L., and
Wise, Sr., J.P. A Comparison of the Cytotoxicity and Genotoxicity of Particulate and
Soluble Hexavalent Chromium in Human and Leatherback Sea Turtle (Dermochelys
coriacea) Lung Cells. Proceedings of the 8th Aquatic Animal Models of Human Disease
Conference, 2017.
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7. Speer, R.M., Young, J.L., Wise, S.S., Raph, S.M., Martin Bras, M., Barandiarin, M.,
Marquez-D’Acunti, L., and Wise, Sr., J.P. Using Leatherback Sea Turtles (Dermochelys
coriacea) as a Model Species for Metal Toxicology Research and Public Education in
Vieques, Puerto Rico. Toxicological Sciences, 156(1): 263, 2017.
8. Wise, Sr., J.P., Browning, C.L., Wise, S.S., Speer, R., and Lu, H. Homologous
Recombination Repair in Chemical Carcinogenesis: Hexavalent Chromium Induces DNA
Strand Breaks while Targeting Rad51 to Inhibit Their Repair. Presented at the 19th Annual
Midwest DNA Repair Symposium, p. 16, Dayton, OH, May, 2017.
9. Speer, R.M., Browning, C.L. and Wise, Sr., J.P. Chromate-Induced Suppression of
E2F1 and RAD51 in the Homologous Recombination Response. Presented at the Ohio
Valley Chapter of the Society of Toxicology (OVSOT) annual meeting, December, 2017.
10. Wise, Jr., J.P. Montalvo, C.L., Wise, C.F., Wise, S.S., Wise, J.T.F., Speer, R.M., Li
Chen, T., Abouiessa, A., Perkins, C., Bras, M.M., Savery, L.C., Urbán, J. and Wise, Sr.,
J.P. A Whale of a Tale: Using a One Health Approach to Study Metal Pollution in the Sea
of Cortez. Presented at the annual meeting of the Southern California Marine Mammal
Workshop (SCMMW), Newport Beach, CA, January, 2018.
11. Speer, R.M., Browning, C.L. and Wise, Sr., J.P. Chromate-Induced Suppression of
E2F1 and RAD51 in the Homologous Recombination Response. Toxicological Sciences,
150(1): 480, 2018.
12. Wise, Jr., J.P. Montalvo, C.L., Wise, C.F., Wise, S.S., Wise, J.T.F., Speer, R.M., Li
Chen, T., Abouiessa, A., Perkins, C., Bras, M.M., Savery, L.C., Urbán, J. and Wise, Sr.,
J.P. Of Whales and Men: A One Health Approach to Study Metal Pollution in the Sea of
Cortez. Presented at the annual meeting of the International Association for Aquatic
Animal Medicine (IAAAM), Long Beach, CA, May, 2018.
13. Speer, R.M., Browning, C.L., and Wise, Sr. J.P. Mechanisms of E2F1 Suppression
of RAD51 in Chromate-Induced Failure of Homologous Recombination. Presented at the
20th Annual Midwest DNA Repair Symposium, Columbus, OH, May, 2018.
14. Wise, Sr., J.P., Wise, S.S., Speer, R.M., Toyoda, J.H. and Meaza, I. Caracterización
de los Efectos Toxicológicos del Cromo Particulado Hexavalente en Cultivos Celulares
Primarios de Rorcual Común y Yubarta (Characterization of the Toxicological Effects of
Particulate Hexavalent Chromium in Fin Whale and Humpback Whale Primary Cell
Cultures). Congreso de la Sociedad Española de Cetaceos (Spanish Society of
Cetaceans Congress), Bilbao, Spain, October 2018.
15. Speer, R.M., Browning, C.L., and Wise, Sr., J.P. Suppression of E2F1 and RAD51 in
Chromate-Induced Failure of Homologous Recombination. Presented at the annual
meeting of the Ohio Valley Regional Chapter of the Society of Toxicology (OVSOT),
Louisville, KY, November, 2018.
16. Speer, R.M., Wise, C.F., Wise, S.S., Martin Bras, M., Barandiarin, M., Marquez, L.,
Bermudez, E., and Wise, Sr., J.P. Environmental Impacts on Leatherback Sea Turtle
Health: Using a One Health Approach to Study Metal Pollution in WIldlife. Presented at
the International Sea Turtle Symposium, February, 2019.
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17. Speer, R.M., Browning, C.L., and Wise, Sr., J.P. Suppression of E2F1 and RAD51 in
Chromate-Induced Failure of Homologous Recombination. Presented at the annual
meeting of the Society of Toxicology (SOT), Baltimore, MD, March, 2019.
18. Lu, H., Browning, C.L., Wise, S.S., Toyoda, J.H., Speer, R.M., Raph, S., Wise, J.P.,
Sr. Prolonged Particulate Chromate Exposure Does Not Inhibit Homologous
Recombination Repair in Bowhead Whale Lung Cells. Presented at the Annual Meeting
of the Society of Toxicology (SOT), Baltimore, MD, March, 2019.
19. Wise, Jr., J.P., Croom-Perez, T.J., Meaza, I., Montalvo, C.L., Wise, C.F., Wise, S.S.,
Wise, J.T.F., Speer, R.M., Abouiessa, A., Bras, M.M., Savery, L.C., Urbán, J., Young, J.L.,
and Wise, Sr., J.P. A Whale of a Tale: A One Environmental Health Approach to Study
Metal Pollution in the Sea of Cortez. Presented at the Annual Meeting of the Society of
Toxicology (SOT), Baltimore, MD, March, 2019.
20. Lu, H., Browning, C.L, Wise, S.S., Toyoda, J.H., Speer, R.M., and Wise, Sr., J.P.
Bowhead Whale Lung Cells Maintain Homologous Recombination Repair and Resist
Genomic Instability during Prolonged Particulate Chromate Exposure. Presented at the
Annual Meeting of the Environmental Mutagenesis and Genomics Society (EMGS),
Washington, D.C., September, 2019.
21. Wise, Sr., J.P., Wise, Jr., J.P., Toyoda, J.H., Croom-Perez, T.J., Aboueissa, A., ,
Montalvo, C.L., Isusi, I.M., Wise, S.S., Wise, C.F., Wise, J.T.F., Li Chen, T., Perkins, C.R.,
Bras, M.M., Speer, R.M., and Urbán, J. Of Whales and Men: Understanding Metal
Pollution in the Sea of Cortez through a One Environmental Health Approach. Presented
at the World Marine Mammal Science Conference, Barcelona, Spain, December, 2019.
22. Isusi, I.M., Speer, R.M., Toyoda, J.H., and Wise, Sr., J.P. The Characterization of the
Toxicologic Effects of Particulate Hexavalent Chromium in Female and Male Fin Whale
Cells. Presented at the World Marine Mammal Science Conference, Barcelona, Spain,
December, 2019.
23. Speer, R.M., Zhou, X., Liu, K.J., Browning, C.L., Kondo, K., Wise, Sr., J.P. ChromateInduced Loss of E2F1 Inhibits RAD51 Response in Homologous Recombination Repair.
Presented at the Ohio Valley Chapter of the Society of Toxicology (OVSOT) annual
meeting, October, 2019.
24. Meaza, I., Speer, R.M., Toyoda, J.H. Wise, J.P., Sr. Particulate Hexavalent Chromium
Induces Cytotoxicity and Genotoxicity in Female and Male Fin Whale Primary Fibroblasts.
Presented at the Ohio Valley Chapter of the Society of Toxicology (OVSOT) annual
meeting, October, 2019.
25. Wise, J.P., Jr., Lu, H., Meaza, I., Wise, S.S., Croom-Perez, T., Speer, R.M., Toyoda,
J.H., Ali, Abdulmehdi, Cai, L., Liu, K.J., Wise, J.T.F., Young, J.L., Wise, J.P., Sr. An
Environmental Toxicology Assessment of Heavy Metal Accumulation in American
Alligators in Florida. Presented at the Ohio Valley Chapter of the Society of Toxicology
(OVSOT) annual meeting, October, 2019.
26. Meaza, I.M., Speer, R.M., Toyoda, J.H., Wise, Sr., J.P. Particulate Hexavalent
Chromium Induces Cytotoxicity and Genotoxicity in Female and Male Fin Whale Cells.
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Official abstract for the Society of Toxicology annual meeting, March 2020 (Canceled –
Covid-19).
27. Speer, R.M., Zhou, X., Liu, K.J., Browning, C.L., Kondo, K., Wise, Sr., J.P. ChromateInduced Loss of E2F1 Inhibits RAD51 Response in Homologous Recombination Repair.
Official abstract for the Society of Toxicology annual meeting, March 2020 (Canceled –
Covid-19).
28. Lu, H., Browning, C.L., Wise, S.S., Speer, R.M., Lu, K.J., Wise, Sr., J.P. How
Chromium Induces Genomic Instability: Lessons from Human and Whale Cells. Presented
at the Sixteenth International Symposium on Recent Advances in Environmental Health
Research, March, 2020 (Postponed – Covid-19).
University Student Research Day Presentations
1. Speer, R.M., The, T., and Wise, Sr., J.P. The Cytotoxicity and Genotoxicity of
Particulate and Soluble Cobalt in Human Urothelial Cells. Presented at
Research!Louisville, University of Louisville, 2015.
2. Speer, R.M., Young, J.L., Martin Bras, M., Barandiaran, M. Marquez-D’Acunti, L. and
Wise, Sr., J.P. A Comparison of the Cytotoxicity and Genotoxicity of Particulate and
Soluble Hexavalent Chromium Leatherback Sea Turtle (Dermochelys coriacea) Lung
Cells. Research!Louisville, 2016.
3. Rossman, J., Speer, R.M., Wise, S.S. and Wise, Sr., J.P. Cytotoxic Effects of Chromate
Exposure on Alligotr Skin and Bronchial Cells. Presented at Research!Louisville,
University of Louisville, 2016.
4. Speer, R.M., Browning, C.L. and Wise, Sr., J.P. Chromate-Induced Suppression of
E2F1 and RAD51 in the Homologous Recombination Response. Presented at
Research!Louisville, University of Louisville, 2017.
5. McBride, D.E., Perez, A.A., Raph S.M., Speer R.M., Croom-Perez T.J., Wise S.S. and
Wise, Sr., J.P. A One Health Case Study: Comparison of DNA Damage Response to
Hexavalent Chromium in Alligator and Human Lung Fibroblasts. Presented at
Research!Louisville, University of Louisville, 2017.
6. Toyoda, J.H., Martino, J., Speer, R.M., and Wise, Sr., J.P. Mechanisms of Hexavalent
Chromium-Induced Centriole Disengagement and Centrosome Amplification. Presented
at Research!Louisville, University of Louisville, 2017.
7. Speer, R.M., Young, J.L., Wise, S.S., Raph, S.M., Martin Bras, M., Barandiarin, M.,
Marquez-D’Acunti, L., and Wise, Sr., J.P. Using Leatherback Sea Turtles (Dermochelys
coriacea) as a Model Species for Metal Toxicology Research and Public Education in
Vieques, Puerto Rico. Presented at the Graduate Student Regional Research
Conference, University of Louisville, 2018.
8. Speer, R.M., Browning, C.L, and Wise, Sr., J.P. Suppression of E2F1 and RAD51 in
Chromate-Induced
Failure
of
Homologous
Recombination.
Presented
at
Research!Louisville, 2018.
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9. Speer, R.M., Zhou, X., Liu, K.J., Browning, C.L., Kondo, K., Wise, Sr., J.P. ChromateInduced Loss of E2F1 Inhibits RAD51 Response in Homologous Recombination Repair.
Presented at
Research!Louisville!, 2019.
10. Wise, S.S., Miller, E., Daniel, S., Meaza, I., Toyoda, J.H., Lu, H., Speer, R. M., Young,
J. L., Isakov, R., Jaggers, H., Wise, Jr., J. P., Croom-Perez, T. J., Cai, L., Hoyle, G., Wise,
Sr., J. P. Effects of Chronic Exposure to Particulate Chromate in Rat Lungs. Presented at
Research!Louisville, 2019.
Seminars/Oral Presentations
2019 Tox on the Clock, Three Minute Thesis Competition, Ohio Valley Regional Chapter
of the Society of Toxicology (OVSOT) annual meeting, Cincinnati, Ohio.
2019 Speer, R.M., Browning, C.L., Wise, J.P., Sr. “The Role of E2F1 in ChromateInduced RAD51 Suppression” Graduate Student Research Conference, University
of Louisville, Louisville, KY.
2019 Speer, R.M., Wise, C.F., Wise, S.S., Martin Bras, M., Barandiaran, M., Marquez,
L., Bermudez, E., Wise, J.P., Sr. Environmental Impacts on Leatherback Sea
Turtle Health: Using a One Health Approach to Study Metal Pollution in Wildlife.
International Sea Turtle Symposium, Charleston, SC.
2019 Speer, R.M. “Methods to Characterize and Assess Genotoxicity in Leatherback
Sea Turtles.” Environmental Contaminants in Sea Turtles Workshop, International
Sea Turtle Symposium, Charleston, SC.
2018 “Mechanisms of E2F1 Suppression of RAD51 in Chromate-Induced Failure of
Homologous Recombination.” 20th Annual Midwest DNA Repair Symposium,
Columbus, OH. May, 2018.
2017 “A Comparison of the Cytotoxicity and Genotoxicity of Particulate and Soluble
Hexavalent Chromium in Human and Leatherback Sea Turtle (Dermochelys
coriacea) Lung Cells.” 8th Meeting of Aquatic Animal Models of Human Disease,
University of Alabama, Birmingham, AL. January, 2017.
2016 “Developing a Thesis: The Role of E2F1 in Cr(VI)-Induced Carcinogenesis.”
Cancer Center Colloquia Series, University of Louisville, Louisville, KY. April, 2016.
2014 “Cytotoxicity and Genotoxicity of Particulate and Soluble Cobalt in Human
Urothelial Cells.” Department of Applied Medical Sciences Seminar Series.
University of Southern Maine, Portland, ME.
Public Presentations
2018 “One Environmental Health: Investigating Toxicology with Sea Turtles and
Humans.” Vieques Conservation and Historical Trust Speaker Series, Vieques,
Puerto Rico.
2017 “The What, How, and What Now of Toxicology.” Future Problem Solvers Mentor
Training, Kentucky Association Academic Conference, Louisville, KY.
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2016 “Wise Laboratory Research in Vieques: Implications and Future Directions.”
Vieques Conservation and Historical Trust Speaker Series, Vieques, Puerto Rico.
Field Work
2018

Conducted alligator sampling expedition at Kennedy Space Center, Lake
Woodruff and Lake Apopoka, Florida.

2017

Conducted sample collecting in the Gulf of California (Sea of Cortez),
Mexico during the spring season. Biopsies were taken from fin, humpback,
minke, Bryde’s, blue, pilot and sperm whales.
2017-Present Conducted sample collecting in the Gulf of Maine during the fall season.
Biopsies were taken from fin, humpback and minke whales.
2015-Present Conducted alligator sampling expeditions at Kennedy Space Center,
Florida.
2015-Present Developed a marine field research laboratory in Vieques, Puerto Rico.
Conducted sampling programs for fish and sea turtles.
Committees
2018-Present Policy Coordinator, Science Policy and Outreach Group, University of
Louisville
2019-2020

Member, FUTURE Committee, Society of Toxicology

2019-2020

Member, Programming Subcommittee, Graduate Student Leadership
Committee, Society of Toxicology

2018-2020

Metals Specialty Section Graduate Student Representative

2018-2019

President of the Pharmacology and Toxicology student body, Department
of Pharmacology and Toxicology, University of Louisville

2018-2019

Research Grant Review Committee, Graduate Student Council, University
of Louisville

2018-2019

Member, Continuing Education Committee
Representative, Society of Toxicology

2018-2019

Member Professional Development Subcommittee, Graduate Student
Leadership Committee, Society of Toxicology

2017-2018

President of third year graduate student class,
Pharmacology and Toxicology, University of Louisville

Graduate

Student

Department

of

Continuing Education Coursework
2020 Professional Development Webinar, “Navigating the K99/R00 Grant Process,”
American Society for Cell Biology.
2020 Professional Development Webinar, “Transitioning to Independence Webinar
Series Part 3: How to Get the Most out of Your Mentoring Relationships,”
Postdoctoral Assembly, Society of Toxicology.
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2019 Continuing Education Course, “Assay Development Principles and Good
Research Practices for Rigor and Reproducibility in In Vitro Toxicology,” Society of
Toxicology.
2018 Superfund Seminar Series, “Superfund Research Program Progress in Research
Webinar Part 2: University of Louisville, University of New Mexico, and University
of Washington,”
2018 Superfund Seminar Series, “Superfund Research Program Progress in Research
Webinar Part 3: Columbia University, Massachusetts Institute of Technology, and
University of Rhode Island,”
2018 Superfund Seminar Series, “Superfund Research Program Progress in Research
Webinar Part 4: Boston University, Texas A&M University, and University of
California, Davis,”
2017 Webinar, “Defining a cancer cell-specific mechanism
Topoisomerase I poisons,” Society of Toxicology Webinar.

of

resistance

to

2017 Webinar, “Finding Your Dream Job in Regulatory Toxicology,” Society of
Toxicology Webinar.
2017 Continuing Education Course, “Basic Principles of Human Risk Assessment,”
Society of Toxicology.
2014 Webinar, “New Frontiers in Chemical Carcinogenesis, Association of Scientists of
Indian Origin,” Society of Toxicology.
2014 Webinar, “Increasing Your Visibility and Participation in SOT as an Early Career
Toxicologist, SOT Postdoctoral Assembly,” Society of Toxicology.
2014 Webinar, “Postdoctoral Representative Fall Webinar,” SOT Postdoctoral
Assembly, Society of Toxicology.
Professional Memberships & Societies:
2020-Present Graduate Student Member, Society of Environmental Toxicology and
Chemistry
2017-Present Graduate Student Member, Women in Toxicology Special Interest Group,
Society of Toxicology
2016-Present Graduate Student member, National Postdoctoral Association
2015-Present Graduate Student Member, Science Policy and Outreach Group
2015-Present Graduate Student Member, American Association for the Advancement of
Science,
2015-Present Graduate Student Member, Ohio Valley Regional Chapter, Society of
Toxicology
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2014-Present Graduate Student Member, Society of Toxicology
2014-Present Graduate Student Member, Carcinogenesis Specialty Section, Society of
Toxicology
2014-Present Graduate Student Member, Metals Specialty Section, Society of
Toxicology
2014-2015

Northeast Regional Chapter, Society of Toxicology

Volunteer and Community Work
2020 Head Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville,
KY.
2019 Activity Leader, Girls Rule STEM+Health Summit, Speed School of Engineering,
University of Louisville, Louisville, KY.
2019 Event Leader, Louisville Regional Science and Engineering Fair Advocacy Day at
the Capital, Frankfort, KY.
2019 Head Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville,
KY.
2018 Project Mentor, Central High School Students for Kentucky Science Fair, Kentucky
Science Center, Louisville, KY.
2018 Presenter and Program Organizer, Manta Environmental Summer Education
Programs, Vieques Conservation and Historical Trust, Vieques, Puerto Rico.
2017 Program Organizer, Future Problem Solver’s Competition Preparation Workshop,
Kentucky Association for Academic Competition, University of Louisville,
Louisville, KY.
2017 Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville, KY.
2017 Program Assistant, Manta Environmental Summer Education Program, Vieques
Conservation and Historical Trust, Vieques, Puerto Rico.
2016 Volunteer, U.S. Fish and Wildlife Service beach clean-up program, Vieques,
Puerto Rico.
2016 Program Assistant, Manta Environmental Summer Education Program, Vieques
Conservation and Historical Trust, Vieques, Puerto Rico.
2016 Head Poster Judge, Kentucky Science Fair, Kentucky Science Center, Louisville,
KY. Judged posters for middle school students.
2015 Program Assistant, Manta Environmental Summer Education Program, Vieques
Conservation and Historical Trust, Vieques, Puerto Rico.
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2015 Project Mentor, Science Fair Student Mentoring Session, Science Policy and
Outreach Group, University of Louisville and Kentucky Science Center, Louisville,
KY.
2015 Project Assistant, Research!Louisville High School Student Graduate School
Information Session, Science Policy and Outreach Group, University of Louisville
and Kentucky Science Center, Louisville, KY.
2014 Event Volunteer, Annual Wild & Scenic Film Festival, Friends of Casco Bay,
Portland, ME.
Volunteer, Annual beach clean-ups, Environmental Health and Toxicology Club,
University of Southern Maine, Portland, ME.
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